0001144204-12-045626.txt : 20120814 0001144204-12-045626.hdr.sgml : 20120814 20120814160302 ACCESSION NUMBER: 0001144204-12-045626 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20120630 FILED AS OF DATE: 20120814 DATE AS OF CHANGE: 20120814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTERLEUKIN GENETICS INC CENTRAL INDEX KEY: 0001037649 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 943123681 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-32715 FILM NUMBER: 121032725 BUSINESS ADDRESS: STREET 1: 135 BEAVER ST CITY: WATHAM STATE: MA ZIP: 02452 BUSINESS PHONE: 1-781-398-0700 MAIL ADDRESS: STREET 1: 135 BEAVER ST CITY: WATHAM STATE: MA ZIP: 02452 FORMER COMPANY: FORMER CONFORMED NAME: MEDICAL SCIENCE SYSTEMS INC DATE OF NAME CHANGE: 19971003 10-Q 1 v318596_10q.htm FORM 10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2012

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

For the transition period from _______ to _______

Commission File Number: 001-32715

INTERLEUKIN GENETICS, INC.

(Exact name of registrant in its charter)

Delaware		94-3123681
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

135 Beaver Street, Waltham, MA		02452
(Address of principal executive offices)		(Zip Code)

Registrant’s Telephone Number: (781) 398-0700

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES x NO ¨

Indicate by check mark whether each registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES x NO ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨	Accelerated filer ¨

Non-Accelerated filer ¨ (Do not check if a smaller reporting company)	Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ¨ NO x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Outstanding at July 31, 2012
Common Stock, par value $0.001 per share		36,761,864

INTERLEUKIN GENETICS, INC.

FORM 10-Q

FOR THE QUARTER ENDED June 30, 2012

Table of Contents

	Page
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements
Condensed Balance Sheets as of June 30, 2012 (Unaudited) and December 31, 2011	3
Condensed Statements of Operations (Unaudited)	4
Condensed Statements of Stockholders’ Deficit (Unaudited)	5
Condensed Statements of Cash Flows (Unaudited)	6
Notes to Condensed Financial Statements (Unaudited)	7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3. Quantitative and Qualitative Disclosures About Market Risk	18
Item 4. Controls and Procedures	19
PART II—OTHER INFORMATION
Item 1. Legal Proceedings	19
Item 1A. Risk Factors	19
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	19
Item 3. Defaults Upon Senior Securities	20
Item 4. Mine Safety Disclosures	20
Item 5. Other Information	20
Item 6. Exhibits	20

Smaller Reporting Company – Scaled Disclosure

Pursuant to Item 10(f) of Regulation S-K promulgated under the Securities Act of 1933, as amended, as indicated herein, we have elected to comply with the scaled disclosure requirements applicable to “smaller reporting companies”.

PART I —FINANCIAL INFORMATION

Item 1. Financial Statements

INTERLEUKIN GENETICS, INC.

CONDENSED BALANCE SHEETS

	June 30, 2012			December 31, 2011
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	3,831,625		$	1,728,222
Accounts receivable from related party		4,916			2,662
Trade accounts receivable		31,238			55,892
Inventory		88,368			107,758
Prepaid expenses		243,596			217,387
Total current assets		4,199,743			2,111,921
Fixed assets, net		183,656			289,011
Intangible assets, net		456,857			514,584
Other assets		38,001			38,001
Total assets	$	4,878,257		$	2,953,517

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable	$	569,108		$	369,306
Accrued expenses		234,781			182,597
Deferred revenue		970,943			824,845
Notes payable		14,316,255			13,000,000
Total current liabilities		16,091,087			14,376,748

Commitments and contingencies (Note 8)

Stockholders’ deficit:

Convertible preferred stock, $0.001 par value — 6,000,000 shares authorized; 5,500,000 and 5,000,000 shares issued and outstanding at June 30, 2012 and December 31, 2011; aggregate liquidation preference of $24,000,000 at June 30, 2012		5,500			5,000
Common stock, $0.001 par value — 100,000,000 shares authorized; 36,761,864 and 36,709,706 shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively		36,762			36,710
Additional paid-in capital		93,966,029			91,111,640
Accumulated deficit		(105,221,121	)		(102,576,581	)
Total stockholders’ deficit		(11,212,830	)		(11,423,231	)
Total liabilities and stockholders’ deficit	$	4,878,257		$	2,953,517

The accompanying notes are an integral part of these financial statements.

INTERLEUKIN GENETICS, INC.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2012			2011			2012			2011
Revenue:
Genetic testing	$	777,549		$	779,116		$	1,454,717		$	1,498,563
Other		21,886			17,749			22,603			17,787
Total revenue		799,435			796,865			1,477,320			1,516,350
Cost of revenue		393,122			438,464			769,333			796,053
Gross profit		406,313			358,401			707,987			720,297
Operating expenses:
Research and development		317,440			359,799			763,714			664,618
Selling, general and administrative		1,176,110			1,253,143			2,312,760			2,455,598
Amortization of intangibles		28,863			28,863			57,726			57,726
Total operating expenses		1,522,413			1,641,805			3,134,200			3,177,942
Loss from operations		(1,116,100	)		(1,283,404	)		(2,426,213	)		(2,457,645	)
Other income (expense):
Interest income		860			1,901			1,603			4,307
Interest expense		(114,594	)		(89,130	)		(219,930	)		(177,281	)
Gain on disposal of assets		—			—			—			4,275
Total other income (expense)		(113,734	)		(87,229	)		(218,327	)		(168,699	)
Loss from continuing operations before income taxes		(1,229,834	)		(1,370,633	)		(2,644,540	)		(2,626,344	)
Benefit for income taxes		—			—			—			—
Loss from continuing operations		(1,229,834	)		(1,370,633	)		(2,644,540	)		(2,626,344	)
Income from discontinued operations, net of income taxes		—			158,366			—			158,366
Net loss	$	(1,229,834	)	$	(1,212,267	)	$	(2,644,540	)	$	(2,467,978	)
Basic and diluted net loss per common share from:
Continuing operations	$	(0.03	)	$	(0.04	)	$	(0.07	)	$	(0.07	)
Discontinued operations		—			0.01			0.00			0.00
Net loss	$	(0.03	)	$	(0.03	)	$	(0.07	)	$	(0.07	)
Weighted average common shares outstanding, basic and diluted		36,756,802			36,650,158			36,752,456			36,634,173

The accompanying notes are an integral part of these financial statements.

INTERLEUKIN GENETICS, INC.

CONDENSED STATEMENTS OF STOCKHOLDERS’ DEFICIT

For the Six Months Ended June 30, 2012 and 2011

(Unaudited)

	Convertible Preferred Stock				Common Stock
	Shares		Amount		Shares		Amount		Additional Paid-in Capital		Accumulated Deficit			Total
Balance as of December 31, 2010		5,000,000	$	5,000		36,594,799	$	36,594	$	90,851,709	$	(97,551,399	)	$	(6,658,096	)
Net loss		—		—		—		—		—		(2,467,978	)		(2,467,978	)
Common stock issued:
Employee stock purchase plan		—		—		64,134		65		16,900		—			16,965
Stock-based compensation expense		—		—		—		—		130,966		—			130,966
Balance as of June 30, 2011		5,000,000	$	5,000		36,658,933	$	36,659	$	90,999,575	$	(100,019,377	)	$	(8,978,143	)

Balance as of December 31, 2011		5,000,000	$	5,000		36,709,706	$	36,710	$	91,111,640	$	(102,576,581	)	$	(11,423,231	)
Net loss		—		—		—		—		—		(2,644,540	)		(2,644,540	)
Private placement of preferred stock, net of offering costs of $354,907		500,000		500		—		—		2,644,593		—			2,645,093
Warrants issued in connection with private placement of preferred stock		—		—		—		—		104,907		—			104,907
Common stock issued: Employee stock purchase plan		—		—		52,158		52		8,758		—			8,810
Stock-based compensation expense		—		—		—		—		96,131		—			96,131
Balance as of June 30, 2012		5,500,000	$	5,500		36,761,864	$	36,762	$	93,966,029	$	(105,221,121	)	$	(11,212,830	)

The accompanying notes are an integral part of these financial statements.

INTERLEUKIN GENETICS, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the Six Months Ended June 30,
	2012			2011
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(2,644,540	)	$	(2,467,978	)
Income from discontinued operations		—			158,366
Loss from continuing operations		(2,644,540	)		(2,626,344	)
Adjustments to reconcile loss from continuing operations to net cash used in operating activities:
Depreciation and amortization		168,082			202,897
Stock-based compensation expense		96,131			130,966
Changes in operating assets and liabilities:
Accounts receivable		24,654			(30,390	)
Federal grant receivable		—			117,946
Receivable from related party		(2,254	)		(99,757	)
Inventory		19,390			20,509
Prepaid expenses and other current assets		(26,209	)		7,306
Accounts payable		(10,198	)		(46,602	)
Accrued expenses		12,184			(217,417	)
Deferred revenue		146,098			246,424
Net cash used in operating activities of discontinued operations		—			(5,875	)
Net cash used in operating activities		(2,216,662	)		(2,300,337	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital additions		(5,000	)		(1,681	)
Net cash used in investing activities		(5,000	)		(1,681	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of notes payable		1,316,255			—
Proceeds from private placement of preferred stock		3,000,000			—
Proceeds from employee stock purchase plan		8,810			16,965
Net cash provided by financing activities		4,325,065			16,965
Net increase (decrease) in cash and cash equivalents		2,103,403			(2.285,053	)
Cash and cash equivalents, beginning of period		1,728,222			3,999,029
Cash and cash equivalents, end of period	$	3,831,625		$	1,713,976

Supplemental disclosures of cash flow information:
Cash paid for interest	$	204,884		$	178,260

Supplemental disclosures of non-cash investing and financing activities:
Warrants issued in connection with preferred stock financing	$	104,907		$	—

The accompanying notes are an integral part of these financial statements.

INTERLEUKIN GENETICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

June 30, 2012

Note 1—Basis of Presentation

Interleukin Genetics, Inc. (“the Company”) develops genetic tests for sale into the emerging personalized health market and performs testing services that can help individuals improve and maintain their health through preventive measures. The Company’s principal operations and markets are located in the United States.

The accompanying condensed financial statements include the accounts of the Company as of June 30, 2012 and December 31, 2011 and for the three and six months ended June 30, 2012 and 2011.

The financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America for interim financial reporting. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles for complete financial statements. These unaudited condensed financial statements, which, in the opinion of management, reflect all adjustments (including normal recurring adjustments) necessary for a fair presentation, should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. Operating results are not necessarily indicative of the results that may be expected for any future interim period or for the entire fiscal year.

For information regarding our critical accounting policies and estimates, please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Estimates” contained in our Annual Report on Form 10-K for the year ended December 31, 2011 and Note 4 to our condensed financial statements contained herein.

Note 2—Operating Matters and Liquidity

The Company has experienced net operating losses since its inception through June 30, 2012, including a net loss of $2.6 million for the six months then ended, contributing to an accumulated deficit of $105 million as of June 30, 2012. The Company has borrowings of $14.3 million at June 30, 2012 under its line of credit with Pyxis Innovations, Inc., an affiliate of Alticor (“Pyxis”). On June 29, 2012, the maturity date of the line of credit was extended from June 30, 2012 to November 30, 2012.

The Company was successful in 2011 and 2012 in reducing costs and continues to explore additional ways to reduce operating costs, including manufacturing costs as well as general and administrative expenses however, the opportunities to do so are very limited. Cost savings were achieved through process improvements in manufacturing, reductions in personnel and the subleasing of underutilized rental space. Management believes that the current laboratory space is adequate to process high volumes of genetic tests.

On June 29, 2012, the Company entered into a Stock Purchase Agreement with Delta Dental Plan of Michigan, Inc. (“Delta Dental”), pursuant to which, Delta Dental purchased 500,000 shares of Series B convertible preferred stock for net proceeds of $2,750,000.

The Company’s financial statements have been prepared assuming that it will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company expects to incur additional losses in 2012 and, accordingly, is dependent on finding additional sources of liquidity to fund its operations. Management’s plans include identifying additional sources of debt and/or equity financing, further extending the due date of its existing debt, growing its sources of revenue and further reducing expenditures. However, no assurance can be given at this time as to whether management will be able to achieve these plans. If the Company is not successful in raising additional debt or equity funding, further extending the due date of its existing debt, completing negotiations with commercial distribution partners or reducing expenditures, it will not be able to fund operations beyond November 30, 2012. However, if the due date of the debt is extended beyond November 30, 2012, the Company estimates that it would have sufficient operating cash flows to fund operations through January 31, 2013. The financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

In its report on our financial statements included in the Form 10-K for the year ended December 31, 2011, our independent registered public accounting firm, Grant Thornton LLP, included an explanatory paragraph in their report indicating that there was substantial doubt concerning the Company’s ability to continue as a going concern.

The ability of the Company to realize the carrying value of its fixed assets and intangible assets is especially dependent on management’s ability to successfully execute on its plan. As noted above, the Company needs to generate additional funds in order to meet its financial obligations beyond November 30, 2012. If it is unsuccessful in doing so, the Company may not be able to realize the carrying value of its fixed assets and intangible assets.

Note 3—Discontinued Operations

In August 2006, the Company acquired the assets and business of the Alan James Group, LLC (the Alan James Group). The Alan James Group was a provider of products and services in the consumer healthcare marketplace and the acquired business primarily developed, marketed and sold nutritional products and engaged in related activities. Prior to the opening of business on July 1, 2009, the Company and its wholly-owned subsidiary, AJG Brands, Inc. entered into an asset purchase agreement with Nutraceutical Corporation and Pep Products, Inc., a wholly-owned subsidiary of Nutraceutical Corporation, pursuant to which substantially all of the Alan James Group business and assets of AJG Brands, Inc. were sold to Pep Products, Inc.

Prior to June 30, 2011, we reserved for estimated sales returns, discontinued items and trade promotions applicable to the non-acquired accounts resulting from our sale of substantially all of the assets of the Alan James Group business. The Company completed an analysis of all return activity since the time of sale and determined that the remaining reserve was no longer required. The adjustment is reflected in income from discontinued operations in the June 30, 2011 statement of operations.

Note 4—Significant Accounting Policies

Revenue Recognition

Revenue from genetic testing services is recognized when there is persuasive evidence of an arrangement, service has been rendered, the sales price is determinable and collectability is reasonably assured. Service is deemed to be rendered when the results have been reported to the individual who ordered the test. To the extent that tests have been prepaid but results have not yet been reported, recognition of all related revenue is deferred. As of June 30, 2012 and December 31, 2011, the Company has deferred genetic test revenue of $970,943 and $824,845, respectively.

Sales Commission

The Company accounts for sales commissions due to Amway Global under the Merchant Channel and Partner Agreement in accordance with SEC Staff Accounting Bulletin (“SAB”) 104. Commissions are recorded as an expense at the time they become due which is at the point of sale. Commissions were $452,000 and $543,000 for the six months ended June 30, 2012 and 2011.

Accounts Receivable

Accounts receivable is stated at estimated net realizable value, which is generally the invoiced amount less any estimated discount related to payment terms. The Company offers its commercial genetic test customers a 2% cash discount if payment is made by bank wire transfer within 10 days of the invoice date.

Inventory

Inventory is carried at lower of cost or market and no inventory reserve is deemed necessary at June 30, 2012. As the Company does not manufacture any products, no overhead costs are included in inventory. When a kit is sold, the corresponding cost of the kit is recorded as cost of goods sold and removed from inventory.

Inventory consisted of the following at June 30, 2012 and December 31, 2011:

	June 30, 2012		December 31, 2011

Raw materials	$	83,895	$	100,433
Finished goods		4,473		7,325
Total inventory	$	88,368	$	107,758

Income Taxes

The Company accounts for income taxes in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, Income Taxes, which requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the financial statements or tax returns. The measurement of current and deferred tax liabilities and assets is based on provisions of the enacted tax law; the effects of future changes in tax laws or rates are not anticipated. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized.

Significant management judgment is required in determining the Company’s provision (benefit) for income taxes, its deferred tax assets and liabilities and any valuation allowance recorded against deferred tax assets. The Company has recorded a full valuation allowance against its deferred tax assets of approximately $30.5 million as of June 30, 2012, due to uncertainties related to its ability to utilize these assets. The valuation allowance is based on management’s estimates of taxable income by jurisdiction in which the Company operates and the period over which the deferred tax assets will be recoverable. In the event that actual results differ from these estimates or management adjusts these estimates in future periods, the Company may need to adjust its valuation allowance, which could materially impact its financial position and results of operations.

The Company files a combined Massachusetts tax return with certain Alticor affiliated entities, referred to herein as “the unitary group”. Massachusetts law requires corporations with net operating loss carryforwards to go back to each year in which the loss was generated and recompute the loss as if it occurred on a consolidated basis. The Company was required to include data from the newly formed unitary group as if the unitary group was in place during the loss years. As a result, the losses generated by the Company were eliminated through this required computation. The combined filing has had no impact on the Company's financial statements.

The Company reviews its recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. The Company reviews all material tax positions for all years open to statute to determine whether it is more likely than not that the positions taken would be sustained based on the technical merits of those positions. The Company did not recognize any adjustments for uncertain tax positions as of and during the three and six months ended June 30, 2012 and 2011, respectively.

Research and Development

Research and development costs are expensed as incurred.

Basic and Diluted Net Loss per Common Share

The Company applies the provisions of FASB ASC 260, Earnings per Share, which establishes standards for computing and presenting earnings per share. Basic and diluted net loss per share was determined by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is the same as basic net loss per share for all the periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the loss in each period. Potential common stock equivalents excluded from the calculation of diluted net loss per share consists of stock options, warrants, convertible preferred stock and convertible debt as set forth in the table below:

	As of June 30,
	2012		2011
Options outstanding		2,100,267		2,217,267
Warrants outstanding		2,587,158		2,150,000
Convertible preferred stock		39,089,161		28,160,200
Convertible debt		2,521,222		1,937,200
Total		46,297,808		34,464,667

Fair Value of Financial Instruments

The Company, using available market information, has determined the estimated fair values of financial instruments. The stated values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to the nature of these instruments. The fair value of our convertible debt is inherently difficult to determine as a result of the Company’s financial condition and history of operating losses. For financial reporting purposes, the Company has estimated the fair value of its debt as the difference between the book value of its assets less liabilities to third parties other than the debt holder.

Cash and Cash Equivalents

The Company maintains its cash and cash equivalents with domestic financial institutions that the Company believes to be of high credit standing. Cash and cash equivalents are available on demand and at times may be in excess of FDIC insurance limits. The Company believes that, as of June 30, 2012, its concentration of credit risk related to cash and cash equivalents was not significant.

Recent Accounting Pronouncements

Please see the discussion of “Recent Accounting Pronouncements” in Note 4, Significant Accounting Policies contained in the Notes to Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. No new updates or other guidance issued to date by the FASB in 2012 are expected to have a material impact on the Company’s financial statements.

Note 5—Strategic Alliance with Alticor Inc.

Since March 2003, the Company has maintained a broad strategic alliance with several affiliates of the Alticor family of companies to develop and market novel nutritional and skin care products. The alliance previously included an equity investment, a multi-year research and development agreement, a licensing agreement with royalties on marketed products, the deferment of outstanding loan repayment and the refinancing of bridge financing obligations.

In October 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (“Amway Global”), a subsidiary of Alticor Inc. Pursuant to this Agreement, Amway Global sells the Company’s Inherent Health^® brand of genetic tests through its e-commerce website via a hyperlink to our e-commerce site. We paid Amway Global $452,000 and $543,000 in commissions for each of the six months ended June 30, 2012 and 2011, representing a percentage of net sales to their customers.

Note 6—Convertible Debt

On August 17, 2006, our existing credit facility with Pyxis was amended to provide the Company with access to approximately $14.3 million of additional working capital borrowings at any time prior to August 17, 2008. Any amounts borrowed thereunder bear interest at the prime rate and require quarterly interest payments. This credit facility has been extended several times. Most recently, on June 29, 2012, the date was extended to November 30, 2012.

On April 13, 2012, the Company borrowed the remaining $1,316,255 of available credit, leaving the full amount of $14,316,255 due on November 30, 2012. The fair value of convertible debt is estimated to be approximately $3.1 million at June 30, 2012. The principal amount of borrowings under this credit facility is convertible at Pyxis’ election into 2,521,222 shares of common stock, reflecting a conversion price of $5.6783 per share.

Note 7—Intangible Assets

Intangible assets at June 30, 2012 and December 31, 2011 consisted of the following:

	June 30, 2012			December 31, 2011
Patent costs	$	1,154,523		$	1,154,523
Less — Accumulated amortization		(697,666	)		(639,939	)
Total	$	456,857		$	514,584

Patent amortization was $57,726 for the six months ended June 30, 2012 and 2011, respectively.

Patent costs, which are amortized on a straight-line basis over a 10-year life, are scheduled to amortize as follows:

Year ended December 31,

2012 (remaining six months)		57,725
2013.		109,266
2014.		94,100
2015.		77,656
Thereafter.		118,110
	$	456,857

Note 8—Commitments and Contingencies

Employment Agreements

On February 14, 2011, the Company entered into an employment agreement with Lewis H. Bender, its Chief Executive Officer. The agreement replaced and superseded the employment agreement between the Company and Mr. Bender that expired by its terms on January 22, 2011. The agreement has an initial term of one year and is automatically renewable for successive one year periods unless at least 90 days prior notice is given by either the Company or Mr. Bender. The agreement automatically renewed for a one year period on February 14, 2012. The agreement also provides that Mr. Bender will serve as a member of the Company’s Board of Directors for as long as he serves as the Company’s Chief Executive Officer, subject to any required approval of the Company’s shareholders.

The agreement is terminable by the Company for cause or upon thirty days prior written notice without cause and by Mr. Bender upon thirty days prior written notice for “good reason” (as defined in the agreement) or upon ninety days prior written notice without good reason. If the Company terminates Mr. Bender without cause or Mr. Bender terminates his employment for good reason, then the Company will pay Mr. Bender, in addition to any accrued, but unpaid compensation prior to the termination, an amount equal to six months of his base salary. If the Company terminates Mr. Bender without cause or Mr. Bender terminates his employment with good reason within six months after a “change of control” (as defined in the agreement), then the Company will pay Mr. Bender, in addition to any accrued, but unpaid compensation prior to the termination, an amount equal to twelve months of his base salary, and all unvested stock options will automatically vest.

The agreement also includes non-compete and non-solicitation provisions for a period of six months following the termination of Mr. Bender’s employment with the Company.

On April 25, 2012, the Company executed an amendment, effective as of March 31, 2012, to the Employment Agreement dated as of November 12, 2008 by and between the Company and Kenneth S. Kornman, its President and Chief Scientific Officer to extend the term through November 30, 2012.

Operating Lease

The Company leases its office and laboratory space under a non-cancelable operating lease expiring on March 31, 2014. In May 2010, the Company completed a sublease of approximately 6,000 square feet of underutilized office and laboratory space which successfully reduced our total space operating costs. The sublease expires on March 31, 2013 and has a one year renewal option. Rent expense, net of the benefit of the sublease, was $167,000 and $161,000 for the six months ended June 30, 2012 and 2011, respectively.

Note 9—Capital Stock

Authorized Preferred and Common Stock

At June 30, 2012, the Company had authorized 6,000,000 shares of $0.001 par value preferred stock, of which 5,000,000 shares, designated as Series A-1 Convertible Preferred Stock, were issued and outstanding and 500,000 shares, designated as Series B Convertible Preferred Stock, were issued and outstanding (collectively, the “Preferred Stock”). At June 30, 2012, the Company had authorized 100,000,000 shares of $0.001 par value common stock of which 85,317,885 shares were outstanding or reserved for issuance. Of those, 36,761,864 shares were outstanding; 39,089,161 shares were reserved for the conversion of the outstanding Preferred Stock to common stock; 2,521,222 shares were reserved for the conversion of the $14,316,255 of debt outstanding under the credit facility with Pyxis; 4,358,480 shares were reserved for the potential exercise of authorized and outstanding stock options; 400,000 shares were reserved for the exercise of outstanding warrants to purchase common stock at an exercise price of $2.50 per share which are exercisable currently until the expiration date of August 9, 2012; 1,750,000 shares were reserved for the exercise of outstanding warrants to purchase common stock at an exercise price of $1.30 per share which are exercisable currently until the expiration date of March 5, 2015; and 437,158 shares were reserved for the exercise of outstanding warrants to purchase common stock at an exercise price of $0.2745 per share which are exercisable currently until the expiration date of June 29, 2017.

On August 7, 2012, at the Company’s 2012 annual meeting, the Company’s shareholders approved an amendment to the Company’s Charter affecting an increase in authorized shares of common stock from 100,000,000 to 150,000,000 shares. The Company believes that the availability of additional shares for issuance from time to time in the Board of Directors’ discretion in connection with future financings, investment opportunities, stock splits or dividends, possible acquisitions or for other corporate purposes is desirable in order to avoid repeated separate amendments to the Company’s Charter and the delay and expense incurred in holding special meetings of the stockholders to approve such amendments. The Company currently has no specific understandings, arrangements, or agreements with respect to any financings, investment opportunities, stock splits or dividends, or acquisitions or for any other corporate purposes that would require the Company to issue a material amount of new shares of common stock.

Preferred Stock

On June 29, 2012, the Company entered into an agreement with Pyxis to exchange the 5,000,000 shares of Series A Convertible Preferred Stock held for 5,000,000 shares of Series A-1 Convertible Preferred Stock and filed a new Certficate of Designation, Preferences and Rights of Preferred Stock with the State of Delaware for the Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock. Concurrently therewith, the Company completed a financing with Delta Dental pursuant to which Delta Dental purchased 500,000 shares of Series B Convertible Preferred Stock for gross proceeds of $3,000,000. Each share of Series B Preferred Stock is convertible into approximately 21.86 shares of common stock reflecting a conversion price of $0.2745 per share. Net proceeds to the Company after fees and expenses were approximately $2.75 million. In addition, fully vested warrants to purchase 437,158 shares of common stock at an exercise price of $0.2745 per share were issued to the placement agent in the transaction. These warrants expire in five years. For purposes of determining the fair value of the warrants issued in the Preferred Stock transaction, the Black-Scholes pricing model was used with the following assumptions:

Risk-free interest rate	1	%
Expected life	5 years
Expected volatility	142.36	%
Dividend yield	0	%

Using these assumptions, the fair value of the warrants reflected in the June 30, 2012 Statement of Stockholders’ Deficit is $104,907.

The Preferred Stock accrues dividends at the rate of 8% of the original purchase price per year, payable only when, as and if declared by the Board of Directors and are non-cumulative. To date, no dividends have been declared on these shares. If the Company declares a distribution, with certain exceptions, payable in securities of other persons, evidences of indebtedness issued by the Company or other persons, assets (excluding cash dividends) or options or rights to purchase any such securities or evidences of indebtedness, then, in each such case the holders of the Preferred Stock shall be entitled to a proportionate share of any such distribution as though the holders of the Preferred Stock were the holders of the number of shares of common stock into which their respective shares of Preferred Stock are convertible as of the record date fixed for the determination of the holders of common stock entitled to receive such distribution.

In the event of any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, the holders of the Preferred Stock shall be entitled to receive on a pari passu basis, prior and in preference to any distribution of any of the Company’s assets or surplus funds to the holders of its common stock by reason of their ownership thereof, the amount of two times the then-effective purchase price per share, as adjusted for any stock dividends, combinations or splits with respect to such shares, plus all declared but unpaid dividends on such shares for each share of Preferred Stock then held by them. The liquidation preference at June 30, 2012 was $24,000,000, reflecting a liquidation preference of $18,000,000 for the Series A-1 Convertible Preferred Stock and $6,000,000 for the Series B Convertible Preferred Stock. After receiving this amount, the holders of the Preferred Stock are entitled to participate on an as-converted basis with the holders of common stock in any of the remaining assets.

Each share of Series A-1 Preferred Stock is convertible at any time at the option of the holder into a number of shares of the Company’s common stock determined by dividing the then-effective purchase price ($1.80, and subject to further adjustment) by the conversion price in effect on the date the certificate is surrendered for conversion. As of June 30, 2012, the Series A-1 Preferred Stock was convertible into 28,160,200 shares of common stock reflecting a current conversion price of $0.3196 per share. Each share of Series B Preferred Stock is convertible at any time at the option of the holder into a number of shares of the Company’s common stock determined by dividing the then-effective purchase price ($6.00, and subject to further adjustment) by the conversion price in effect on the date the certificate is surrendered for conversion. As of June 30, 2012, the Series B Preferred Stock was convertible into 10,928,961 shares of common stock reflecting a current conversion price of $0.2745 per share.

Each holder of Preferred Stock is entitled to vote its shares of Preferred Stock on an as-converted basis with the holders of common stock as a single class on all matters submitted to a vote of the stockholders, except as otherwise required by applicable law. This means that each share of Preferred Stock will be entitled to a number of votes equal to the number of shares of common stock into which it is convertible on the applicable record date.

Note 10—Stock-Based Compensation Arrangements

Total compensation cost that has been charged against income for stock-based compensation arrangements is as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2012		2011		2012		2011
Stock option grants beginning of period	$	48,185	$	44,949	$	94,796	$	73,600
Stock-based arrangements during the period:
Stock option grants		3		14,092		3		54,511
Restricted stock issued:
Employee stock purchase plan		169		1,450		1,332		2,855
	$	48,357	$	60,491	$	96,131	$	130,966

Stock option and restricted stock grants

The following table details stock option and restricted stock activity for the six months ended June 30, 2012 and 2011:

	Six Months Ended June 30, 2012					Six Months Ended June 30, 2011
	Shares			Weighted Avg. Exercise Price		Shares			Weighted Avg. Exercise Price
Outstanding, beginning of period		2,228,067		$	1.14		1,611,267		$	1.54
Granted		500			0.34		781,000			0.35
Exercised		(2,500	)		0.00		(2,500	)		0.00
Canceled/Expired		(125,800	)		0.59		(172,500	)		1.18
Outstanding, end of period		2,100,267		$	1.17		2,217,267		$	1.15
Exercisable, end of period		1,393,217		$	1.50		1,086,967		$	1.75

During the six month period ended June 30, 2012, the Company granted stock options under the 2004 Employee, Director & Consultant Stock Plan. At June 30, 2012, the Company had an aggregate of 2,258,213 shares of Common Stock available for grant under this plan.

It is the Company’s policy to grant stock options with an exercise price equal to the fair market value of the Company’s common stock at the grant date, and stock options to employees generally vest over four years based upon continuous service. Historically, the majority of the Company’s stock options have been granted in connection with the employee’s start date with the Company. In addition, the Company may grant stock options in recognition of promotion and/or performance.

Employee Stock Purchase Plan

Purchases made under the Company’s Employee Stock Purchase Plan are deemed to be compensatory because employees may purchase stock at a price equal to 85% of the fair market value of the Company’s common stock on either the first day or the last day of a calendar quarter, whichever is lower. The Company’s Employee Stock Purchase plan is authorized to issue 500,000 shares. On March 31, 2012, there were 5,631 shares in the plan reserved for issuance. During the three months ended June 30, 2012, 5,628 shares were issued and the remaining shares were cancelled with the termination of the plan. At the Company’s 2012 annual meeting on August 7, 2012, the Company’s stockholders approved a new Employee Stock Purchase Plan, pursuant to which 750,000 shares of common stock are authorized to be issued. During the six months ended June 30, 2012 and 2011, employees purchased 52,158 and 64,134 shares, respectively, of common stock at a weighted-average purchase price of $0.17 and $0.26, respectively, while the weighted-average fair value was $0.20 and $0.31 per share, respectively, resulting in compensation expense of $1,332 and $2,855, respectively.

Restricted Stock Awards

Holders of restricted stock awards participate fully in the rewards of stock ownership of the Company, including voting and dividend rights. Recipients of restricted stock awards are generally not required to pay any consideration to the Company for these restricted stock awards. The Company measures the fair value of the shares based on the last reported price at which the Company’s common stock traded on the date of the grant and compensation cost is recognized over the remaining service period. During each of the six months ended June 30, 2012 and 2011, the Company granted no restricted stock awards.

At June 30, 2012, there was approximately $217,000 of total unrecognized compensation related to non-vested share-based compensation arrangements granted under the Company’s stock plans.

Note 11—Industry Risk and Concentration

The Company develops genetic risk assessment tests and performs research for its own benefit. As of June 30, 2012, the Company has introduced four genetic risk assessment tests commercially. Commercial success of the Company’s genetic risk assessment tests will depend on their success at being deemed to be scientifically credible and cost-effective by consumers and the marketing success of the Company and its collaborative partner.

Research in the field of disease predisposing genes and genetic markers is intense and highly competitive. The Company has many competitors in the United States and abroad that have considerably greater financial, technical, marketing, and other resources available. If the Company does not discover disease predisposing genes or genetic markers and develop risk assessment tests and launch such services or products before its competitors, then the potential for significant revenues may be reduced or eliminated.

During the six months ended June 30, 2012, approximately 63% of our revenue came from sales through our Merchant Network and Channel Partner Agreement with Amway Global, a subsidiary of Alticor.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction with the unaudited condensed financial statements and the notes thereto included elsewhere in this document.

General Overview and Trends

Interleukin Genetics, Inc. is a personalized health company that develops specific, health area focused, unique genetic tests. Our overall mission is to provide test products that can help individuals improve or maintain their health through preventive measures or lifestyle changes. Our vision is to use the science of applied genetics to empower individuals and physicians to better understand the set of actions and steps necessary to guide the best lifestyle and treatment options. We believe that the science of applied genetics can help companies provide improved services to their consumers, and assist in improving outcomes in drug development and use.

During the three months ended June 30, 2012, we continued to focus our resources on conducting the large Periodontal Disease Prevention Study, PDPS, with the University of Michigan and Renaissance Health Services Corporation and the sales of our Inherent Health® brand of genetic tests and related programs. The objective of the PDPS is to improve dental care by identifying and using certain risk factors, including genetic risk factors as determined by our PST genetic test, to set preventative treatment regimens. In December 2011 we entered into an agreement with Renaissance Health Services Corporation to initiate a pilot program to determine the feasibility of marketing the PST genetic test to employees through their dental benefit package. On January 1, 2012, the test was offered to select dental group employees affiliated with Renaissance. On March 28, 2012, we jointly announced with the University of Michigan that the PDPS had been fully enrolled with approximately 5,400 consenting adults. On August 6, 2012 we announced that we had received top line preliminary results from the PDPS. The results indicate that in Low Risk patients, there was no significant difference between two dental preventive visits per year and one preventive visit per year in reducing the percentage of patients who had tooth extractions over the 16 year monitoring period; 13.8% versus 16.4% (p=.092 n.s.). In addition, results indicate that in High Risk patients, two preventive visits per year significantly reduced the percentage of patients who had extractions over a 16 year monitoring period compared to one preventive visit per year; 16.9% vs. 22.1% (p=0.002). There was also a positive relationship between number of risk factors and the percentage of patients with extractions (p<0.001). Low Risk patients (47% of the study population) were defined as non-smokers, genetically negative per our PST test and no history of diabetes. High Risk patients were defined as having one or more risk factors, PST positive, diabetes or smoking.

Our Inherent Health brand of genetic tests includes the first-of-its-kind test for weight management that identifies an individual’s genetic tendencies for weight gain related to either fat or carbohydrates in the diet. The brand offers customers a full suite of affordable, easy-to-use and meaningful genetic tests in weight management, heart health, bone health and nutritional needs. In addition, we offer additional products under the name Wellness Select that allows our e-commerce customers to purchase any combination of our Inherent Health® genetic tests at a discounted price.

Sales of our genetic tests are driven primarily by the marketing efforts of Amway Global, related to our Weight Management Genetic Test. In addition, we sell our genetic test kits to commercial distribution partners. Regional weight loss centers have incorporated our weight management genetic test into their weight loss programs. These companies purchase genetic tests in bulk from us and obtain discounted pricing at significant volumes. We plan on continuing to support this sales channel. In addition, we continue to see sales of genetic tests through our Merchant Network and Channel Partner Agreement with Amway Global.

In the genetic test business, competition is in flux and the markets and customer base are not well established. Adoption of new technologies by consumers requires substantial market development and customer education. Historically, we focused on our relationship with our primary customer, Alticor, a significant direct marketing company, in order to assist us in developing the market for our products and educating our potential customers. Our challenge in 2012 and beyond will be to develop the market for our other personalized health products, such as PST. We continue to allocate considerable resources to our PST and Inherent Health^® brands of genetic tests and their related programs. Due to the early stage of these initiatives, we cannot predict with certainty fluctuations we may experience in our genetic test revenues or whether revenues derived from the Merchant Network and Channel Partner Agreement with Amway Global will ever be material or if material, will be sustained in future periods.

Results of Operations

Three Months Ended June 30, 2012 and June 30, 2011

Total revenue for the three months ended June 30, 2012 was $799,000, compared to $797,000 for the three months ended June 30, 2011. Revenue in both periods is primarily attributable to sales of our Inherent Health^®brand of genetic tests through our Merchant Network and Channel Partner Agreement with Amway Global. Genetic testing revenue is derived from tests sold and processed, which is driven by consumer demand.

During the three months ended June 30, 2012, 62% of our sales revenue came through our Merchant Network and Channel Partner Agreement with Amway Global compared to 69% during the three months ended June 30, 2011. Pursuant to this agreement, Amway Global sells our genetic tests through its e-commerce web site via a hyperlink to our e-commerce site.

Cost of revenue for the three months ended June 30, 2012 was $393,000, or 49.2% of revenue, compared to $438,000, or 55.0% of revenue, for the three months ended June 30, 2011. The decrease in the cost of revenue as a percentage of revenue is primarily attributable to more efficient processing of genetic tests. We continue to work with our genetic testing supply vendors to provide more efficient materials that result in a lower cost of production.

Research and development expenses were $317,000 for the three months ended June 30, 2012, compared to $360,000 for the three months ended June 30, 2011. The decrease of $43,000, or 11.9%, in research and development expenses is primarily attributable to decreased consulting costs related to our weight management genetic test partially offset by increased compensation costs.

Selling, general and administrative expenses were $1.2 million for the three months ended June 30, 2012, compared to $1.3 million for the three months ended June 30, 2011. The decrease of $0.1 million, or 6.1%, is primarily attributable to decreased expenses related to lower compensation and sales commissions paid to Amway Global as part of our Merchant Network and Channel Partner Agreement partially offset by increased patent related legal fees, consulting and professional fees.

Interest expense was $115,000 for the three months ended June 30, 2012, as compared to $89,000 for the three months ended June 30, 2011. The increase in interest expense of $26,000 is attributable to higher borrowings on our credit facility with Pyxis.

Six Months Ended June 30, 2012 and June 30, 2011

Total revenue was $1.5 million for the six months ended June 30, 2012 and 2011. Revenue in both periods is primarily attributable to sales of our Inherent Health^®brand of genetic tests through our Merchant Network and Channel Partner Agreement with Amway Global and, to a lesser extent in 2012 only, revenue recognized as part of our PST validation study with the University of Michigan and Renaissance Health Services Corporation.

During the six months ended June 30, 2012, 63% of our sales revenue came through our Merchant Network and Channel Partner Agreement with Amway Global compared to 67% during the six months ended June 30, 2011.

Cost of revenue for the six months ended June 30, 2012 was $769,000 or 52.1% of revenue, compared to $796,000, or 52.5% of revenue, for the six months ended June 30, 2011.

Research and development expenses were $764,000 for the six months ended June 30, 2012, compared to $665,000 for the six months ended June 30, 2011. The increase of $99,000 or 14.9%, in research and development expenses is primarily attributable to increased compensation and clinical study costs partially offset by decreased consulting expenses.

Selling, general and administrative expenses were $2.3 million for the six months ended June 30, 2012, compared to $2.5 million for the six months ended June 30, 2011. The decrease of $143,000, or 5.8%, is primarily attributable to decreased compensation, promotional and insurance costs and sales commissions paid to Amway Global as part of our Merchant Network and Channel Partner Agreement expenses partially offset by increased patent related legal fees, consulting and corporate professional fees.

Interest expense was $220,000 for the six months ended June 30, 2012, as compared to $177,000 for the six months ended June 30, 2011. The increase in interest expense of $43,000 is attributable to higher borrowings on our credit facility with Pyxis.

Liquidity and Capital Resources

As of June 30, 2012, we had cash and cash equivalents of $3.8 million. On April 13, 2012, we elected to draw down the remaining $1,316,255 available under our existing convertible credit facility. After taking into account the April 13, 2012 draw down, we have no remaining availability to borrow under the credit facility. On June 29, 2012, the due date of the credit facility was extended from June 30, 2012 to November 30, 2012. The aggregate principal amount of $14,316,255, plus interest, is due and payable in full on November 30, 2012.

Cash used in operations was $2.2 million for the six months ended June 30, 2012, as compared to $2.3 million for the six months ended June 30, 2011. Cash used in operations is primarily impacted by operating results and changes in working capital, particularly the timing of the collection of receivables, inventory levels, receipt of orders and the timing of payments to suppliers. Cash received from genetic test sales, which is reflected in deferred revenue until the test report is issued, increased by $146,000 to $971,000 during the six months ended June 30, 2012.

Cash used in investing activities was $5,000 for the six months ended June 30, 2012, compared to $1,681 for the six months ended June 30, 2011 and consisted of capital additions. We believe that based on current and projected volumes, our laboratory equipment is sufficient to process genetic tests and no additional material capital purchases will be needed in the foreseeable future.

Cash provided by financing activities was $4.3 million for the six months ended June 30, 2012 compared to $16,965 for the six months ended June 30, 2011. On April 13, 2012, we received $1.3 million in proceeds from the issuance of a note payable under our credit facility with Pyxis. We received no proceeds from this facility during the six months ended June 30, 2011. On June 29, 2012, we completed a financing with Delta Dental of Michigan, Inc. pursuant to which Delta Dental purchased 500,000 shares of Series B Convertible Preferred Stock for gross proceeds of $3,000,000. Each share of Series B Preferred Stock is convertible into approximately 21.86 shares of common stock reflecting a conversion price of $0.2745 per share. Net proceeds to the Company after fees and expenses were approximately $2.75 million. We received $8,810 from stock purchases through the employee stock purchase plan during the six months ending June 30, 2012 compared to $16,965 for the six months ended June 30, 2011.

The amount of cash we generate from operations is not sufficient to continue to fund and grow our business. We believe our success depends on our ability to have sufficient capital and liquidity to achieve our objectives of closing negotiations with partners and creating additional distribution channels for our genetic testing products and technology. In addition to extending our current operating line of credit we will need to raise additional capital. Even though we have historically experienced sales increases in our genetic testing business we continue to explore additional steps to reduce our operating costs. We are able to process high volumes of genetic tests in our current laboratory. We continue to reduce our cost of processing samples in our laboratory by working with our raw material vendors to make our genetic testing process more efficient resulting in lower processing costs. We have significantly reduced our research and development programs to only those that focus on technology related to agreements with potential commercial partners. We have taken steps to reduce our corporate administrative expenses by working with or seeking new vendors who offer the same service for a lower cost.

Our financial statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We expect to incur further losses in the development of our business and have been dependent on funding operations through the issuance of convertible debt and the sale of equity securities. These conditions raise substantial doubt about our ability to continue as a going concern. Management’s plans include continuing to finance operations through the private or public placement of debt and/or equity securities, increasing revenue through new arrangements with commercial distribution partners and the reduction of expenditures. However, no assurance can be given at this time as to whether we will be able to achieve these objectives. The financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

We expect that our current and anticipated financial resources, including the $1.3 million borrowed on April 13, 2012 under our credit facility with Pyxis and the $2.75 million in net proceeds from the sale of Series B Convertible Preferred Stock on June 29, 2012 are adequate to maintain current and planned operations at least through November 30, 2012, however, if we are not successful in additional capital raising efforts, partnering negotiations, extending the due date of our debt or in generating additional revenues, we will not be able to fund operations beyond such date. However, if the due date of the debt is extended beyond November 30, 2012, we have sufficient cash flows to fund operations through January 31, 2013. We continue to attempt to raise additional capital, seek additional streams of revenue, extend the due date of our debt and improve sales with new and existing channels. Our common stock was delisted from the NYSE Amex in 2010 and is currently trading on the OTCQB™. As a result, our access to capital through the public markets may be limited.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements. The preparation of these financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires us to (i) make judgments, assumptions and estimates that affect the reported amounts of assets, liabilities, revenue and expenses; and (ii) disclose contingent assets and liabilities. A critical accounting estimate is an assumption that could have a material effect on our financial statements if another, also reasonable, amount were used or a change in the estimates is reasonably likely from period to period. We base our accounting estimates on historical experience and other factors that we consider reasonable under the circumstances. However, actual results may differ from these estimates. To the extent there are material differences between our estimates and the actual results, our future financial condition and results of operations will be affected. Our most critical accounting policies and estimates upon which our financial condition depends, and which involve the most complex or subjective decisions or assessments are set forth in Note 4 to our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2011. There have been no significant changes in our accounting policies or changes from the methodology applied by management for critical accounting estimates previously disclosed in our most recent Annual Report on Form 10-K.

Recent Accounting Pronouncements

Please see the discussion of “Recent Accounting Pronouncements” in Note 4; Significant Accounting Policies contained in the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2011. No new updates or other guidance issued to date by the FASB in 2012 are expected to have a material impact on the Company’s financial statements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

As a smaller reporting company, we have elected scaled disclosure reporting obligations and therefore are not required to provide the information required by this Item 3.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures. Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15(d)-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q, have concluded that, based on such evaluation, our disclosure controls and procedures were adequate and effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

(b) Changes in Internal Control Over Financial Reporting. No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15(d)-15(f)) occurred during the quarter ended June 30, 2012 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

Not applicable.

Item 1A. Risk Factors

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2011. which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K are not the only risks that we face. In addition, risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. There have been no material changes in or additions to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2011.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q and, in particular, our Management’s Discussion and Analysis of Financial Condition and Results of Operations set forth in Part I – Item 2 contain or incorporate a number of forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. Any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be wrong. They can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Many factors mentioned in our discussion in this Quarterly Report on Form 10-Q will be important in determining future results. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially.

Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects” and similar expressions are intended to identify forward-looking statements. There are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements, many of which are beyond our control, including the factors set forth under “Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2011 and under “Item 1A. Risk Factors” above in this Quarterly Report on Form 10-Q. In addition, the forward-looking statements contained herein represent our estimates and expectations only as of the date of this filing and should not be relied upon as representing our estimates and expectations as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Please refer to the Current Report on Form 8-K filed by us with the SEC on July 2, 2012.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4 Mine Safety Disclosures

Not applicable.

Item 5. Other Information.

Not applicable.

Item 6. Exhibits.

Exhibit Number		Exhibit
3.1		Certificate of Incorporation of the Company, as filed with the Delaware Secretary of State on March 28, 2000 (incorporated herein by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q filed August 14, 2000)
3.2		Certificate of Designations, Preferences and Rights of Series A Preferred Stock, as filed with the Delaware Secretary of State on March 5, 2003 (incorporated herein by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed on March 5, 2003)
3.3		Certificate of Amendment to Certificate of Incorporation, as filed with the Delaware Secretary of State on August 5, 2003 (incorporated herein by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q filed on November 12, 2003)
3.4		Certificate of Amendment to Certificate of Incorporation, as filed with the Delaware Secretary of State on June 21, 2007 (incorporated herein by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q filed on August 9, 2007)
3.5		Corrected Certificate of Amendment filed with the Delaware Secretary of State on June 29, 2012 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on July 2, 2012 (File No. 001-32715)).
3.6		Certificate of of Elimination of the Series A Preferred Stock filed with the Delaware Secretary of State on June 29, 2012 (incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K filed on July 2, 2012 (File No. 001-32715)).
3.7		Certificate of Designations, Preferences, and Rights of Series A-1 Preferred Stock and Series B Preferred Stock filed with the Delaware Secretary of State on June 29, 2012 (incorporated by reference to Exhibit 3.3 of the Current Report on Form 8-K filed on July 2, 2012 (File No. 001-32715)).
4.1		Form of Amended and Restated Promissory Note under credit facility with Pyxis Innovations Inc. (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed on July 2, 2012 (File No. 001-32715)).
10.1		First Amendment, effective as of March 31, 2012, to the Employment Agreement, dated as of November 12, 2008, by and between Interleukin Genetics, Inc. and Kenneth S. Kornman (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed on April 26, 2012 (File No. 001-32715)).
10.2		Exchange Agreement, dated June 29, 2012, between Interleukin and Pyxis Innovations Inc. (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed on July 2, 2012 (File No. 001-32715)).
10.3		Stock Purchase Agreement, dated June 29, between Interleukin and Delta Dental Plan of Michigan, Inc. (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed on July 2, 2012 (File No. 001-32715)).
10.4		Registration Rights Agreement, dated June 29, between Interleukin and Delta Dental Plan of Michigan, Inc. (incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K filed on July 2, 2012 (File No. 001-32715)).
10.5		Fourth Amendment, dated June 29, 2012, to the Amended and Restated Note Purchase Agreement, dated March 11, 2009, between Interleukin and Pyxis Innovations Inc. (incorporated by reference to Exhibit 10.4 of the Current Report on Form 8-K filed on July 2, 2012 (File No. 001-32715)).

10.6		Third Amendment, dated June 29, 2012, to the Stock Purchase Agreement, dated March 3, 2003, between Interleukin and Pyxis Innovations Inc. (incorporated by reference to Exhibit 10.5 of the Current Report on Form 8-K filed on July 2, 2012 (File No. 001-32715)).
31.1		Certification by Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification by Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101*		The following materials from Interleukin Genetics, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2012, formatted in XBRL (eXtensible Business Reporting Language): (i) the Unaudited Condensed Balance Sheets, (ii) the Unaudited Condensed Statements of Operations, (iii) the Unaudited Condensed Statements of Stockholders’ Equity (Deficit), (iv) the Unaudited Condensed Statements of Cash Flows, and (v) Notes to Unaudited Condensed Financial Statements, tagged as blocks of text.

Users of the XBRL data are advised pursuant to Rule 406T of Regulation S-T that this interactive data file is deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

3.1		Certificate of Incorporation of the Company, as filed with the Delaware Secretary of State on March 28, 2000 (incorporated herein by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q filed August 14, 2000)
3.2		Certificate of Designations, Preferences and Rights of Series A Preferred Stock, as filed with the Delaware Secretary of State on March 5, 2003 (incorporated herein by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed on March 5, 2003)
3.3		Certificate of Amendment to Certificate of Incorporation, as filed with the Delaware Secretary of State on August 5, 2003 (incorporated herein by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q filed on November 12, 2003)
3.4		Certificate of Amendment to Certificate of Incorporation, as filed with the Delaware Secretary of State on June 21, 2007 (incorporated herein by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q filed on August 9, 2007)
3.5		Corrected Certificate of Amendment filed with the Delaware Secretary of State on June 29, 2012 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on July 2, 2012 (File No. 001-32715)).
3.6		Certificate of of Elimination of the Series A Preferred Stock filed with the Delaware Secretary of State on June 29, 2012 (incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K filed on July 2, 2012 (File No. 001-32715)).
3.7		Certificate of Designations, Preferences, and Rights of Series A-1 Preferred Stock and Series B Preferred Stock filed with the Delaware Secretary of State on June 29, 2012 (incorporated by reference to Exhibit 3.3 of the Current Report on Form 8-K filed on July 2, 2012 (File No. 001-32715)).
4.1		Form of Amended and Restated Promissory Note under credit facility with Pyxis Innovations Inc. (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed on July 2, 2012 (File No. 001-32715)).
10.1		First Amendment, effective as of March 31, 2012, to the Employment Agreement, dated as of November 12, 2008, by and between Interleukin Genetics, Inc. and Kenneth S. Kornman (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed on April 26, 2012 (File No. 001-32715)).
10.2		Exchange Agreement, dated June 29, 2012, between Interleukin and Pyxis Innovations Inc. (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed on July 2, 2012 (File No. 001-32715)).
10.3		Stock Purchase Agreement, dated June 29, between Interleukin and Delta Dental Plan of Michigan, Inc. (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed on July 2, 2012 (File No. 001-32715)).
10.4		Registration Rights Agreement, dated June 29, between Interleukin and Delta Dental Plan of Michigan, Inc. (incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K filed on July 2, 2012 (File No. 001-32715)).

10.5		Fourth Amendment, dated June 29, 2012, to the Amended and Restated Note Purchase Agreement, dated March 11, 2009, between Interleukin and Pyxis Innovations Inc. (incorporated by reference to Exhibit 10.4 of the Current Report on Form 8-K filed on July 2, 2012 (File No. 001-32715)).
10.6		Third Amendment, dated June 29, 2012, to the Stock Purchase Agreement, dated March 3, 2003, between Interleukin and Pyxis Innovations Inc. (incorporated by reference to Exhibit 10.5 of the Current Report on Form 8-K filed on July 2, 2012 (File No. 001-32715)).
31.1		Certification by Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification by Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101*		The following materials from Interleukin Genetics, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2012, formatted in XBRL (eXtensible Business Reporting Language): (i) the Unaudited Condensed Balance Sheets, (ii) the Unaudited Condensed Statements of Operations, (iii) the Unaudited Condensed Statements of Stockholders' Equity (Deficit), (iv) the Unaudited Condensed Statements of Cash Flows, and (v) Notes to Unaudited Condensed Financial Statements, tagged as blocks of text.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Interleukin Genetics, Inc.

Date: August 14, 2012	By:	/s/ Lewis H. Bender
		Lewis H. Bender
		Chief Executive Officer
		(Principal Executive Officer)

Date: August 14, 2012	By:	/s/ Eliot M. Lurier
		Eliot M. Lurier
		Chief Financial Officer
		(Principal Financial Officer)

EX-31.1 2 v318596_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
SECTION 302 OF
SARBANES-OXLEY ACT OF 2002

I, Lewis H. Bender, certify that:

I have reviewed this quarterly report on Form 10-Q of Interleukin Genetics, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2012	/s/ Lewis H. Bender
	Lewis H. Bender
	Chief Executive Officer

EX-31.2 3 v318596_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO
SECTION 302 OF
SARBANES-OXLEY ACT OF 2002

I, Eliot M. Lurier, certify that:

I have reviewed this quarterly report on Form 10-Q of Interleukin Genetics, Inc.;

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2012	/s/ Eliot M. Lurier
	Eliot M. Lurier
	Chief Financial Officer

EX-32.1 4 v318596_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(SUBSECTIONS (A) AND (B) OF SECTION 1350, CHAPTER 63 OF TITLE 18,
UNITED STATES CODE)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18 United States Code), each of the undersigned officers of Interleukin Genetics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 14, 2012	/s/ Lewis H. Bender
	Lewis H. Bender
	Chief Executive Officer

Date: August 14, 2012	/s/ Eliot M. Lurier
	Eliot M. Lurier
	Chief Financial Officer

EX-101.INS 5 iliu-20120630.xml XBRL INSTANCE DOCUMENT

14300000

36761864

150000000

750000 6000

5000000

437158 P5Y 0.2745

500000

0.2745

5000000

1086967

-8978143

1.75

1.15

1713976

2217267

5000

5000000

36659

36658933

-100019377

90999575

14316255

30500000

38001

77656

1393217

-11212830

456857

1154523

100000000

1.50

36761864

569108

243596

109266

970943

6000000

-105221121

4878257

1.17

31238

88368

0.001

4878257

3831625

36761864

456857

234781

83895

94100

16091087

970943

2100267

36762

0.001

697666

4199743

4473

5500000

57725

5500000

5500

183656

93966029

24000000

4916

39089161 4358480 500000 5631 118110 85317885 4

5.6783

14316255

3100000

2521222 2521222

2258213

5500

5500000

36762

36761864

-105221121

93966029

400000 2012-08-09 2.50 1750000 2015-03-05 1.30 437158 2017-06-29 0.2745

500000

6000000

10928961 0.2745

5000000

18000000

28160200 0.3196

-6658096

1.54

3999029

1611267

5000

5000000

36594

36594799

-97551399

90851709

13000000

38001

-11423231

1154523

100000000

36709706

369306

217387

824845

6000000

-102576581

2953517

1.14

55892

107758

0.001

2953517

1728222

36709706

514584

182597

100433

14376748

824845

2228067

36710

0.001

639939

2111921

7325

5000000

5000

289011

91111640

2662

5000

5000000

36710

36709706

-102576581

91111640

-2457645

-46602

0.26

-2626344

4275

130966

-5875

130966

0.35

1.18

-0.07

2500

99757

202897

2855

-2300337

0.00

-1681

4307

16965

246424

0.00

158366

1681

-7306

64134

1498563

30390

-2626344

664618

16965

796053

3177942

-0.07

-20509

161000

172500

1516350

720297

543000

17787

178260

543000

36634173

34464667

-2467978

-168699

2455598

-117946

781000

57726

-217417

177281

0.31

64134

-2467978

130966

16900

2855

54511

73600

28160200

2150000

1937200

2217267

ILIU INTERLEUKIN GENETICS INC false Smaller Reporting Company Q2 2012 10-Q 2012-06-30 0001037649 --12-31

<div style="FONT: 10pt Times New Roman, Times, Serif"> Note 9—Capital Stock   Authorized Preferred and Common Stock   At June 30, 2012, the Company had authorized 6,000,000 shares of $0.001 par value preferred stock, of which 5,000,000 shares, designated as Series A-1 Convertible Preferred Stock, were issued and outstanding and 500,000 shares, designated as Series B Convertible Preferred Stock, were issued and outstanding (collectively, the “Preferred Stock”). At June 30, 2012, the Company had authorized 100,000,000 shares of $0.001 par value common stock of which 85,317,885 shares were outstanding or reserved for issuance. Of those, 36,761,864 shares were outstanding; 39,089,161 shares were reserved for the conversion of the outstanding Preferred Stock to common stock; 2,521,222 shares were reserved for the conversion of the $14,316,255 of debt outstanding under the credit facility with Pyxis; 4,358,480 shares were reserved for the potential exercise of authorized and outstanding stock options; 400,000 shares were reserved for the exercise of outstanding warrants to purchase common stock at an exercise price of $2.50 per share which are exercisable currently until the expiration date of August 9, 2012; 1,750,000 shares were reserved for the exercise of outstanding warrants to purchase common stock at an exercise price of $1.30 per share which are exercisable currently until the expiration date of March 5, 2015; and 437,158 shares were reserved for the exercise of outstanding warrants to purchase common stock at an exercise price of $0.2745 per share which are exercisable currently until the expiration date of June 29, 2017.   On August 7, 2012, at the Company’s 2012 annual meeting, the Company’s shareholders approved an amendment to the Company’s Charter affecting an increase in authorized shares of common stock from 100,000,000 to 150,000,000 shares. The Company believes that the availability of additional shares for issuance from time to time in the Board of Directors’ discretion in connection with future financings, investment opportunities, stock splits or dividends, possible acquisitions or for other corporate purposes is desirable in order to avoid repeated separate amendments to the Company’s Charter and the delay and expense incurred in holding special meetings of the stockholders to approve such amendments. The Company currently has no specific understandings, arrangements, or agreements with respect to any financings, investment opportunities, stock splits or dividends, or acquisitions or for any other corporate purposes that would require the Company to issue a material amount of new shares of common stock.   Preferred Stock   On June 29, 2012, the Company entered into an agreement with Pyxis to exchange the 5,000,000 shares of Series A Convertible Preferred Stock held for 5,000,000 shares of Series A-1 Convertible Preferred Stock and filed a new Certficate of Designation, Preferences and Rights of Preferred Stock with the State of Delaware for the Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock. Concurrently therewith, the Company completed a financing with Delta Dental pursuant to which Delta Dental purchased 500,000 shares of Series B Convertible Preferred Stock for gross proceeds of $3,000,000. Each share of Series B Preferred Stock is convertible into approximately 21.86 shares of common stock reflecting a conversion price of $0.2745 per share. Net proceeds to the Company after fees and expenses were approximately $2.75 million. In addition, fully vested warrants to purchase 437,158 shares of common stock at an exercise price of $0.2745 per share were issued to the placement agent in the transaction. These warrants expire in five years. For purposes of determining the fair value of the warrants issued in the Preferred Stock transaction, the Black-Scholes pricing model was used with the following assumptions:     <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.25in" cellspacing="0" cellpadding="0"> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 87%">Risk-free interest rate</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%" nowrap="nowrap">1</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">%</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Expected life</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right" nowrap="nowrap">5 years</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Expected volatility</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right" nowrap="nowrap">142.36</td> <td style="TEXT-ALIGN: left">%</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Dividend yield</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right" nowrap="nowrap">0</td> <td style="TEXT-ALIGN: left">%</td> </tr> </table>   Using these assumptions, the fair value of the warrants reflected in the June 30, 2012 Statement of Stockholders’ Deficit is $104,907.   The Preferred Stock accrues dividends at the rate of 8% of the original purchase price per year, payable only when, as and if declared by the Board of Directors and are non-cumulative. To date, no dividends have been declared on these shares. If the Company declares a distribution, with certain exceptions, payable in securities of other persons, evidences of indebtedness issued by the Company or other persons, assets (excluding cash dividends) or options or rights to purchase any such securities or evidences of indebtedness, then, in each such case the holders of the Preferred Stock shall be entitled to a proportionate share of any such distribution as though the holders of the Preferred Stock were the holders of the number of shares of common stock into which their respective shares of Preferred Stock are convertible as of the record date fixed for the determination of the holders of common stock entitled to receive such distribution.   In the event of any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, the holders of the Preferred Stock shall be entitled to receive on a pari passu basis, prior and in preference to any distribution of any of the Company’s assets or surplus funds to the holders of its common stock by reason of their ownership thereof, the amount of two times the then-effective purchase price per share, as adjusted for any stock dividends, combinations or splits with respect to such shares, plus all declared but unpaid dividends on such shares for each share of Preferred Stock then held by them. The liquidation preference at June 30, 2012 was $24,000,000, reflecting a liquidation preference of $18,000,000 for the Series A-1 Convertible Preferred Stock and $6,000,000 for the Series B Convertible Preferred Stock. After receiving this amount, the holders of the Preferred Stock are entitled to participate on an as-converted basis with the holders of common stock in any of the remaining assets.   Each share of Series A-1 Preferred Stock is convertible at any time at the option of the holder into a number of shares of the Company’s common stock determined by dividing the then-effective purchase price ($1.80, and subject to further adjustment) by the conversion price in effect on the date the certificate is surrendered for conversion. As of June 30, 2012, the Series A-1 Preferred Stock was convertible into 28,160,200 shares of common stock reflecting a current conversion price of $0.3196 per share. Each share of Series B Preferred Stock is convertible at any time at the option of the holder into a number of shares of the Company’s common stock determined by dividing the then-effective purchase price ($6.00, and subject to further adjustment) by the conversion price in effect on the date the certificate is surrendered for conversion. As of June 30, 2012, the Series B Preferred Stock was convertible into 10,928,961 shares of common stock reflecting a current conversion price of $0.2745 per share.   Each holder of Preferred Stock is entitled to vote its shares of Preferred Stock on an as-converted basis with the holders of common stock as a single class on all matters submitted to a vote of the stockholders, except as otherwise required by applicable law. This means that each share of Preferred Stock will be entitled to a number of votes equal to the number of shares of common stock into which it is convertible on the applicable record date. </div>

-2426213

<div style="FONT: 10pt Times New Roman, Times, Serif"> Revenue Recognition   Revenue from genetic testing services is recognized when there is persuasive evidence of an arrangement, service has been rendered, the sales price is determinable and collectability is reasonably assured. Service is deemed to be rendered when the results have been reported to the individual who ordered the test. To the extent that tests have been prepaid but results have not yet been reported, recognition of all related revenue is deferred. As of June 30, 2012 and December 31, 2011, the Company has deferred genetic test revenue of $970,943 and $824,845, respectively. </div>

-10198

0.01

<div style="FONT: 10pt Times New Roman, Times, Serif"> Inventory   Inventory is carried at lower of cost or market and no inventory reserve is deemed necessary at June 30, 2012. As the Company does not manufacture any products, no overhead costs are included in inventory. When a kit is sold, the corresponding cost of the kit is recorded as cost of goods sold and removed from inventory.   Inventory consisted of the following at June 30, 2012 and December 31, 2011:   <table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.25in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">June 30, 2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">December 31, 2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold"> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt; WIDTH: 74%"> Raw materials</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">83,895</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">100,433</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Finished goods</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 4,473</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 7,325</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Total inventory</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 88,368</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 107,758</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> </div>

104907

0.17

-2644540

96131

<div style="FONT: 10pt Times New Roman, Times, Serif"> Cash and Cash Equivalents   The Company maintains its cash and cash equivalents with domestic financial institutions that the Company believes to be of high credit standing. Cash and cash equivalents are available on demand and at times may be in excess of FDIC insurance limits. The Company believes that, as of June 30, 2012, its concentration of credit risk related to cash and cash equivalents was not significant. </div>

96131

0.34

0.85

0.08

0.59

-0.07

2500

<div style="FONT: 10pt Times New Roman, Times, Serif"> Note 11—Industry Risk and Concentration   The Company develops genetic risk assessment tests and performs research for its own benefit. As of June 30, 2012, the Company has introduced four genetic risk assessment tests commercially. Commercial success of the Company’s genetic risk assessment tests will depend on their success at being deemed to be scientifically credible and cost-effective by consumers and the marketing success of the Company and its collaborative partner.   Research in the field of disease predisposing genes and genetic markers is intense and highly competitive. The Company has many competitors in the United States and abroad that have considerably greater financial, technical, marketing, and other resources available. If the Company does not discover disease predisposing genes or genetic markers and develop risk assessment tests and launch such services or products before its competitors, then the potential for significant revenues may be reduced or eliminated.   During the six months ended June 30, 2012, approximately 63% of our revenue came from sales through our Merchant Network and Channel Partner Agreement with Amway Global, a subsidiary of Alticor. </div>

2254

<div style="FONT: 10pt Times New Roman, Times, Serif"> Note 1—Basis of Presentation   Interleukin Genetics, Inc. (“the Company”) develops genetic tests for sale into the emerging personalized health market and performs testing services that can help individuals improve and maintain their health through preventive measures. The Company’s principal operations and markets are located in the United States.   The accompanying condensed financial statements include the accounts of the Company as of June 30, 2012 and December 31, 2011 and for the three and six months ended June 30, 2012 and 2011.   The financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America for interim financial reporting. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles for complete financial statements. These unaudited condensed financial statements, which, in the opinion of management, reflect all adjustments (including normal recurring adjustments) necessary for a fair presentation, should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. Operating results are not necessarily indicative of the results that may be expected for any future interim period or for the entire fiscal year.   For information regarding our critical accounting policies and estimates, please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Estimates” contained in our Annual Report on Form 10-K for the year ended December 31, 2011 and Note 4 to our condensed financial statements contained herein. </div>

<div style="FONT: 10pt Times New Roman, Times, Serif"> Note 7—Intangible Assets   Intangible assets at June 30, 2012 and December 31, 2011 consisted of the following:   <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">June 30, 2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">December 31, 2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -10pt; PADDING-LEFT: 20pt; WIDTH: 74%"> Patent costs</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">1,154,523</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">1,154,523</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -10pt; PADDING-LEFT: 20pt"> Less — Accumulated amortization</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (697,666</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (639,939</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Total</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 456,857</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 514,584</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table>   Patent amortization was $57,726 for the six months ended June 30, 2012 and 2011, respectively.   Patent costs, which are amortized on a straight-line basis over a 10-year life, are scheduled to amortize as follows:     <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Year ended December 31, </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-INDENT: 9pt; PADDING-LEFT: 0px; WIDTH: 87%">2012 (remaining six months)</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%">57,725</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-INDENT: 9pt; PADDING-LEFT: 0px">2013.</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">109,266</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-INDENT: 9pt; PADDING-LEFT: 0px">2014.</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">94,100</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-INDENT: 9pt; PADDING-LEFT: 0px">2015.</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">77,656</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-INDENT: 9pt; PADDING-LEFT: 0px">Thereafter.</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 118,110</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 456,857</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> </div>

168082

1332

<div style="FONT: 10pt Times New Roman, Times, Serif"> For purposes of determining the fair value of the warrants issued in the Preferred Stock transaction, the Black-Scholes pricing model was used with the following assumptions:     <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.25in" cellspacing="0" cellpadding="0"> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 87%">Risk-free interest rate</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%" nowrap="nowrap">1</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">%</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Expected life</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right" nowrap="nowrap">5 years</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Expected volatility</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right" nowrap="nowrap">142.36</td> <td style="TEXT-ALIGN: left">%</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Dividend yield</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right" nowrap="nowrap">0</td> <td style="TEXT-ALIGN: left">%</td> </tr> </table> </div>

<div style="FONT: 10pt Times New Roman, Times, Serif"> Total compensation cost that has been charged against income for stock-based compensation arrangements is as follows:   <table style="WIDTH: 95%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap"> Three Months Ended June 30,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap"> Six Months Ended June 30,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 48%">Stock option grants beginning of period</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">48,185</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">44,949</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">94,796</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">73,600</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Stock-based arrangements during the period:</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -10pt; PADDING-LEFT: 20pt">Stock option grants</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">3</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">14,092</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">3</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">54,511</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -10pt; PADDING-LEFT: 20pt"> Restricted stock issued:</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -12.2pt; PADDING-LEFT: 32.2pt"> Employee stock purchase plan</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 169</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,450</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,332</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 2,855</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 26pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 48,357</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 60,491</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 96,131</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 130,966</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> </div>

-2216662

0.00

-5000

1603

8810

146098

0.00

<div style="FONT: 10pt Times New Roman, Times, Serif"> Note 3—Discontinued Operations   In August 2006, the Company acquired the assets and business of the Alan James Group, LLC (the Alan James Group). The Alan James Group was a provider of products and services in the consumer healthcare marketplace and the acquired business primarily developed, marketed and sold nutritional products and engaged in related activities. Prior to the opening of business on July 1, 2009, the Company and its wholly-owned subsidiary, AJG Brands, Inc. entered into an asset purchase agreement with Nutraceutical Corporation and Pep Products, Inc., a wholly-owned subsidiary of Nutraceutical Corporation, pursuant to which substantially all of the Alan James Group business and assets of AJG Brands, Inc. were sold to Pep Products, Inc.   Prior to June 30, 2011, we reserved for estimated sales returns, discontinued items and trade promotions applicable to the non-acquired accounts resulting from our sale of substantially all of the assets of the Alan James Group business. The Company completed an analysis of all return activity since the time of sale and determined that the remaining reserve was no longer required. The adjustment is reflected in income from discontinued operations in the June 30, 2011 statement of operations. </div>

0.00

<div style="FONT: 10pt Times New Roman, Times, Serif"> Intangible assets at June 30, 2012 and December 31, 2011 consisted of the following:   <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">June 30, 2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">December 31, 2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -10pt; PADDING-LEFT: 20pt; WIDTH: 74%"> Patent costs</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">1,154,523</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">1,154,523</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -10pt; PADDING-LEFT: 20pt"> Less — Accumulated amortization</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (697,666</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (639,939</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Total</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 456,857</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 514,584</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> </div>

2645093

5000

<div style="FONT: 10pt Times New Roman, Times, Serif"> Inventory consisted of the following at June 30, 2012 and December 31, 2011:   <table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.25in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">June 30, 2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">December 31, 2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold"> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt; WIDTH: 74%"> Raw materials</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">83,895</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">100,433</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Finished goods</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 4,473</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 7,325</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Total inventory</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 88,368</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 107,758</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> </div>

2103403

<div style="FONT: 10pt Times New Roman, Times, Serif"> Accounts Receivable   Accounts receivable is stated at estimated net realizable value, which is generally the invoiced amount less any estimated discount related to payment terms. The Company offers its commercial genetic test customers a 2% cash discount if payment is made by bank wire transfer within 10 days of the invoice date. </div>

26209

<div style="FONT: 10pt Times New Roman, Times, Serif"> The following table details stock option and restricted stock activity for the six months ended June 30, 2012 and 2011: <table style="WIDTH: 92%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap"> Six Months Ended June 30, 2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap"> Six Months Ended June 30, 2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Shares</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Weighted Avg. Exercise Price</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Shares</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Weighted Avg. Exercise Price</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-INDENT: -10pt; PADDING-LEFT: 10pt; WIDTH: 48%"> Outstanding, beginning of period</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%">2,228,067</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">1.14</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%">1,611,267</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">1.54</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-INDENT: -10pt; PADDING-LEFT: 20pt">Granted</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">500</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0.34</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">781,000</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0.35</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-INDENT: -10pt; PADDING-LEFT: 20pt">Exercised</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">(2,500</td> <td style="TEXT-ALIGN: left">)</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0.00</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">(2,500</td> <td style="TEXT-ALIGN: left">)</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0.00</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; TEXT-INDENT: -10pt; PADDING-LEFT: 20pt"> Canceled/Expired</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (125,800</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 0.59</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (172,500</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1.18</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Outstanding, end of period</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,100,267</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1.17</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,217,267</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1.15</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Exercisable, end of period</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,393,217</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1.50</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,086,967</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1.75</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> </div>

1.4236

52158

1454717

P5Y

-24654

-2644540

763714

4325065

769333

<div style="FONT: 10pt Times New Roman, Times, Serif"> Income Taxes   The Company accounts for income taxes in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, Income Taxes, which requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the financial statements or tax returns. The measurement of current and deferred tax liabilities and assets is based on provisions of the enacted tax law; the effects of future changes in tax laws or rates are not anticipated. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized.   Significant management judgment is required in determining the Company’s provision (benefit) for income taxes, its deferred tax assets and liabilities and any valuation allowance recorded against deferred tax assets. The Company has recorded a full valuation allowance against its deferred tax assets of approximately $30.5 million as of June 30, 2012, due to uncertainties related to its ability to utilize these assets. The valuation allowance is based on management’s estimates of taxable income by jurisdiction in which the Company operates and the period over which the deferred tax assets will be recoverable. In the event that actual results differ from these estimates or management adjusts these estimates in future periods, the Company may need to adjust its valuation allowance, which could materially impact its financial position and results of operations.   The Company files a combined Massachusetts tax return with certain Alticor affiliated entities, referred to herein as “the unitary group”. Massachusetts law requires corporations with net operating loss carryforwards to go back to each year in which the loss was generated and recompute the loss as if it occurred on a consolidated basis. The Company was required to include data from the newly formed unitary group as if the unitary group was in place during the loss years. As a result, the losses generated by the Company were eliminated through this required computation. The combined filing has had no impact on the Company's financial statements.   The Company reviews its recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. The Company reviews all material tax positions for all years open to statute to determine whether it is more likely than not that the positions taken would be sustained based on the technical merits of those positions. The Company did not recognize any adjustments for uncertain tax positions as of and during the three and six months ended June 30, 2012 and 2011, respectively. </div>

<div style="FONT: 10pt Times New Roman, Times, Serif"> Potential common stock equivalents excluded from the calculation of diluted net loss per share consists of stock options, warrants, convertible preferred stock and convertible debt as set forth in the table below:     <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap">As of June 30,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt; WIDTH: 74%"> Options outstanding</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%">2,100,267</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%">2,217,267</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt">Warrants outstanding</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">2,587,158</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">2,150,000</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Convertible preferred stock</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">39,089,161</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">28,160,200</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Convertible debt</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 2,521,222</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,937,200</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Total</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 46,297,808</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 34,464,667</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> </div>

3134200

-0.07

-19390

167000

125800

<div style="FONT: 10pt Times New Roman, Times, Serif"> Research and Development   Research and development costs are expensed as incurred. </div>

3000000

1477320

707987

452000

22603

<div style="FONT: 10pt Times New Roman, Times, Serif"> Note 6—Convertible Debt   On August 17, 2006, our existing credit facility with Pyxis was amended to provide the Company with access to approximately $14.3 million of additional working capital borrowings at any time prior to August 17, 2008. Any amounts borrowed thereunder bear interest at the prime rate and require quarterly interest payments. This credit facility has been extended several times. Most recently, on June 29, 2012, the date was extended to November 30, 2012.    On April 13, 2012, the Company borrowed the remaining $1,316,255 of available credit, leaving the full amount of $14,316,255 due on November 30, 2012. The fair value of convertible debt is estimated to be approximately $3.1 million at June 30, 2012. The principal amount of borrowings under this credit facility is convertible at Pyxis’ election into 2,521,222 shares of common stock, reflecting a conversion price of $5.6783 per share. </div>

204884

452000

<div style="FONT: 10pt Times New Roman, Times, Serif"> Note 8—Commitments and Contingencies   Employment Agreements   On February 14, 2011, the Company entered into an employment agreement with Lewis H. Bender, its Chief Executive Officer. The agreement replaced and superseded the employment agreement between the Company and Mr. Bender that expired by its terms on January 22, 2011. The agreement has an initial term of one year and is automatically renewable for successive one year periods unless at least 90 days prior notice is given by either the Company or Mr. Bender. The agreement automatically renewed for a one year period on February 14, 2012. The agreement also provides that Mr. Bender will serve as a member of the Company’s Board of Directors for as long as he serves as the Company’s Chief Executive Officer, subject to any required approval of the Company’s shareholders.   The agreement is terminable by the Company for cause or upon thirty days prior written notice without cause and by Mr. Bender upon thirty days prior written notice for “good reason” (as defined in the agreement) or upon ninety days prior written notice without good reason. If the Company terminates Mr. Bender without cause or Mr. Bender terminates his employment for good reason, then the Company will pay Mr. Bender, in addition to any accrued, but unpaid compensation prior to the termination, an amount equal to six months of his base salary. If the Company terminates Mr. Bender without cause or Mr. Bender terminates his employment with good reason within six months after a “change of control” (as defined in the agreement), then the Company will pay Mr. Bender, in addition to any accrued, but unpaid compensation prior to the termination, an amount equal to twelve months of his base salary, and all unvested stock options will automatically vest.   The agreement also includes non-compete and non-solicitation provisions for a period of six months following the termination of Mr. Bender’s employment with the Company.    On April 25, 2012, the Company executed an amendment, effective as of March 31, 2012, to the Employment Agreement dated as of November 12, 2008 by and between the Company and Kenneth S. Kornman, its President and Chief Scientific Officer to extend the term through November 30, 2012.   Operating Lease   The Company leases its office and laboratory space under a non-cancelable operating lease expiring on March 31, 2014. In May 2010, the Company completed a sublease of approximately 6,000 square feet of underutilized office and laboratory space which successfully reduced our total space operating costs. The sublease expires on March 31, 2013 and has a one year renewal option. Rent expense, net of the benefit of the sublease, was $167,000 and $161,000 for the six months ended June 30, 2012 and 2011, respectively. </div>

354907

36752456

46297808

<div style="FONT: 10pt Times New Roman, Times, Serif"> Patent costs, which are amortized on a straight-line basis over a 10-year life, are scheduled to amortize as follows:     <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Year ended December 31, </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-INDENT: 9pt; PADDING-LEFT: 0px; WIDTH: 87%">2012 (remaining six months)</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%">57,725</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-INDENT: 9pt; PADDING-LEFT: 0px">2013.</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">109,266</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-INDENT: 9pt; PADDING-LEFT: 0px">2014.</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">94,100</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-INDENT: 9pt; PADDING-LEFT: 0px">2015.</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">77,656</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-INDENT: 9pt; PADDING-LEFT: 0px">Thereafter.</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 118,110</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 456,857</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> </div>

-2644540

1316255

-218327

2312760

P10Y

500

<div style="FONT: 10pt Times New Roman, Times, Serif"> Note 4—Significant Accounting Policies   Revenue Recognition   Revenue from genetic testing services is recognized when there is persuasive evidence of an arrangement, service has been rendered, the sales price is determinable and collectability is reasonably assured. Service is deemed to be rendered when the results have been reported to the individual who ordered the test. To the extent that tests have been prepaid but results have not yet been reported, recognition of all related revenue is deferred. As of June 30, 2012 and December 31, 2011, the Company has deferred genetic test revenue of $970,943 and $824,845, respectively.   Sales Commission   The Company accounts for sales commissions due to Amway Global under the Merchant Channel and Partner Agreement in accordance with SEC Staff Accounting Bulletin (“SAB”) 104. Commissions are recorded as an expense at the time they become due which is at the point of sale. Commissions were $452,000 and $543,000 for the six months ended June 30, 2012 and 2011.   Accounts Receivable   Accounts receivable is stated at estimated net realizable value, which is generally the invoiced amount less any estimated discount related to payment terms. The Company offers its commercial genetic test customers a 2% cash discount if payment is made by bank wire transfer within 10 days of the invoice date.     Inventory   Inventory is carried at lower of cost or market and no inventory reserve is deemed necessary at June 30, 2012. As the Company does not manufacture any products, no overhead costs are included in inventory. When a kit is sold, the corresponding cost of the kit is recorded as cost of goods sold and removed from inventory.   Inventory consisted of the following at June 30, 2012 and December 31, 2011:   <table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.25in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">June 30, 2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">December 31, 2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold"> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt; WIDTH: 74%"> Raw materials</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">83,895</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">100,433</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Finished goods</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 4,473</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 7,325</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Total inventory</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 88,368</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 107,758</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table>   Income Taxes   The Company accounts for income taxes in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, Income Taxes, which requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the financial statements or tax returns. The measurement of current and deferred tax liabilities and assets is based on provisions of the enacted tax law; the effects of future changes in tax laws or rates are not anticipated. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized.   Significant management judgment is required in determining the Company’s provision (benefit) for income taxes, its deferred tax assets and liabilities and any valuation allowance recorded against deferred tax assets. The Company has recorded a full valuation allowance against its deferred tax assets of approximately $30.5 million as of June 30, 2012, due to uncertainties related to its ability to utilize these assets. The valuation allowance is based on management’s estimates of taxable income by jurisdiction in which the Company operates and the period over which the deferred tax assets will be recoverable. In the event that actual results differ from these estimates or management adjusts these estimates in future periods, the Company may need to adjust its valuation allowance, which could materially impact its financial position and results of operations.   The Company files a combined Massachusetts tax return with certain Alticor affiliated entities, referred to herein as “the unitary group”. Massachusetts law requires corporations with net operating loss carryforwards to go back to each year in which the loss was generated and recompute the loss as if it occurred on a consolidated basis. The Company was required to include data from the newly formed unitary group as if the unitary group was in place during the loss years. As a result, the losses generated by the Company were eliminated through this required computation. The combined filing has had no impact on the Company's financial statements.   The Company reviews its recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. The Company reviews all material tax positions for all years open to statute to determine whether it is more likely than not that the positions taken would be sustained based on the technical merits of those positions. The Company did not recognize any adjustments for uncertain tax positions as of and during the three and six months ended June 30, 2012 and 2011, respectively.   Research and Development   Research and development costs are expensed as incurred.   Basic and Diluted Net Loss per Common Share   The Company applies the provisions of FASB ASC 260, Earnings per Share, which establishes standards for computing and presenting earnings per share. Basic and diluted net loss per share was determined by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is the same as basic net loss per share for all the periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the loss in each period. Potential common stock equivalents excluded from the calculation of diluted net loss per share consists of stock options, warrants, convertible preferred stock and convertible debt as set forth in the table below:     <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap">As of June 30,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt; WIDTH: 74%"> Options outstanding</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%">2,100,267</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%">2,217,267</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt">Warrants outstanding</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">2,587,158</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">2,150,000</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Convertible preferred stock</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">39,089,161</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">28,160,200</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Convertible debt</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 2,521,222</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,937,200</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Total</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 46,297,808</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 34,464,667</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table>   Fair Value of Financial Instruments   The Company, using available market information, has determined the estimated fair values of financial instruments. The stated values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to the nature of these instruments. The fair value of our convertible debt is inherently difficult to determine as a result of the Company’s financial condition and history of operating losses. For financial reporting purposes, the Company has estimated the fair value of its debt as the difference between the book value of its assets less liabilities to third parties other than the debt holder.   Cash and Cash Equivalents   The Company maintains its cash and cash equivalents with domestic financial institutions that the Company believes to be of high credit standing. Cash and cash equivalents are available on demand and at times may be in excess of FDIC insurance limits. The Company believes that, as of June 30, 2012, its concentration of credit risk related to cash and cash equivalents was not significant.   Recent Accounting Pronouncements   Please see the discussion of “Recent Accounting Pronouncements” in Note 4, Significant Accounting Policies contained in the Notes to Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. No new updates or other guidance issued to date by the FASB in 2012 are expected to have a material impact on the Company’s financial statements. </div>

<div style="FONT: 10pt Times New Roman, Times, Serif"> Basic and Diluted Net Loss per Common Share   The Company applies the provisions of FASB ASC 260, Earnings per Share, which establishes standards for computing and presenting earnings per share. Basic and diluted net loss per share was determined by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is the same as basic net loss per share for all the periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the loss in each period. Potential common stock equivalents excluded from the calculation of diluted net loss per share consists of stock options, warrants, convertible preferred stock and convertible debt as set forth in the table below:     <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap">As of June 30,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt; WIDTH: 74%"> Options outstanding</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%">2,100,267</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%">2,217,267</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt">Warrants outstanding</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">2,587,158</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">2,150,000</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Convertible preferred stock</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">39,089,161</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">28,160,200</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Convertible debt</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 2,521,222</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,937,200</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Total</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 46,297,808</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 34,464,667</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> </div>

<div style="FONT: 10pt Times New Roman, Times, Serif"> Note 10—Stock-Based Compensation Arrangements   Total compensation cost that has been charged against income for stock-based compensation arrangements is as follows:   <table style="WIDTH: 95%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap"> Three Months Ended June 30,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap"> Six Months Ended June 30,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 48%">Stock option grants beginning of period</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">48,185</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">44,949</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">94,796</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">73,600</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Stock-based arrangements during the period:</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -10pt; PADDING-LEFT: 20pt">Stock option grants</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">3</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">14,092</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">3</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">54,511</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -10pt; PADDING-LEFT: 20pt"> Restricted stock issued:</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -12.2pt; PADDING-LEFT: 32.2pt"> Employee stock purchase plan</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 169</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,450</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,332</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 2,855</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 26pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 48,357</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 60,491</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 96,131</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 130,966</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table>    Stock option and restricted stock grants   The following table details stock option and restricted stock activity for the six months ended June 30, 2012 and 2011: <table style="WIDTH: 92%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap"> Six Months Ended June 30, 2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap"> Six Months Ended June 30, 2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Shares</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Weighted Avg. Exercise Price</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Shares</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Weighted Avg. Exercise Price</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">  </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-INDENT: -10pt; PADDING-LEFT: 10pt; WIDTH: 48%"> Outstanding, beginning of period</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%">2,228,067</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">1.14</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%">1,611,267</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">1.54</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-INDENT: -10pt; PADDING-LEFT: 20pt">Granted</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">500</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0.34</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">781,000</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0.35</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-INDENT: -10pt; PADDING-LEFT: 20pt">Exercised</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">(2,500</td> <td style="TEXT-ALIGN: left">)</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0.00</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">(2,500</td> <td style="TEXT-ALIGN: left">)</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0.00</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; TEXT-INDENT: -10pt; PADDING-LEFT: 20pt"> Canceled/Expired</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (125,800</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 0.59</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (172,500</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1.18</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Outstanding, end of period</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,100,267</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1.17</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,217,267</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1.15</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -10pt; PADDING-LEFT: 10pt"> Exercisable, end of period</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,393,217</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1.50</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,086,967</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1.75</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table>   During the six month period ended June 30, 2012, the Company granted stock options under the 2004 Employee, Director & Consultant Stock Plan. At June 30, 2012, the Company had an aggregate of 2,258,213 shares of Common Stock available for grant under this plan.   It is the Company’s policy to grant stock options with an exercise price equal to the fair market value of the Company’s common stock at the grant date, and stock options to employees generally vest over four years based upon continuous service. Historically, the majority of the Company’s stock options have been granted in connection with the employee’s start date with the Company. In addition, the Company may grant stock options in recognition of promotion and/or performance.   Employee Stock Purchase Plan   Purchases made under the Company’s Employee Stock Purchase Plan are deemed to be compensatory because employees may purchase stock at a price equal to 85% of the fair market value of the Company’s common stock on either the first day or the last day of a calendar quarter, whichever is lower. The Company’s Employee Stock Purchase plan is authorized to issue 500,000 shares. On March 31, 2012, there were 5,631 shares in the plan reserved for issuance. During the three months ended June 30, 2012, 5,628 shares were issued and the remaining shares were cancelled with the termination of the plan. At the Company’s 2012 annual meeting on August 7, 2012, the Company’s stockholders approved a new Employee Stock Purchase Plan, pursuant to which 750,000 shares of common stock are authorized to be issued. During the six months ended June 30, 2012 and 2011, employees purchased 52,158 and 64,134 shares, respectively, of common stock at a weighted-average purchase price of $0.17 and $0.26, respectively, while the weighted-average fair value was $0.20 and $0.31 per share, respectively, resulting in compensation expense of $1,332 and $2,855, respectively.   Restricted Stock Awards   Holders of restricted stock awards participate fully in the rewards of stock ownership of the Company, including voting and dividend rights. Recipients of restricted stock awards are generally not required to pay any consideration to the Company for these restricted stock awards. The Company measures the fair value of the shares based on the last reported price at which the Company’s common stock traded on the date of the grant and compensation cost is recognized over the remaining service period. During each of the six months ended June 30, 2012 and 2011, the Company granted no restricted stock awards.   At June 30, 2012, there was approximately $217,000 of total unrecognized compensation related to non-vested share-based compensation arrangements granted under the Company’s stock plans. </div>

57726

<div style="FONT: 10pt Times New Roman, Times, Serif"> Fair Value of Financial Instruments   The Company, using available market information, has determined the estimated fair values of financial instruments. The stated values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to the nature of these instruments. The fair value of our convertible debt is inherently difficult to determine as a result of the Company’s financial condition and history of operating losses. For financial reporting purposes, the Company has estimated the fair value of its debt as the difference between the book value of its assets less liabilities to third parties other than the debt holder. </div>

<div style="FONT: 10pt Times New Roman, Times, Serif"> Sales Commission   The Company accounts for sales commissions due to Amway Global under the Merchant Channel and Partner Agreement in accordance with SEC Staff Accounting Bulletin (“SAB”) 104. Commissions are recorded as an expense at the time they become due which is at the point of sale. Commissions were $452,000 and $543,000 for the six months ended June 30, 2012 and 2011. </div>

12184

219930

0.20

104907 <div style="FONT: 10pt Times New Roman, Times, Serif"> Note 2—Operating Matters and Liquidity   The Company has experienced net operating losses since its inception through June 30, 2012, including a net loss of $2.6 million for the six months then ended, contributing to an accumulated deficit of $105 million as of June 30, 2012. The Company has borrowings of $14.3 million at June 30, 2012 under its line of credit with Pyxis Innovations, Inc., an affiliate of Alticor (“Pyxis”). On June 29, 2012, the maturity date of the line of credit was extended from June 30, 2012 to November 30, 2012.   The Company was successful in 2011 and 2012 in reducing costs and continues to explore additional ways to reduce operating costs, including manufacturing costs as well as general and administrative expenses however, the opportunities to do so are very limited. Cost savings were achieved through process improvements in manufacturing, reductions in personnel and the subleasing of underutilized rental space. Management believes that the current laboratory space is adequate to process high volumes of genetic tests.   On June 29, 2012, the Company entered into a Stock Purchase Agreement with Delta Dental Plan of Michigan, Inc. (“Delta Dental”), pursuant to which, Delta Dental purchased 500,000 shares of Series B convertible preferred stock for net proceeds of $2,750,000.   The Company’s financial statements have been prepared assuming that it will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company expects to incur additional losses in 2012 and, accordingly, is dependent on finding additional sources of liquidity to fund its operations. Management’s plans include identifying additional sources of debt and/or equity financing, further extending the due date of its existing debt, growing its sources of revenue and further reducing expenditures. However, no assurance can be given at this time as to whether management will be able to achieve these plans. If the Company is not successful in raising additional debt or equity funding, further extending the due date of its existing debt, completing negotiations with commercial distribution partners or reducing expenditures, it will not be able to fund operations beyond November 30, 2012. However, if the due date of the debt is extended beyond November 30, 2012, the Company estimates that it would have sufficient operating cash flows to fund operations through January 31, 2013. The financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.    In its report on our financial statements included in the Form 10-K for the year ended December 31, 2011, our independent registered public accounting firm, Grant Thornton LLP, included an explanatory paragraph in their report indicating that there was substantial doubt concerning the Company’s ability to continue as a going concern.   The ability of the Company to realize the carrying value of its fixed assets and intangible assets is especially dependent on management’s ability to successfully execute on its plan. As noted above, the Company needs to generate additional funds in order to meet its financial obligations beyond November 30, 2012. If it is unsuccessful in doing so, the Company may not be able to realize the carrying value of its fixed assets and intangible assets. </div> <div style="FONT: 10pt Times New Roman, Times, Serif"> Recent Accounting Pronouncements   Please see the discussion of “Recent Accounting Pronouncements” in Note 4, Significant Accounting Policies contained in the Notes to Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. No new updates or other guidance issued to date by the FASB in 2012 are expected to have a material impact on the Company’s financial statements. </div> <div style="FONT: 10pt Times New Roman, Times, Serif"> Note 5—Strategic Alliance with Alticor Inc.   Since March 2003, the Company has maintained a broad strategic alliance with several affiliates of the Alticor family of companies to develop and market novel nutritional and skin care products. The alliance previously included an equity investment, a multi-year research and development agreement, a licensing agreement with royalties on marketed products, the deferment of outstanding loan repayment and the refinancing of bridge financing obligations.   In October 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (“Amway Global”), a subsidiary of Alticor Inc. Pursuant to this Agreement, Amway Global sells the Company’s Inherent Health® brand of genetic tests through its e-commerce website via a hyperlink to our e-commerce site. We paid Amway Global $452,000 and $543,000 in commissions for each of the six months ended June 30, 2012 and 2011, representing a percentage of net sales to their customers. </div> 0.02 2012-11-30

0.63

P10D

500

500000

52158

-2644540

104907

96131

8758

2644593

217000

1332

94796

6.00 1.80

39089161

2587158

2521222

2100267

2014-03-31

2013-03-31

P1Y P1Y P90D P1Y P30D P30D P90D

2012-11-30

2750000

3000000

21.86

1316255

-1283404

-1370633

60491

-0.03

0.01

1901

158366

779116

-1370633

359799

438464

1641805

-0.04

796865

358401

17749

36650158

-1212267

-87229

1253143

28863

89130

1450

14092

44949

-1116100

-1229834

48357

-0.03

860

5628

777549

-1229834

317440

393122

1522413

-0.03

799435

406313

21886

36756802

-1229834

-113734

1176110

28863

114594

169

48185

0001037649 iliu:OptionOutstandingMember 2012-04-01 2012-06-30 0001037649 iliu:StockGrantsMember 2012-04-01 2012-06-30 0001037649 iliu:EmployeeStockPurchasePlanMember 2012-04-01 2012-06-30 0001037649 2012-04-01 2012-06-30 0001037649 iliu:OptionOutstandingMember 2011-04-01 2011-06-30 0001037649 iliu:StockGrantsMember 2011-04-01 2011-06-30 0001037649 iliu:EmployeeStockPurchasePlanMember 2011-04-01 2011-06-30 0001037649 2011-04-01 2011-06-30 0001037649 iliu:PyxisInnovationsIncMember 2012-03-10 2012-04-13 0001037649 us-gaap:SeriesBPreferredStockMember 2012-05-30 2012-06-29 0001037649 iliu:ExtendedMaturityMember 2012-05-30 2012-06-29 0001037649 us-gaap:ChiefExecutiveOfficerMember 2011-01-15 2011-02-14 0001037649 iliu:SubleaseMember 2012-01-01 2012-06-30 0001037649 iliu:OperatingLeasesMember 2012-01-01 2012-06-30 0001037649 iliu:OptionOutstandingMember 2012-01-01 2012-06-30 0001037649 us-gaap:ConvertibleDebtMember 2012-01-01 2012-06-30 0001037649 us-gaap:WarrantMember 2012-01-01 2012-06-30 0001037649 us-gaap:ConvertiblePreferredStockMember 2012-01-01 2012-06-30 0001037649 iliu:SeriesAOnePreferredStockMember 2012-01-01 2012-06-30 0001037649 us-gaap:SeriesBPreferredStockMember 2012-01-01 2012-06-30 0001037649 iliu:OptionOutstandingMember 2012-01-01 2012-06-30 0001037649 iliu:StockGrantsMember 2012-01-01 2012-06-30 0001037649 iliu:EmployeeStockPurchasePlanMember 2012-01-01 2012-06-30 0001037649 us-gaap:RestrictedStockMember 2012-01-01 2012-06-30 0001037649 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-06-30 0001037649 us-gaap:RetainedEarningsMember 2012-01-01 2012-06-30 0001037649 us-gaap:CommonStockMember 2012-01-01 2012-06-30 0001037649 us-gaap:PreferredStockMember 2012-01-01 2012-06-30 0001037649 us-gaap:MaximumMember 2012-01-01 2012-06-30 0001037649 iliu:AmwayGlobalMember 2012-01-01 2012-06-30 0001037649 iliu:PyxisInnovationsIncMember 2012-01-01 2012-06-30 0001037649 2012-01-01 2012-06-30 0001037649 iliu:OptionOutstandingMember 2011-01-01 2011-06-30 0001037649 us-gaap:ConvertibleDebtMember 2011-01-01 2011-06-30 0001037649 us-gaap:WarrantMember 2011-01-01 2011-06-30 0001037649 us-gaap:ConvertiblePreferredStockMember 2011-01-01 2011-06-30 0001037649 iliu:OptionOutstandingMember 2011-01-01 2011-06-30 0001037649 iliu:StockGrantsMember 2011-01-01 2011-06-30 0001037649 iliu:EmployeeStockPurchasePlanMember 2011-01-01 2011-06-30 0001037649 us-gaap:AdditionalPaidInCapitalMember 2011-01-01 2011-06-30 0001037649 us-gaap:RetainedEarningsMember 2011-01-01 2011-06-30 0001037649 us-gaap:CommonStockMember 2011-01-01 2011-06-30 0001037649 2011-01-01 2011-06-30 0001037649 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0001037649 us-gaap:RetainedEarningsMember 2011-12-31 0001037649 us-gaap:CommonStockMember 2011-12-31 0001037649 us-gaap:PreferredStockMember 2011-12-31 0001037649 2011-12-31 0001037649 us-gaap:AdditionalPaidInCapitalMember 2010-12-31 0001037649 us-gaap:RetainedEarningsMember 2010-12-31 0001037649 us-gaap:CommonStockMember 2010-12-31 0001037649 us-gaap:PreferredStockMember 2010-12-31 0001037649 2010-12-31 0001037649 iliu:SeriesAOnePreferredStockMember 2012-06-30 0001037649 us-gaap:SeriesBPreferredStockMember 2012-06-30 0001037649 iliu:WarrantThreeMember 2012-06-30 0001037649 iliu:WarrantTwoMember 2012-06-30 0001037649 iliu:WarrantOneMember 2012-06-30 0001037649 us-gaap:AdditionalPaidInCapitalMember 2012-06-30 0001037649 us-gaap:RetainedEarningsMember 2012-06-30 0001037649 us-gaap:CommonStockMember 2012-06-30 0001037649 us-gaap:PreferredStockMember 2012-06-30 0001037649 iliu:StockIncentivePlanMember 2012-06-30 0001037649 iliu:PyxisInnovationsIncMemberus-gaap:MaximumMember 2012-06-30 0001037649 iliu:PyxisInnovationsIncMember 2012-06-30 0001037649 2012-06-30 0001037649 us-gaap:AdditionalPaidInCapitalMember 2011-06-30 0001037649 us-gaap:RetainedEarningsMember 2011-06-30 0001037649 us-gaap:CommonStockMember 2011-06-30 0001037649 us-gaap:PreferredStockMember 2011-06-30 0001037649 2011-06-30 0001037649 iliu:SeriesAOnePreferredStockMember 2012-06-29 0001037649 us-gaap:SeriesBPreferredStockMember 2012-06-29 0001037649 2012-06-29 0001037649 iliu:SubleaseMember 2010-05-31 0001037649 us-gaap:SubsequentEventMember 2012-08-07 0001037649 2012-07-31 0001037649 iliu:PyxisInnovationsIncMemberiliu:WorkingCapitalMember 2006-08-17 iso4217:USD shares iliu:sqft iso4217:USD shares pure

EX-101.SCH 6 iliu-20120630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - CONDENSED BALANCE SHEETS link:calculationLink link:presentationLink link:definitionLink 104 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - CONDENSED STATEMENTS OF OPERATIONS link:calculationLink link:presentationLink link:definitionLink 106 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT link:calculationLink link:presentationLink link:definitionLink 107 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 108 - Statement - CONDENSED STATEMENTS OF CASH FLOWS link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Operating Matters and Liquidity link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Discontinued Operations link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Strategic Alliance with Alticor Inc. link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Convertible Debt link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Intangible Assets link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Capital Stock link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Stock-Based Compensation Arrangements link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Industry Risk and Concentration link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Capital Stock (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Stock-Based Compensation Arrangements (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Operating Matters and Liquidity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Inventory (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Potential Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Strategic Alliance with Alticor Inc - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Convertible Debt - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Intangible Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Patent Costs Amortized on Straight-Line Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Capital Stock - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Black-Scholes Pricing Model Assumptions to Determine Fair Value of Warrants (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Total Compensation Cost Recorded for Stock-Based Compensation (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Stock Option and Restricted Stock Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Stock-Based Compensation Arrangements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Industry Risk and Concentration - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 iliu-20120630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 iliu-20120630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 iliu-20120630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounts Payable Current Accounts payable Accounts Receivable Net Current Trade accounts receivable Accounts Receivable Related Parties Current Accounts receivable from related party Accrued Liabilities Current Accrued expenses Additional Paid In Capital Additional paid-in capital Additional Paid In Capital [Member] Additional Paid-in Capital Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Stock-based compensation expense Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Private placement of preferred stock, offering costs Adjustments To Additional Paid In Capital Warrant Issued Warrants issued in connection with private placement of preferred stock Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile loss from continuing operations to net cash used in operating activities: Amended and Restated Date Amended And Restated Date Credit facility extended date Amendment Flag Amendment Flag Amortization Of Intangible Assets Amortization of intangibles Patent amortization expense Amway Global [Member] Amway Global [Member] Amway Global Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Potential common stock equivalents excluded from the calculation of diluted net loss per share Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] Assets Total assets Assets [Abstract] ASSETS Assets Current Total current assets Assets Current [Abstract] Current assets: Average Purchase Price Per Share of Issued Shares Average Purchase Price Per Share Of Issued Shares Convertible preferred stock, effective purchase price Award Type [Axis] Award Type [Axis] Basis Of Accounting Basis of Presentation Business Acquisition [Line Items] Business Acquisition [Line Items] Cash And Cash Equivalents At Carrying Value Cash and cash equivalents, end of period Cash and cash equivalents, beginning of period Cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease Net increase (decrease) in cash and cash equivalents Cash And Cash Equivalents Policy [Text Block] Cash and Cash Equivalents Cash Discount Discount Rate Cash Discount Discount Rate Percentage of cash discount offered to customers Cash Discount Invoice Terms Cash Discount Invoice Terms Cash discount payment period Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Supplemental disclosures of non-cash investing and financing activities: Cash Provided By Used In Operating Activities Discontinued Operations Net cash used in operating activities of discontinued operations Chief Executive Officer [Member] Chief Executive Officer Class Of Stock [Domain] Class of Stock [Domain] Class Of Warrant Or Right [Axis] Class of Warrant or Right [Axis] Class Of Warrant Or Right [Domain] Class of Warrant or Right [Domain] Class of Warrant or Right, Expiration Period Class Of Warrant Or Right Expiration Period Warrant expiration period Collaborative and License Arrangement Disclosure Collaborative And License Arrangement Disclosure [Text Block] Strategic Alliance with Alticor Inc. Commissions Expense Policy Policy [Text Block] Sales Commissions Commitments And Contingencies Commitments and contingencies (Note 8) Commitments And Contingencies Disclosure [Text Block] Commitments and Contingencies Common Shares Issuable upon Conversion of Convertible Debt Common Shares Issuable Upon Conversion Of Convertible Debt Shares reserved for conversion of debt Common Shares Issuable upon Conversion of Convertible Stock Common Shares Issuable Upon Conversion Of Convertible Stock Shares reserved for conversion of Preferred to common stock Common Stock Issuable upon Exercise of Warrants Common Stock Issuable Upon Exercise Of Warrants Shares reserved for exercise of outstanding warrants Common Stock [Member] Common Stock Common Stock Par Or Stated Value Per Share Common stock, par value Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Common Stock Shares Outstanding Or Reserved For Issuance Common Stock Shares Outstanding Or Reserved For Issuance Common stock, outstanding or reserved for issuance Common Stock Transactions [Abstract] Common Stock Transactions [Abstract] Common stock issued: Common Stock Value Common stock, $0.001 par value - 100,000,000 shares authorized; 36,761,864 and 36,709,706 shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively Concentration Risk Disclosure [Text Block] Industry Risk and Concentration Concentration Risk [Line Items] Concentration Risk [Line Items] Concentration Risk [Table] Concentration Risk [Table] Conversion Of Preferred Stock To Common Stock Shares Conversion Of Preferred Stock To Common Stock Shares Conversion of Series B convertible preferred Stock to Common Stock Convertible Debt Fair Value Disclosures Fair value of convertible debt Convertible Debt [Member] Convertible Debt Convertible Preferred Stock [Member] Convertible Preferred Stock Cost Of Revenue Cost of revenue Current Fiscal Year End Date Current Fiscal Year End Date Debt Disclosure [Text Block] Convertible Debt Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument Convertible Conversion Price 1 Convertible debt conversion price Debt Instrument, Convertible, Number Of Share Debt Instrument Convertible Number Of Share Principal amount of borrowing convertible in to common stock shares Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument Name [Domain] Debt Instrument, Name [Domain] Debt Instrument [Table] Schedule of Long-term Debt Instruments [Table] Deferred Revenue Deferred revenue Deferred Revenue Current Deferred revenue Deferred Tax Assets Valuation Allowance Deferred tax assets, valuation allowance Depreciation And Amortization Depreciation and amortization Disclosure - Black-Scholes Pricing Model Assumptions to Determine Fair Value of Warrants [Abstract] Disclosure Black Scholes Pricing Model Assumptions To Determine Fair Value Of Warrants [Abstract] Disclosure - Black-Scholes Pricing Model Assumptions to Determine Fair Value of Warrants [Abstract] Disclosure - Capital Stock - Additional Information [Abstract] Disclosure Capital Stock Additional Information [Abstract] Disclosure - Capital Stock - Additional Information [Abstract] Disclosure - Commitments and Contingencies - Additional Information [Abstract] Disclosure Commitments And Contingencies Additional Information [Abstract] Disclosure - Commitments and Contingencies - Additional Information [Abstract] Disclosure - Convertible Debt - Additional Information [Abstract] Disclosure Convertible Debt Additional Information [Abstract] Disclosure - Convertible Debt - Additional Information [Abstract] Disclosure - Industry Risk and Concentration - Additional Information [Abstract] Disclosure Industry Risk And Concentration Additional Information [Abstract] Disclosure - Industry Risk and Concentration - Additional Information [Abstract] Disclosure - Intangible Assets [Abstract] Disclosure Intangible Assets [Abstract] Disclosure - Intangible Assets [Abstract] Disclosure - Intangible Assets - Additional Information [Abstract] Disclosure Intangible Assets Additional Information [Abstract] Disclosure - Intangible Assets - Additional Information [Abstract] Disclosure - Inventory [Abstract] Disclosure Inventory [Abstract] Disclosure - Inventory [Abstract] Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Stock-Based Compensation Arrangements Disclosure - Operating Matters and Liquidity - Additional Information [Abstract] Disclosure Operating Matters And Liquidity Additional Information [Abstract] Disclosure - Operating Matters and Liquidity - Additional Information [Abstract] Disclosure - Patent Costs Amortized on Straight-Line Basis [Abstract] Disclosure Patent Costs Amortized On Straight Line Basis [Abstract] Disclosure - Patent Costs Amortized on Straight-Line Basis [Abstract] Disclosure - Potential Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share [Abstract] Disclosure Potential Common Stock Equivalents Excluded From Calculation Of Diluted Net Loss Per Share [Abstract] Disclosure - Potential Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share [Abstract] Disclosure - Significant Accounting Policies - Additional Information [Abstract] Disclosure Significant Accounting Policies Additional Information [Abstract] Disclosure - Significant Accounting Policies - Additional Information [Abstract] Disclosure - Stock-Based Compensation Arrangements - Additional Information [Abstract] Disclosure Stock Based Compensation Arrangements Additional Information [Abstract] Disclosure - Stock-Based Compensation Arrangements - Additional Information [Abstract] Disclosure - Stock Option and Restricted Stock Activity [Abstract] Disclosure Stock Option And Restricted Stock Activity [Abstract] Disclosure - Stock Option and Restricted Stock Activity [Abstract] Disclosure - Strategic Alliance with Alticor Inc - Additional Information [Abstract] Disclosure Strategic Alliance With Alticor Inc Additional Information [Abstract] Disclosure - Strategic Alliance with Alticor Inc - Additional Information [Abstract] Disclosure - Total Compensation Cost Recorded for Stock-Based Compensation [Abstract] Disclosure Total Compensation Cost Recorded For Stock Based Compensation [Abstract] Disclosure - Total Compensation Cost Recorded for Stock-Based Compensation [Abstract] Disposal Groups Including Discontinued Operations Disclosure [Text Block] Discontinued Operations Document - Document and Entity Information [Abstract] Document Documentand Entity Information [Abstract] Document - Document and Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Information [Line Items] Document Information [Line Items] Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share Basic And Diluted Net loss Earnings Per Share Basic And Diluted [Abstract] Basic and diluted net loss per common share from: Earnings Per Share Policy [Text Block] Basic and Diluted Net Loss per Common Share Employee Service Share Based Compensation Unrecognized Compensation Costs On Nonvested Stock Employee Service Share Based Compensation Unrecognized Compensation Costs On Nonvested Stock Unrecognized compensation cost Employee Stock Ownership Plan E S O P Compensation Expense Compensation expense Employee Stock Ownership Plan E S O P Weighted Average Purchase Price Of Shares Purchased Weighted-average purchase price Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan Employment Agreement Extension Period Employment Agreement Extension Period Employment agreement, automatic renewal period Entities [Table] Entities [Table] Entity Central Index Key Entity Central Index Key Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Entity Wide Revenue Major Customer Percentage Percentage of sales revenue Equity Component [Domain] Equity Component [Domain] Exercise Price Of Warrants Exercise Price Of Warrants Warrants exercise price per share Expected Amortization Expense [Line Items] Expected Amortization Expense [Line Items] Expected Amortization Expense [Line Items] Expected Amortization Expense [Table] Expected Amortization Expense [Table] Expected Amortization Expense [Table] Extended Maturity [Member] Extended Maturity [Member] Extended Maturity Fair Value Assumptions Expected Dividend Rate Dividend yield Fair Value Assumptions Expected Term Expected life Fair Value Assumptions Expected Volatility Rate Expected volatility Fair Value Assumptions Risk Free Interest Rate Risk-free interest rate Fair Value By Balance Sheet Grouping [Text Block] Black-Scholes Pricing Model Assumptions to Determine Fair Value of Warrants Fair Value Of Financial Instruments Policy Fair Value of Financial Instruments Finite Lived Intangible Assets Accumulated Amortization Less - Accumulated amortization Finite Lived Intangible Assets Amortization Expense Next Twelve Months 2013. Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year 2012 (remaining six months) Finite Lived Intangible Assets, Amortization Expense, Year Four and Thereafter Finite Lived Intangible Assets Amortization Expense Year Four And Thereafter Thereafter. Finite Lived Intangible Assets Amortization Expense Year Three 2015. Finite Lived Intangible Assets Amortization Expense Year Two 2014. Finite Lived Intangible Assets Net Finite-Lived Intangible Assets, Net, Total Finite Lived Intangible Asset Useful Life Patent life Finite Lived Patents Gross Patent costs Gain Loss On Disposition Of Assets Gain on disposal of assets Going Concern Disclosure Going Concern Disclosure [Text Block] Operating Matters and Liquidity Gross Profit Gross profit Income Loss From Continuing Operations Loss from continuing operations Loss from continuing operations Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments Loss from continuing operations before income taxes Income Loss From Continuing Operations Per Basic And Diluted Share Continuing operations Income Loss From Discontinued Operations Net Of Tax Income from discontinued operations Income from discontinued operations, net of income taxes Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share Discontinued operations Income Statement [Abstract] Income Statement [Abstract] Income Tax Expense Benefit Benefit for income taxes Income Tax Policy [Text Block] Income Taxes Increase Decrease In Accounts Payable Accounts payable Increase Decrease In Accounts Receivable Accounts receivable Increase Decrease In Accrued Liabilities Accrued expenses Increase Decrease In Deferred Revenue Deferred revenue Increase Decrease In Due From Related Parties Current Receivable from related party Increase Decrease In Inventories Inventory Increase Decrease In Operating Capital [Abstract] Changes in operating assets and liabilities: Increase Decrease In Other Receivables Federal grant receivable Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid expenses and other current assets Initial Term of Employment Agreement Initial Term Of Employment Agreement Employment agreement, initial term Intangible Assets Disclosure [Text Block] Intangible Assets Intangible Assets Net Excluding Goodwill Intangible assets, net Total Interest Expense Interest expense Interest Paid Cash paid for interest Inventory Disclosure [Line Items] Inventory Disclosure [Line Items] Inventory Disclosure [Line Items] Inventory Disclosure [Table] Inventory Disclosure [Table] Inventory Disclosure [Table] Inventory Finished Goods Finished goods Inventory Net Inventory Total inventory Inventory Policy [Text Block] Inventory Inventory Raw Materials Raw materials Investment Income Interest Interest income Lease Commitment [Axis] Lease Commitment [Axis] Lease Commitment [Axis] Lease Commitment [Domain] Lease Commitment [Domain] Lease Commitment [Domain] Lease Expiration Date 1 Lease commitments, expiration date Legal Entity [Axis] Legal Entity [Axis] Liabilities And Stockholders Equity Total liabilities and stockholders' deficit Liabilities And Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS' DEFICIT Liabilities Current Total current liabilities Liabilities Current [Abstract] Current liabilities: Line Of Credit Facility Amount Outstanding Debt outstanding Principal outstanding under the credit facility Line Of Credit Facility [Axis] Lender Name [Axis] Line Of Credit Facility Expiration Date 1 Extended date of the credit facility Line Of Credit Facility Increase Additional Borrowings Amount borrowed under credit facility Line Of Credit Facility Lender [Domain] Line of Credit Facility, Lender [Domain] Line Of Credit Facility [Line Items] Line of Credit Facility [Line Items] Line Of Credit Facility Maximum Borrowing Capacity Working capital borrowings Line Of Credit Facility [Table] Line of Credit Facility [Table] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Loss Contingencies [Table] Loss Contingencies [Table] Maximum [Member] Maximum Net Cash Provided By Used In Financing Activities Net cash provided by financing activities Net Cash Provided By Used In Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided By Used In Investing Activities Net cash used in investing activities Net Cash Provided By Used In Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided By Used In Operating Activities Net cash used in operating activities Net Cash Provided By Used In Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Income Loss Net loss Net loss Nonoperating Income Expense Total other income (expense) Nonoperating Income Expense [Abstract] Other income (expense): Notes Payable Current Current notes payable Notes payable Number of Genetic Risk Assessment Tests Introduced Number Of Genetic Risk Assessment Tests Introduced Number of genetic risk assessment tests introduced commercially EX-101.PRE 10 iliu-20120630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R39.htm IDEA: XBRL DOCUMENT

Industry Risk and Concentration - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2012
Concentration Risk [Line Items]
Number of genetic risk assessment tests introduced commercially	4
Amway Global
Concentration Risk [Line Items]
Percentage of sales revenue	63.00%

XML 12 R33.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail) (USD $)	6 Months Ended		1 Months Ended	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Feb. 14, 2011 Chief Executive Officer	Jun. 30, 2012 Operating Leases	Jun. 30, 2012 Sublease	May 31, 2010 Sublease sqft
Loss Contingencies [Line Items]
Employment agreement, initial term			1 year
Employment agreement, automatic renewal period			1 year
Prior notice period not to automatically renew employment			90 days
Agreement termination period by the Company without cause			30 days
Agreement termination period by Mr. Bender with good reason			30 days
Agreement termination period by Mr. Bender with out good reason			90 days
Lease commitments, expiration date				Mar. 31, 2014	Mar. 31, 2013
Lease commitments, office space						6,000
Renewal option					1 year
Lease commitments, rent expense	$ 167,000	$ 161,000

XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2011
Significant Accounting Policies [Line Items]
Deferred revenue	$ 970,943		$ 824,845
Sales commissions	452,000	543,000
Percentage of cash discount offered to customers	2.00%
Deferred tax assets, valuation allowance	$ 30,500,000
Maximum
Significant Accounting Policies [Line Items]
Cash discount payment period	10 days

- Definition

Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.

+ References+ Details

XML 15 R37.htm IDEA: XBRL DOCUMENT

Stock Option and Restricted Stock Activity (Detail) (USD $)	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Shares
Outstanding, beginning of period	2,228,067	1,611,267
Granted	500	781,000
Exercised	(2,500)	(2,500)
Canceled/Expired	(125,800)	(172,500)
Outstanding, end of period	2,100,267	2,217,267
Exercisable, end of period	1,393,217	1,086,967
Weighted Avg Exercise Price
Outstanding, beginning of period	$ 1.14	$ 1.54
Granted	$ 0.34	$ 0.35
Exercised	$ 0.00	$ 0.00
Canceled/Expired	$ 0.59	$ 1.18
Outstanding, end of period	$ 1.17	$ 1.15
Exercisable, end of period	$ 1.50	$ 1.75

XML 16 R9.htm IDEA: XBRL DOCUMENT

Operating Matters and Liquidity

6 Months Ended

Jun. 30, 2012

Operating Matters and Liquidity

Note 2—Operating Matters and Liquidity

EXCEL 17 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]C9#$X-61B-5\W-#!A7S0T,S!?.68R85]B,#AB M8CEA93$R9#@B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D1%3E-%1%]35$%414U%3E137T]&7T-!4TA?1CPO M>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D]P97)A=&EN9U]-871T97)S7V%N9%],:7%U:61I=#PO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D1I#I%>&-E M;%=O#I%>&-E;%=O#I% M>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN=&%N9VEB;&5?07-S971S/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K0F%S961?0V]M<&5N#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I7;W)K#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E M;%=O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN9'5S=')Y7U)I#I7;W)K#I3='EL97-H965T M($A2968],T0B5V]R:W-H965T3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C9#$X-61B-5\W-#!A7S0T,S!?.68R M85]B,#AB8CEA93$R9#@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M8V0Q.#5D8C5?-S0P85\T-#,P7SEF,F%?8C`X8F(Y864Q,F0X+U=O'0O:'1M;#L@8VAA M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$6UB;VP\+W1D/@T*("`@("`@ M("`\=&0@8VQA2!296=I'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2!#;VUM;VX@4W1O8VLL(%-H87)E'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA&5D(&%SF5D.R`S-BPW-C$L.#8T(&%N9"`S-BPW M,#DL-S`V('-H87)E3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]C9#$X-61B-5\W-#!A7S0T,S!?.68R85]B M,#AB8CEA93$R9#@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V0Q M.#5D8C5?-S0P85\T-#,P7SEF,F%?8C`X8F(Y864Q,F0X+U=O'0O:'1M;#L@8VAAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV M+#`P,"PP,#`\F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P M+#`P,#QS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'!E;G-E*3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65E('-T;V-K('!U'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XY-BPQ,S$\'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]C9#$X-61B-5\W-#!A7S0T,S!?.68R85]B,#AB8CEA93$R9#@- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V0Q.#5D8C5?-S0P85\T M-#,P7SEF,F%?8C`X8F(Y864Q,F0X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XY-BPQ,S$\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$6%B M;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE$$P.S$F(W@R M,#$T.T)A6QE/3-$)U1% M6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/B8C>$$P.SPO9F]N=#X\+W`^#0H\ M<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&IU#L@1D].5#H@ M,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE M3L@34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E$$P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU2P@=&AE>2!D;R!N;W0@:6YC;'5D92!A;&P@;V8@=&AE M(&EN9F]R;6%T:6]N(&%N9"!N;W1E2!F;W(-"F$@9F%I2!F M=71U6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE7-I#(P,40[(&-O;G1A:6YE M9"!I;B!O=7(-"D%N;G5A;"!297!O65A3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]C9#$X-61B-5\W-#!A7S0T,S!?.68R85]B,#AB8CEA M93$R9#@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V0Q.#5D8C5? M-S0P85\T-#,P7SEF,F%?8C`X8F(Y864Q,F0X+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^/&1I M=B!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)U1%6%0M24Y$14Y4.B`P:6X[($U!4D=) M3CH@,'!T(#!P>#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E3L@5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3L@5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE"!M;VYT:',@=&AE;B!E;F1E9"P@8V]N=')I8G5T:6YG('1O(&%N#0IA M8V-U;75L871E9"!D969I8VET(&]F("0Q,#4@;6EL;&EO;B!A7AI&ES)B-X,C`Q1#LI+B!/ M;B!*=6YE(#(Y+"`R,#$R+"!T:&4@;6%T=7)I='D@9&%T90T*;V8@=&AE(&QI M;F4@;V8@8W)E9&ET('=A'1E;F1E9"!F6QE/3-$)U1%6%0M M04Q)1TXZ(&IU$$P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU M7,@=&\@3L@5$585"U)3D1%3E0Z(#`N-6EN.R!-05)' M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M3L@5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@ M,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE M2!E>'!E8W1S('1O(&EN8W5R(&%D M9&ET:6]N86P@;&]S2!F:6YA;F-I;F0T*,S$L(#(P M,3,N(#QF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^5&AE(&9I;F%N8VEA M;"!S=&%T96UE;G1S(&1O#0IN;W0@:6YC;'5D92!A;GD@861J=7-T;65N="!R M96QA=&EN9R!T;R!T:&4@#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE2!T;R!C;VYT:6YU92!A6QE/3-$)U1%6%0M04Q)1TXZ(&IU$$P.SPO<#X-"CQP M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4@=&AE(&-A M#(P,3D[2!E>&5C=71E M(&]N(&ET7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^/&1I=B!S='EL M93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@1D].5#H@8F]L9"`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)U1%6%0M04Q)1TXZ(&IU$$P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&IU2!A8W%U:7)E9"!T:&4@ M87-S971S(&%N9"!B=7-I;F5S2UO=VYE9"!S=6)S:61I87)Y M(&]F#0I.=71R86-E=71I8V%L($-O3L@34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E$$P M.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU0T*8V]M<&QE=&5D(&%N(&%N86QY3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]C9#$X-61B-5\W-#!A7S0T,S!?.68R85]B,#AB8CEA93$R9#@-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V0Q.#5D8C5?-S0P85\T-#,P7SEF M,F%?8C`X8F(Y864Q,F0X+U=O'0O:'1M;#L@8VAA'0^/&1I=B!S='EL93TS1"=& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E$$P.SPO:3X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[ M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE2X\ M+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&IU M#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE2!A8V-O=6YT#(P,4,[4T%")B-X,C`Q1#LI(#$P-"X@0V]M;6ES'!E;G-E(&%T('1H92!T:6UE('1H97D@8F5C;VUE(&1U M92!W:&EC:"!I"!M;VYT M:',@96YD960@2G5N92`S,"P@,C`Q,B!A;F0@,C`Q,2X\+W`^#0H\<"!S='EL M93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ(#!P="`P<'@[($9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&IU$$P.SPO<#X-"CQP M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU2!T:&4@:6YV;VEC960@86UO=6YT(&QE2!O9F9E6UE;G0@ M:7,@;6%D92!B>2!B86YK('=I$$P M.V1A>7,@;V8@=&AE(&EN=F]I8V4@9&%T92X\+W`^#0H\<"!S='EL93TS1"=4 M15A4+4%,24=..B!J=7-T:69Y.R!415A4+4E.1$5.5#H@,"XU:6X[($U!4D=) M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E3PO:3X\+W`^ M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!415A4+4E.1$5. M5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE2!P3L@5$585"U)3D1%3E0Z(#`N-6EN.R!-05)' M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M3L@5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE$$P.SPO M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T M;VTG/@T*/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\ M+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@$$P M.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%, M24=..B!C96YT97(G(&-O;'-P86X],T0R/B8C>$$P.SPO=&0^#0H\=&0^)B-X M03`[/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1( M.B`Q)2<^)#PO=&0^#0H\=&0@6QE M/3-$)U=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!724142#H@,24G/B0\+W1D/@T*/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SXQ,#`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`Q1#LI(#`T*"!L:6%B:6QI=&EE"!L87<[('1H90T*969F96-TF5D+CPO<#X-"CQP M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU$$P.SPO<#X-"CQP('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&IU2!J=7)I"!A M2!N965D('1O(&%D:G5S="!I M=',@=F%L=6%T:6]N(&%L;&]W86YC92P@=VAI8V@@8V]U;&0@;6%T97)I86QL M>0T*:6UP86-T(&ET#L@ M1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P M="!4:6UE2!F:6QE#(P,4,[=&AE#0IU;FET87)Y(&=R;W5P M)B-X,C`Q1#LN($UA65A65A2!T:&4-"D-O;7!A;GD@=V5R M92!E;&EM:6YA=&5D('1H3L@5$585"U)3D1%3E0Z(#`N M-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE3L@5$585"U)3D1%3E0Z(#`N-6EN.R!-05)' M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M"!M;VYT:',-"F5N M9&5D($IU;F4@,S`L(#(P,3(@86YD(#(P,3$L(')E2X\+W`^ M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ(#!P M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&IU#L@1D].5#H@,3!P="!4:6UE M3L@5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[ M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3L@ M5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'!E;G-E9"!A6QE/3-$)U1% M6%0M04Q)1TXZ(&IU#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&IU$$P.SPO<#X-"CQP('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&IU2!D:79I9&EN9R!N970@;&]S&-L=61E9"!F3L@5$585"U)3D1%3E0Z(#`N-6EN.R!- M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE3L@5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U=)1%1(.B`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`E)SXR+#$P,"PR-C<\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS M1"=724142#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SXR+#(Q-RPR-C<\ M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q M)2<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`M,3!P M=#L@4$%$1$E.1RU,1494.B`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`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)U1%6%0M04Q)1TXZ(&IU$$P.SPO<#X- M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU0T*9&EF9FEC=6QT M('1O(&1E=&5R;6EN92!A28C>#(P M,3D[2!O9B!O<&5R M871I;F<@;&]S6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@1D].5#H@,3!P="!4:6UE3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E3L@5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[ M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3L@ M5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!B96QI979E6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@ M,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE M#(P,4,[4F5C96YT($%C8V]U;G1I;F<-"E!R;VYO M=6YC96UE;G1S)B-X,C`Q1#L@:6X@3F]T92`T+"!3:6=N:69I8V%N="!!8V-O M=6YT:6YG(%!O;&EC:65S#0IC;VYT86EN960@:6X@=&AE($YO=&5S('1O($9I M;F%N8VEA;"!3=&%T96UE;G1S(&EN8VQU9&5D(&EN('1H90T*0V]M<&%N>28C M>#(P,3D[65A7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE$$P.S4F M(W@R,#$T.U-T3L@5$58 M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE3L@5$585"U)3D1%3E0Z M(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE2!O9B!C;VUP86YI97,-"G1O(&1E=F5L;W`@86YD(&UA65A<@T*6%L M=&EE6UE;G0@86YD('1H92!R969I;F%N8VEN M9R!O9B!B6QE/3-$)U1%6%0M04Q)1TXZ(&IU$$P.SPO<#X-"CQP('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&IU2!#;W)P+BP@9"]B+V$O($%M=V%Y($=L M;V)A;`T**"8C>#(P,4,[06UW87D@1VQO8F%L)B-X,C`Q1#LI+"!A('-U8G-I M9&EA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C M9#$X-61B-5\W-#!A7S0T,S!?.68R85]B,#AB8CEA93$R9#@-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V0Q.#5D8C5?-S0P85\T-#,P7SEF,F%? M8C`X8F(Y864Q,F0X+U=O'0O:'1M;#L@8VAA'0^/&1I M=B!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)U1%6%0M24Y$14Y4.B`P:6X[($U!4D=) M3CH@,'!T(#!P>#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E#(P,30[0V]N=F5R=&EB;&4@1&5B M=#PO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU$$P.SPO<#X-"CQP M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU0T*)#$T+C,@;6EL;&EO;B!O9B!A9&1I=&EO;F%L M('=O2!T:6UE#0IP2P@;VX@2G5N92`R.2P@,C`Q,BP@=&AE M(&1A=&4@=V%S(&5X=&5N9&5D('1O($YO=F5M8F5R(#,P+`T*,C`Q,BX\+W`^ M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!415A4+4E.1$5. M5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE2`D,RXQ(&UI;&QI;VX@870@2G5N92`S,"P@ M,C`Q,BX@5&AE('!R:6YC:7!A;`T*86UO=6YT(&]F(&)O&ES)B-X,C`Q.3L@96QE8W1I;VX@:6YT;R`R+#4R,2PR,C(@7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^/&1I=B!S='EL93TS1"=& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE#(P M,30[26YT86YG:6)L92!!3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E$$P.SPO<#X- M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU6QE/3-$)U=)1%1(.B`X,"4[($)/4D1%4BU#3TQ,05!313H@8V]L M;&%P6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@ M8F]L9"<@8V]L6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58 M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L$$P.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=) M1%1(.B`Q)2<^)#PO=&0^#0H\=&0@$$P.R8C>#(P,30[ M($%C8W5M=6QA=&5D(&%M;W)T:7IA=&EO;CPO=&0^#0H\=&0@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F M="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1) M3D$$P.SPO=&0^#0H\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T M(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U!!1$1)3D$$P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E$$P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU3L@5$585"U)3D1% M3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE3L@5$585"U)3D1%3E0Z(#`N-6EN M.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UEF5D(&]N(&$@6QE/3-$)U1%6%0M04Q)1TXZ(&IU$$P.SPO<#X-"CQP M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU6QE/3-$)U1%6%0M M04Q)1TXZ(&IU$$P.SPO<#X-"CQT86)L92!S='EL93TS1"=724142#H@.#`E M.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U9% M4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U)3D1%3E0Z("TQ,'!T.R!0 M041$24Y'+4Q%1E0Z(#$P<'0G/@T*665A6QE/3-$)U!!1$1)3D$$P.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@$$P.SPO=&0^#0H\=&0@6QE/3-$)U=)1%1(.B`Q)2<^ M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!7 M24142#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/B8C>$$P.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T M;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`Y<'0[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXY-"PQ,#`\+W1D/@T*/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\+W1R/@T* M/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-! M3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4E.1$5.5#H@ M.7!T.R!0041$24Y'+4Q%1E0Z(#!P>"<^,C`Q-2X\+W1D/@T*/'1D/B8C>$$P M.SPO=&0^#0H\=&0@"<^5&AE6QE/3-$)U!!1$1)3D$$P.SPO=&0^#0H\=&0@$$P.SPO=&0^#0H\=&0@6QE/3-$)U!!1$1)3D$$P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/CQS<&%N/CPO7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^/&1I=B!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)TU!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE#(P,30[0V]M;6ET;65N=',@86YD($-O M;G1I;F=E;F-I97,\+V(^/"]P/@T*/'`@$$P.SPO:3X\+W`^#0H\<"!S='EL93TS1"=415A4+4%,24=. M.B!J=7-T:69Y.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&IU$$P M.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU2!E;G1E2!A;F0@37(N($)E;F1E65A65A#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE7,@<')I;W(@=W)I='1E;B!N;W1I8V4@9F]R("8C>#(P,4,[ M9V]O9"!R96%S;VXF(W@R,#%$.R`H87,-"F1E9FEN960@:6X@=&AE(&%G2!A8V-R=65D+"!B=70-"G5N<&%I9"!C;VUP96YS871I;VX@ M<')I;W(@=&\@=&AE('1E"!M;VYT:',@;V8@:&ES(&)A2!T97)M:6YA=&5S($UR+B!"96YD97(-"G=I=&AO=70@8V%U2!-#L@1D]. M5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4 M:6UE"!M;VYT:',@9F]L M;&]W:6YG('1H92!T97)M:6YA=&EO;B!O9@T*37(N($)E;F1E XML 18 R29.htm IDEA: XBRL DOCUMENT

Convertible Debt - Additional Information (Detail) (Pyxis Innovations Inc, USD $)	1 Months Ended	6 Months Ended
	Apr. 13, 2012	Jun. 30, 2012	Jun. 30, 2012 Maximum	Aug. 17, 2006 Working Capital
Debt Instrument [Line Items]
Working capital borrowings				$ 14,300,000
Credit facility extended date		Nov. 30, 2012
Amount borrowed under credit facility	1,316,255
Principal outstanding under the credit facility		14,316,255
Fair value of convertible debt		$ 3,100,000
Principal amount of borrowing convertible in to common stock shares			2,521,222
Convertible debt conversion price		$ 5.6783

XML 19 R28.htm IDEA: XBRL DOCUMENT

Strategic Alliance with Alticor Inc - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Business Acquisition [Line Items]
Commissions paid	$ 452,000	$ 543,000

XML 20 R30.htm IDEA: XBRL DOCUMENT

Intangible Assets (Detail) (USD $)	Jun. 30, 2012	Dec. 31, 2011
Schedule of Intangible Assets Disclosure [Line Items]
Patent costs	$ 1,154,523	$ 1,154,523
Less - Accumulated amortization	(697,666)	(639,939)
Total	$ 456,857	$ 514,584

XML 21 R31.htm IDEA: XBRL DOCUMENT

Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Schedule of Intangible Assets Disclosure [Line Items]
Patent amortization expense	$ 28,863	$ 28,863	$ 57,726	$ 57,726
Patent life			10 years

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References+ Details

XML 22 R8.htm IDEA: XBRL DOCUMENT

Basis of Presentation

6 Months Ended

Jun. 30, 2012

Basis of Presentation

Note 1—Basis of Presentation

The accompanying condensed financial statements include the accounts of the Company as of June 30, 2012 and December 31, 2011 and for the three and six months ended June 30, 2012 and 2011.

XML 23 R32.htm IDEA: XBRL DOCUMENT

Patent Costs Amortized on Straight-Line Basis (Detail) (USD $)	Jun. 30, 2012
Expected Amortization Expense [Line Items]
2012 (remaining six months)	$ 57,725
2013.	109,266
2014.	94,100
2015.	77,656
Thereafter.	118,110
Finite-Lived Intangible Assets, Net, Total	$ 456,857

XML 24 R2.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS (USD $)	Jun. 30, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 3,831,625	$ 1,728,222
Accounts receivable from related party	4,916	2,662
Trade accounts receivable	31,238	55,892
Inventory	88,368	107,758
Prepaid expenses	243,596	217,387
Total current assets	4,199,743	2,111,921
Fixed assets, net	183,656	289,011
Intangible assets, net	456,857	514,584
Other assets	38,001	38,001
Total assets	4,878,257	2,953,517
Current liabilities:
Accounts payable	569,108	369,306
Accrued expenses	234,781	182,597
Deferred revenue	970,943	824,845
Notes payable	14,316,255	13,000,000
Total current liabilities	16,091,087	14,376,748
Commitments and contingencies (Note 8)
Stockholders' deficit:
Convertible preferred stock, $0.001 par value - 6,000,000 shares authorized; 5,500,000 and 5,000,000 shares issued and outstanding at June 30, 2012 and December 31, 2011; aggregate liquidation preference of $24,000,000 at June 30, 2012	5,500	5,000
Common stock, $0.001 par value - 100,000,000 shares authorized; 36,761,864 and 36,709,706 shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively	36,762	36,710
Additional paid-in capital	93,966,029	91,111,640
Accumulated deficit	(105,221,121)	(102,576,581)
Total stockholders' deficit	(11,212,830)	(11,423,231)
Total liabilities and stockholders' deficit	$ 4,878,257	$ 2,953,517

XML 25 R6.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical) (USD $)	6 Months Ended
	Jun. 30, 2012
Private placement of preferred stock, offering costs	$ 354,907

XML 26 R35.htm IDEA: XBRL DOCUMENT

Black-Scholes Pricing Model Assumptions to Determine Fair Value of Warrants (Detail)	6 Months Ended
	Jun. 30, 2012
Stockholders Equity [Line Items]
Risk-free interest rate	1.00%
Expected life	5 years
Expected volatility	142.36%
Dividend yield	0.00%

XML 27 R22.htm IDEA: XBRL DOCUMENT

Capital Stock (Tables)

6 Months Ended

Jun. 30, 2012

Black-Scholes Pricing Model Assumptions to Determine Fair Value of Warrants

For purposes of determining the fair value of the warrants issued in the Preferred Stock transaction, the Black-Scholes pricing model was used with the following assumptions:

Risk-free interest rate	1	%
Expected life	5 years
Expected volatility	142.36	%
Dividend yield	0	%

- Definition

Tabular disclosure of the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments, assets, and liabilities. Such certain disclosures about the financial instruments, assets, and liabilities include: (1) the fair value of the required items together with their carrying amounts (as appropriate) and (2) the methodology and assumptions used in developing such estimates of fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 14

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Paragraph 18

-Subparagraph c(2), d, e, f

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15

-Subparagraph b-d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13467-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Paragraph 19

-Subparagraph a, b, c(1), d(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6447952&loc=d3e13220-108610

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32

-Subparagraph a, c(1), c(2), c(3), d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13476-108611

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

+ Details

XML 28 R36.htm IDEA: XBRL DOCUMENT

Total Compensation Cost Recorded for Stock-Based Compensation (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 48,357	$ 60,491	$ 96,131	$ 130,966
Stock option grants beginning of period
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	48,185	44,949	94,796	73,600
Stock option grants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	3	14,092	3	54,511
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 169	$ 1,450	$ 1,332	$ 2,855

XML 29 R24.htm IDEA: XBRL DOCUMENT

Operating Matters and Liquidity - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended			1 Months Ended		1 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2011	Jun. 29, 2012 Series B Preferred Stock	Jun. 30, 2012 Series B Preferred Stock	Jun. 29, 2012 Extended Maturity
Line of Credit Facility [Line Items]
Net loss	$ (1,229,834)	$ (1,212,267)	$ (2,644,540)	$ (2,467,978)
Accumulated deficit	(105,221,121)		(105,221,121)		(102,576,581)
Current notes payable	14,316,255		14,316,255		13,000,000
Extended date of the credit facility								Nov. 30, 2012
Convertible preferred stock, shares issued	5,500,000		5,500,000		5,000,000	500,000	500,000
Net Proceeds from issuance of Series B Convertible preferred Stock						$ 2,750,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.

+ References+ Details

XML 30 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'

'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'

'+ "\n"+' '+ "\n"+'

'+ "\n"+'

'+raw+'

'+ "\n"+'

'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 31 R7.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
CONDENSED STATEMENTS OF CASH FLOWS (USD $)	Jun. 30, 2012	Jun. 30, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,644,540)	$ (2,467,978)
Income from discontinued operations		158,366
Loss from continuing operations	(2,644,540)	(2,626,344)
Adjustments to reconcile loss from continuing operations to net cash used in operating activities:
Depreciation and amortization	168,082	202,897
Stock-based compensation expense	96,131	130,966
Changes in operating assets and liabilities:
Accounts receivable	24,654	(30,390)
Federal grant receivable		117,946
Receivable from related party	(2,254)	(99,757)
Inventory	19,390	20,509
Prepaid expenses and other current assets	(26,209)	7,306
Accounts payable	(10,198)	(46,602)
Accrued expenses	12,184	(217,417)
Deferred revenue	146,098	246,424
Net cash used in operating activities of discontinued operations		(5,875)
Net cash used in operating activities	(2,216,662)	(2,300,337)
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital additions	(5,000)	(1,681)
Net cash used in investing activities	(5,000)	(1,681)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of notes payable	1,316,255
Proceeds from private placement of preferred stock	3,000,000
Proceeds from employee stock purchase plan	8,810	16,965
Net cash provided by financing activities	4,325,065	16,965
Net increase (decrease) in cash and cash equivalents	2,103,403
Cash and cash equivalents, beginning of period	1,728,222	3,999,029
Cash and cash equivalents, end of period	3,831,625	1,713,976
Supplemental disclosures of cash flow information:
Cash paid for interest	204,884	178,260
Supplemental disclosures of non-cash investing and financing activities:
Warrants issued in connection with preferred stock financing	$ 104,907

XML 32 R3.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2012	Dec. 31, 2011
Convertible preferred stock, par value	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	6,000,000	6,000,000
Convertible preferred stock, shares issued	5,500,000	5,000,000
Convertible preferred stock, shares outstanding	5,500,000	5,000,000
Convertible preferred stock, liquidation preference	$ 24,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	36,761,864	36,709,706
Common stock, shares outstanding	36,761,864	36,709,706

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References+ Details

- Definition

Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References+ Details

XML 33 R17.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation Arrangements

6 Months Ended

Jun. 30, 2012

Stock-Based Compensation Arrangements

Note 10—Stock-Based Compensation Arrangements

Total compensation cost that has been charged against income for stock-based compensation arrangements is as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2012		2011		2012		2011
Stock option grants beginning of period	$	48,185	$	44,949	$	94,796	$	73,600
Stock-based arrangements during the period:
Stock option grants		3		14,092		3		54,511
Restricted stock issued:
Employee stock purchase plan		169		1,450		1,332		2,855
	$	48,357	$	60,491	$	96,131	$	130,966

Stock option and restricted stock grants

The following table details stock option and restricted stock activity for the six months ended June 30, 2012 and 2011:

	Six Months Ended June 30, 2012					Six Months Ended June 30, 2011
	Shares			Weighted Avg. Exercise Price		Shares			Weighted Avg. Exercise Price
Outstanding, beginning of period		2,228,067		$	1.14		1,611,267		$	1.54
Granted		500			0.34		781,000			0.35
Exercised		(2,500	)		0.00		(2,500	)		0.00
Canceled/Expired		(125,800	)		0.59		(172,500	)		1.18
Outstanding, end of period		2,100,267		$	1.17		2,217,267		$	1.15
Exercisable, end of period		1,393,217		$	1.50		1,086,967		$	1.75

Employee Stock Purchase Plan

Restricted Stock Awards

At June 30, 2012, there was approximately $217,000 of total unrecognized compensation related to non-vested share-based compensation arrangements granted under the Company’s stock plans.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 93-6

-Paragraph 53

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64, 65, A240

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

+ Details

XML 34 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2012	Jul. 31, 2012
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q2
Trading Symbol	ILIU
Entity Registrant Name	INTERLEUKIN GENETICS INC
Entity Central Index Key	0001037649
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		36,761,864

XML 35 R18.htm IDEA: XBRL DOCUMENT

Industry Risk and Concentration

6 Months Ended

Jun. 30, 2012

Industry Risk and Concentration

Note 11—Industry Risk and Concentration

During the six months ended June 30, 2012, approximately 63% of our revenue came from sales through our Merchant Network and Channel Partner Agreement with Amway Global, a subsidiary of Alticor.

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6327-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6442-108592

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13531-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 21, 22, 24

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

+ Details

XML 36 R4.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
CONDENSED STATEMENTS OF OPERATIONS (USD $)	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Revenue:
Genetic testing	$ 777,549	$ 779,116	$ 1,454,717	$ 1,498,563
Other	21,886	17,749	22,603	17,787
Total revenue	799,435	796,865	1,477,320	1,516,350
Cost of revenue	393,122	438,464	769,333	796,053
Gross profit	406,313	358,401	707,987	720,297
Operating expenses:
Research and development	317,440	359,799	763,714	664,618
Selling, general and administrative	1,176,110	1,253,143	2,312,760	2,455,598
Amortization of intangibles	28,863	28,863	57,726	57,726
Total operating expenses	1,522,413	1,641,805	3,134,200	3,177,942
Loss from operations	(1,116,100)	(1,283,404)	(2,426,213)	(2,457,645)
Other income (expense):
Interest income	860	1,901	1,603	4,307
Interest expense	(114,594)	(89,130)	(219,930)	(177,281)
Gain on disposal of assets				4,275
Total other income (expense)	(113,734)	(87,229)	(218,327)	(168,699)
Loss from continuing operations before income taxes	(1,229,834)	(1,370,633)	(2,644,540)	(2,626,344)
Benefit for income taxes
Loss from continuing operations	(1,229,834)	(1,370,633)	(2,644,540)	(2,626,344)
Income from discontinued operations, net of income taxes		158,366		158,366
Net loss	$ (1,229,834)	$ (1,212,267)	$ (2,644,540)	$ (2,467,978)
Basic and diluted net loss per common share from:
Continuing operations	$ (0.03)	$ (0.04)	$ (0.07)	$ (0.07)
Discontinued operations		$ 0.01	$ 0.00	$ 0.00
Net loss	$ (0.03)	$ (0.03)	$ (0.07)	$ (0.07)
Weighted average common shares outstanding, basic and diluted	36,756,802	36,650,158	36,752,456	36,634,173

XML 37 R12.htm IDEA: XBRL DOCUMENT

Strategic Alliance with Alticor Inc.

6 Months Ended

Jun. 30, 2012

Strategic Alliance with Alticor Inc.

Note 5—Strategic Alliance with Alticor Inc.

XML 38 R11.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

6 Months Ended

Jun. 30, 2012

Significant Accounting Policies

Note 4—Significant Accounting Policies

Revenue Recognition

Sales Commission

Accounts Receivable

Inventory

Inventory consisted of the following at June 30, 2012 and December 31, 2011:

	June 30, 2012		December 31, 2011

Raw materials	$	83,895	$	100,433
Finished goods		4,473		7,325
Total inventory	$	88,368	$	107,758

Income Taxes

Research and Development

Research and development costs are expensed as incurred.

Basic and Diluted Net Loss per Common Share

	As of June 30,
	2012		2011
Options outstanding		2,100,267		2,217,267
Warrants outstanding		2,587,158		2,150,000
Convertible preferred stock		39,089,161		28,160,200
Convertible debt		2,521,222		1,937,200
Total		46,297,808		34,464,667

Fair Value of Financial Instruments

Cash and Cash Equivalents

Recent Accounting Pronouncements

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

XML 39 R23.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation Arrangements (Tables)

6 Months Ended

Jun. 30, 2012

Total Compensation Cost Recorded for Stock-Based Compensation

Total compensation cost that has been charged against income for stock-based compensation arrangements is as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2012		2011		2012		2011
Stock option grants beginning of period	$	48,185	$	44,949	$	94,796	$	73,600
Stock-based arrangements during the period:
Stock option grants		3		14,092		3		54,511
Restricted stock issued:
Employee stock purchase plan		169		1,450		1,332		2,855
	$	48,357	$	60,491	$	96,131	$	130,966

Stock Option and Restricted Stock Activity

The following table details stock option and restricted stock activity for the six months ended June 30, 2012 and 2011:

	Six Months Ended June 30, 2012					Six Months Ended June 30, 2011
	Shares			Weighted Avg. Exercise Price		Shares			Weighted Avg. Exercise Price
Outstanding, beginning of period		2,228,067		$	1.14		1,611,267		$	1.54
Granted		500			0.34		781,000			0.35
Exercised		(2,500	)		0.00		(2,500	)		0.00
Canceled/Expired		(125,800	)		0.59		(172,500	)		1.18
Outstanding, end of period		2,100,267		$	1.17		2,217,267		$	1.15
Exercisable, end of period		1,393,217		$	1.50		1,086,967		$	1.75

ZIP 40 0001144204-12-045626-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-12-045626-xbrl.zip M4$L#!!0````(`(:`#D%<]T=-4$%]%1$55MKZMZIF=?%)2$R^S(X`;DLN?7[TF09"1A"23`>.NA MNTH"E-_)D^>6)S]^^>O3_7ST&"1I&$38*HFD\"Z,?'\X6J>>S`\ M&Z69'\W\>1P%'\Z>@_3LKQ___=]^^0_#&(W=7ZV;T54T#Z-@],GX$F1)^#3Z M8QK,@\3/X*-(WSH-1FX\7=P'4?:7T7<_#6:C.!K]8=]\'N%S-!K=9=G#Y<7% MSY\_SX/9#S\QXOR!Y]/X_F)D&*L?^ULQSLO1B)\C<ZF_G>ZZ'G_ZG%MKZ>OW!QO4_27XU4DI=Y-^N+@W3F&(D]@VF MN&+][#2L>C)-;013D'Z6/*_OS'\B#:;G/^+'B^67%\4$ M((.@U6VS(*R^!;ZHN#R*[ MBA^)XBA:W%<+;)8E%]GS0W`!%QEP59"$T_5]AV_:O`$6UP_??UC?=.NGW_,; MEE]4C`V^T4]**^_)OZFX20]DMB7GY93RB^++C4NSRDM9<6EV!EH^&N5Z/K], MY5HW\,S^9)O$\J*?>^1UW27#[X4Q/MK&:T?.G M=':$]M=?6!<%K*7H+S_#8K^Z!0,R"S//G\)8LNLAL]ZB">3Z['C"%BP!^$D6G\MVF:=/+UFSLQ)UKFID0"_DJ5 M$,1\8M(D4DT8_)>R)T:HX+`6%U%8/&^Y.B>_?W7/1K-@&M[[9L*!R08T,,(7`:3Y M$\O8/_WF;8.7[MA3%O,,#V%F4.P00W+F&#;ER,7*MCU+3C`(&?ZPLX^$"XXD MI[]\/U#T&4 MYN[52A(_^A%HWVX_CV'IQ\]!D#_J>I%,[^#RZ[D?_;:X_QXD5[=#$)EE6X*9 MDAC.>,P-JA@RI"N%(EI?4I31?^]WGP^T,< MC9^"9!JF8'3_[FOU@5AR2)C%V4=*!&)R.:^U4921S_TT77]SE>0A\_CI(4SR M57,-P5#8ZASI!"[ABFM3C3%KJJX>]83%V=C`^I?`NXT- M:3NFP5Q'V0ZV'-,BVKOAEU6Z?Y$64,I.37_GQ-$R!\YE`W.?7]TRXLYF6GMW MMC79^W#U->,0>S:>\5J(J4:,:MKE\I2OKJOAR%\NN?:?]4?63S^973WH"]/E M4M)VL/#K#46%=%;3W'K;Q(&;(;:G"D)]*A$W)+/A;T0P(81TE.3%,2Q/@'"HJ;,? MRS*P9=E869APDTT@YQ%:./`'I&-()20D0B7Q[(R_,YWY>Z"=33"S8'7Z/X(- MP]RFT%XQ,W@G@<)CVT44\@<74@"Z:E`+4Y%3:ELI<-^>F=%,_T_O6@>_3D\-;4R!Z*+9WC2W_SY MHE5![C<$&%:UU((S=26`VM)0;&P99`SI#'&00O`[N?0P1$=(0/HH>"D/K@.F M,U4MRF)]D!W8TGF3"328&?($R@A'3H5U!16^)%1-+0I9R0^![" M64L5ZH.D)9";./>7S-J?3T2H['`^R40LH1+.F7K#"=T"VNJ$D@DOH92*D#>< M48)EC<+WT3/*)VH5^.D0$"DB1(-I;1VNY$AU")=-Y!*N@KQ)L8V([0#8W^(L M2,%HZY#,64`R%67-$\$C_;=$)B8.N"4;W#CD^PKPV=PVQAPCPICK.95%]).9V9:,&D$WD5]E=D!27_A9'TX'.JL8* M>HM>@%:.>Q.:%\)P@L_A8S#[%(&Q^A'"]!>W6/=QDH7_R@4S?M)Q2O"/P$^^ MW25!9Q.]`]X9$P40B8$Q%1!?<6E(S&R#2VQ)11%%K@G@R=E'(3@K!:-'`AM6 MH6-7;JV&IRA/2(DB,!/OI]#1^4HB5/LY^&DL28-P=(_&_1;T9RYJKAA(3"CC MDHE:2P8`[.[CAME]GN!!R@?8(,H)HFD8'%'3WX?T*0TOHW#^X2Q+%L&QIE'M M]"B4L%[[F8;Q:Q*G+8]]SRPIKHA4DABFXX+_LFQF6-3D!G8%4M:82-O#A?]" MB%&&2>4TE8?>W3[[43:HYM1@I4NMS;?4AUU6W*L7;=>R"BM^SK8SRK[+BJUV MLG2I^+.<0.,Q!5.`T'-ZN$Y)4FAK$.PU]0'T:R9:ESU1\:.@0KETH!:[H4?!=# M?0\;=3T'-\5&73?;)_6#FY7GO`FF0?B8Y[9!-E";"(X?+B<5?K]J])LX/T5@ M,[,X>>XS9:V)"S1!2O"&+[C*H]UGWZ_]Y"KYFFD[D6]"'M^BU%CSR;%6'^N6 MI(UR7CU,V[WX_G?=10IY.>3I[Z#VPBILXR$0W>^I=XX;Z^)M7I(_:3]])XDY MMA6MR_3+K)5^536>592EQD_3^4+;\E_C>/8SG,^'-K-JM]!6!\:.^TE`&J6% M,%#?@W3#`P%_CC:\3_7@7W$]-_[/+V#6DA!&TAL^2K!M(D\97)BF06W;,R3' MRK!MFU,&^1C#K"C(22(5J_!!Y6&?O,GR,QY:N@D6"OY1SD&.@O6J>QJJ0NM. M)V[J.DJU1]J[5[I,0?L#Y3B,'WN\QWA;[L3;-0#5M_,OE8JR M;1S:?I,^CZ8$KUM3K`9558,9J'77)[604J)L"3<&_$J(HH62W@4S':T-+D;1 MY24J2$6(LC'LCL\4=ED1!7/-ZIQ7>G4+IUGH`U?AG:^3&!QF M]JP/4V=6--,5A0<=L@RPT*=#;DDVVKGV#7_+W\QFH59J?W[MAZ#VCO\09O[@ MR@)$YU-$DTO@4H?T*X/?IZ"?0Q#%K#AUFW\11--@F%J;[]KNW\EZ'OQ- MD`='O"U*DZM4YJK1#;@V6A5'$,C.3E*VK5H3=#&R>E^:$V. MFBNQPHM>5)=)\202./;';@B_S9KH735H6\?;1@@D)2,( M7#+;I6*IAZWOF6:C3'(:RI(O MWB+)0,7I^F.0AO!NF MTWF<@F8?&4(UE<7NN;'ZPM`[\FBG+?T@L.,C=?W$EL72HBW-(Q]0$,PPPA@? M%[AKB"4!O;K8-L*B-F0R82:$(.*)(6JRQF>\:RD-T4I#M@54#V)+NVU;T>2C M'\[UA(`W^U5S51TM2$FQ>F)"4(P;GZ;V.'A@TS9<[H&CXM0&'^5R@YMC3R&$ M!2A>H5RF9DI@$M+E%K;@#DBBFQ-I_1`FB!5A`F+;1<"NS]^7JQ(DQ` M5:7^KH_7[^#LDC!!K`@3$-O9<.U]0CLC3!`KP@3$JKJ_>I_1+@D3Q(HP06.M M:F/OG#!A!VZ7A`EB19B@X>Z6M%\#VS6_YU(`B@BER?0D[B;)S%FA]5DK6JX) M'DZ& MJB[J3,NVV-@9&U2ZCD&=,3H:R/J":9?`O$4C>0R+>2UCP5=[QW6. MQK^!E>P6.#Z!OKTO,[DE@5;-)%YV8B#Y3NWD,>I1RQRL)(,EXO"1.7P[^;J> MM&HG\7+=F.<$:>*8AG;RY*(<(-]Z/5>K93CT0M`/LV]H3EJSS(_3-4%_-V03 M>X76*MG$VJ*.&:S7C M$!^^)U;XI5#ZV>1$:U9XU#V)H34K?-7+>+K>$MO!V>4F)UJSPN?< M>TS1-YS0SC8YT9H5?H52*/6&,]KE)B=:L\+K:$,)/3#5A.N_=;1=[G&B-2D\ MTJ3P4@>M#<">3@J/CG;?M4ZFX&+KAVP;H8.D\&U0HW>/[2AJ]--?6]`UKB51 M-<4$DP;M!>UQ-Q]`>#IW,^Z.N_GXV:EUEAX/@;MY%V-[IVSQR=S-+1(&=PMT M21AL*F'R/3B[)0SNWDIJWD!0;;/B>&+7A,&=@].-+'!'F<.G!F%P*QRXW4\< M@).82EKJVN^=`[=C4S,X#MSNG7O!@8N9X$SVS8';O<[J"K5BA*%WR8&[5SZM MEB7)NBR)WKHLV2(';N?ZE1.`2(5W75FG'+B=X])LR*80[.U(<(]1_>-(N?!` M27"[-_VLPCB^/0ENY[BQ[C[%,C\]=<+V03LDN!VG%&:ME*(G$MS.9Q8R188H MD[1LMMZ*!+?[X$9;:8F9$AONIR\2W./QU2*8*RH;^;9((Q;<=S!O,C\`+;B@ MLM+P=L#U>@*H.ERO^60=2`Z'M?EZI-VMM?FZ"J;!PTCS_7"]=N]X"ZY75%W% MZX7KM=>P\CUPO79>G]9CK.T^[J$ MYBR%GT&5\;Q5Q#U]GVYT$_?3>L77OG>B[]^X0SO9: MM=BZ]TZ\0>_=#LXN>^_8NO=N-\KO?4([Z[UCZ]X[4559ZWU&N^R]8^O>.U&] M1]AY\]T.W"Z;[]BZ^4Y4^9]#8*_`"?NZQ>E3-(WO@\^-6H601#G>X]_90%UJ M*CPV3,\C^D@7-VP*?W-MV[*0/58,'`W-]T,-S3+&RX6:BJ%O)RG3)/#3P`V* M_W^*MCHV>D1:[YQ`SE=L4$T24TY:#L#81+U!IWOU,X*)OPL?=)@U_GIUO;6A MN:;;+4Z*%X9@]6&#%*".?%ZI4QQ+-XR7QSI+=JQ%Z#N:M-0P+XGOBZ;`A29% M+50PCH:X:)1>-!QS0C1%JV?W^)7`O=<3;YOUT)O`C"M\.C@:Y`\%H?DPG@&87#\ M(\J?TC#I/-W M]S]'-&\^D^UMEITDJJU(<-D$N=JC@9\,I_!0-YPOLIZBNQVYUG3DNK)MF.=F M:1OR`)R*)*XH!KN+!&XKA%=$>45\6,A[);\VQ-'B0=B"+'FGO-0(T:%LR%T$ M.@@\L=;8FTO5[V558O-5T4T@;3\F5B66V;VC+]) M/E@V4LMF_Q[AUTST].:D+-/N-\:T=>(PR&I&8\-3!7T4T<#$-`DI:4-]1/L2 MV^K8$YY]=?O-?P)[LV5R&[8RO(4;H44SPVL)\%&(:RF3WFI.AZY,F@G20+Q< M':T/9[DO0JKCVNWY]*D@8Y!P^!KI/NS)6U@\=XEK9 ME5=;8`\&:L&C@[3A'99B)JCFM+./Y< MOXLRM_^-^M1Z"P[U(0W<1(4UX$Q#=(O810G8?:\"K!A'6T^I6A1^!)D=_'L)2H?XD:C.&YWM361 M;)_@3P,?5IW.5$%1YW%NM_LOZ-24'@B/<\K+=?.]"&IEW%X800`^](R;[601 M]>%L'S-)(4CI/R>H.:"HUT;O$YCHZJH M4#@`S!P;@MO"H,Q5AD4(,CP+4XL(97NF.2'Y;B='&]W`>S'TO(L\L"T\FI_8 M9XTR^5-%L!T6Y*9V@,:4Z+P<<<+,<@A0C':K`TUSP(%SO&W"0M07#/#F`INX MO#%7&F]%[I/3"Z::35U/H!?T.C<.X8*1L6.`5[9AE>MWHC,N(?=S'%N@L>N: M;G$HFE&RV?-?/?;_8^_9EMLVEGQG%?]ARFNGDBJ`(>Z@M6>K>/71QI%\9&6S M^W0*(H<2CD&`"X"2^??;W3.X$J1(BY(8KQ\2BR0PT]W3T[?I[FEH=WGR'A[U MT7#*O.&477'G"HB;@U@@2DH+^H)8N38@X0XF MP(5XZ[&CZVH?:SDU8^#8O?Y8TX=:,Q MM;%,`WQ+>*U`_]M0J^6X@F$VPQ_\>_Z93U?< MB+OM7XI:[FAL3L:NKHY&]D@U^UU-=0>VIHZ[8)`,'<,QG1YF1\C3+'#%P:DL M=RXX"K8;SNXIOWIXLS5LZ:EF7URBF&>^'RF&-%6J^([9V@ M=]6C!L[@;^^,T-?Q.*[/4U]E1PV``9\!JM\ M9V/L?46%N]$8NYPA=SFO=_`XO9V/7<$M!N#/8XE:CVV3F_'8Y=E%<8S MM9U9GINH-)OK)RO5-0H-.'KY.+8&]'.*L9HA23_BM;@3SX^?H5)IW^CCGD>3 MMKBE[+EDWJ/$><6LL)>IB3?SFG@\!3YN?M@+GXZ_0&V]F=?6/].9^5$\CI>I MO3?SVGO]0#?D5&LO7Z:(W\R+^%^]$/.5Y-G+4%>D<.Y157.02#MJ-2:0Q#4M M\ZME:%W+_)8&=Z.1[O3MKCJQQB/P&/J..K#=B6IJ]D!SQWUK.+`Q`Y@BH=6R MBF\OSCP"ME9/?RYL=9P<.VR9EO:HW?`RZ)J:;C\7N@9.WL7>=_;CKN$)A0?_ M:6FFT]-01UFF\RS!0N![&2_4RY<`/V.\\$0HZO2L@\V?_<*O.46Q=:QF57M% M?;<$U4R]>W#SK;T(:N0$Q3/2GN'\_^#0ND0\'D'-G*!=;&ZL.?HS'1',N/_^ M.O;P#.;S>G$3'="B4'.Q&"N[_;L!S4FO;TW4B8;1$WUHJ*YM#=6!:6LCO3<8 M3/KN/V7'-L#Q_./Y'__^ZP8T!9!CP#E=7_%;BAF'Z86W.,A`/A:L(#'.+Z[' M5Q_'?_QV?L$^C"_&U^?#S^S\8BC@;P*T0*,/-O$,[>))X!W0>VTW_(8]GHR' MEJMVA[VN:D[Z7=6U-%T=]$==T^D;%A@J_Z0^V7/@2B[@K$!2I_/$#W@\]%)^ M&\4'M!(['IG!ZOT,6PB@8%=\B3'$\)8A5WOANDSG"J`%%J-HNB+<_&0*;@?9 MQQ/X[B!?]`@D!S3^H0MXMX*T#>K_X5[\&C!C%3^,T01U#M(FS-?KY='VXYZ` MTJT%ZC^J@"('\$#L!>?AC'_] MC;_*+L1N+B#RNH9CF[WRMJO!5H`N^Q84[')DFA\"/69\PN@JQEUWP?98*T6\ M,Q=+KH(H6<7\&K`8!/#,L5":`$X#:ZBIIC5T5',$?-(;:$/@I?&H;]BC@>%H M@MM_"M*SF7_/DG0=\+^]F5Q>7+]G6G>9LFM_P1-VP1_85;3P0D5\H;#/P&#S M-S_=IF?M%KZ]S-Z]'O_WM7I^,1KC$%T_/&._]Z\^G%_`!QBNN_QZQL3PH(1G M^\^!I/K)6RS/_NUKOWO6DW\"[N99U@*9Z(NP_+IL@&L+%`.?!10TE_CN MV6D=SY0^N_.`D@5Y;06V%_['A-7-HGF[]98N@6!+ M+V;W%$%=YHN0(.45>(H]W/G3.V;5WE?:K1E/_-L0F[`P+R'(8-B^J@$(X3T' M$P3+HHIE_2Q&?.`Q9SY%X]HM7.JHU%P7/UO5>5CC-(-V:]]96&V2=NOG:026 M$I9<\&`MJ%;LO.%9;;#BI]'9+QU6HGJ[]2C9-8%,E?"LH'N[=2]#U\3O1/6" MZ*ZE&)JCN*Z5O4QXE2D6P1#P`X_O8;9Y%!/26*3>89=S@"Q*N,(,6W%L37%M MLSQ.NU4:Z(P9/:7K]A3-UBJ3509'3*=$=TS+(Q["K\H`U:C'TJB"W!G3%4O7 M%%W7Y33MUA[ST#=O-1/H82NZ9>%7,WZ35G``SQ*TD'@9`/!3-O>F>'J\9@]^ M>L<^K;_ZR1F#02Q7,=WN(P`L([R@V@<9S&7M-,Y:6ER8M3J_7#YQY`@351>^ M<99VJSQX>;`'+Z9#2Z3@4D:FJWSBI0!":8`EE;TC?^D=J\N60`N:6G(3_B6? M%16+0K\'ZW8+_%L_(*1YGF_.9FB'P&C]U2V(,=834N:,:8IC;2!6XT(QU/Z( MM5N;F+$&Q+2.T8A83H4J9FPG8K]C,1I(-L3+.A/2R#0<1;/J;<<-F'(NA)0N%LWIO+ZV.B7->1EF3.UDJA/6I23&"YG? M.TOH"5BU<`6B8,$Y^M:*V+N-C]/J28N8>%D)`]MC^_A#>3X$+ MO/D;+#!GXHRR",@D&"UYALWD<+2K*!V;4K+HNZK#K`N=VZX8'/K\' MZJ5WDAS>O><'(@-G3<(O/YK,-DA9Y;1;-&T*!"<,\5\`%P<:1%X\PQ%&?@Q( M17%2QIG-P%V(.3&P'Z(L"$-$'3Z2X)ZOL!R&S;-R25A./R^3!7F+`0^,*OJX MT$2`=BM9`M"@;6,8'(LNPQG\MHR2A`P&;RJ.32DO'IY!-"+,,@0RQC`<[2+8 MP?`"(.DG9(7$M`$!HR@F/1,!?2)_!O)AR)@8GECI@ MR5CCBJ%]T[18"'AMP5B^7L2_#]$JP+6AOA?"3LDP!NC(-F0>6\B[&H$Z%.,& M2H8@.PI;36PK("'"N%V._L4=L;K-^\/EVJ8XRGJU9OMS2N_#G4KL7VR.DOD) MC!C!Y@;+`/81O5WWK)#I,F>JV95JMX1I?<<#89/L&F*;/Y8-@L)F[@>HH8CS MA_`D['UI(HVD\P5;3Y'O

=A;F8HH/D# M>`3U!B#;:%U+@[U,_4,,[@(CZ0;*H('4VLO`FXHM[-WB_Z4Y@R=5B4<6"NE2 M5-0Y=&2-DYTP]^\Y6W,O!HT[@=7.%11YKT`AK.D`FN.0<\_/HP%2G>=@&,(E9A`%!_43]/P13@":&,LRPB,"]@T(2MD&WS+3J/@B!ZH%W@P40+ MX;Z^?WUI>TJ2?SLL*5F%$IX_ST?7?W_/W.Z[,S:XO!J-K]3AY<>/_4^?Q^\9 MAIV\9<+WGSR#6_TXGA`N.B#SADUY$"1+#U>5$HCP\Q(WC?A<@BW.`!OTA[]] MN+K\XV*$`%U>O6?Q[M?$:(H"__YRQOYK?'5]/NQ_S`AZ$Z5IM"@/-VNB M>\#GZ1G+,'?>T0M7?O)%G8/^0V%$2>\@96##$_726=.8<@1-#%`C>/,K6\'X MUD%BU&C%*-UW;\`@?HB]Y=_>B']I6.T)(+W;>/?7--YOQ4`+I?Q)RT0/8?7! M%.5IX,^;UN.;J?\$DC>2V1*R\X@0[$WJHVZ.*M7OHP#L*?2H3YGVFJEW#/M0 M`%Z?N4?2=61K'ZSC4Z9P]\C$_944T6-GERHJG>]+-?^12!L*S+N2`:/D9A5K MMJJDT8O^@[2L*L=IPG41X8HY*Q]S5T)7(P[>DI^2#?Y6`Y'1Z_X(MU9AN6XP M6CVJ[TN*4$\6@8VEO^B^DPL&3A%L(C\L^5S2BD?3'36$PI;RLK\H!&_AX8X# M')[P//PY'E1.`P^GOEEO"4;2H^AEA5&HRGO>P78'VSZBB#K8U6%4@O7.`\/^ MAO.0Y6-'H63!++1Z/B_[G3D4,!>&.]/8OUD)'X<,\2GX;IZ/CLJ49_R;884A MT23/6Z1#!XI\`?X)/<@)KJGXS0_Q8(S/0I[DGL/-NNJ>Y='.?`A/E,C^S"DK MDBXZ]9*[`N5?*!(GC[;P_5CX_F57#$>F2&,9V+@"'6ZU`CS:HB%&!ADG3Q=? MGN)0"&P6R)3[=B-R`80.`E@%C+OX:2"<-@]]4DJ`B_#,N'">,^!@(4K41S9) M[Z+5[=W.*;.H!CJ(Q)*U!T/JTX&?MGBAY)&+*`(\[XM#VZ4X@RZ]L[%+XNP< M5#CV7I)O"N#<"+B8SK+F_M?2Z53F68H#(0EA">!*1+-"O)A*[+E8AS*9?@BT M"BSG0EU@)Z$TXZW`_]^5/Y.1,J!=$@6"PV!5P+D6Y]/+?/GD3E106M%.!+-P M%:9>3)O3#_./2@-CMEMU1FG<"]ER(INS/-2[]&(?1`L(AB+*VV[=>(F/(B?V M(W$I#]H[PEM M035X*%ZR\P4!1NDP`L"[D?M*X"1.+&HG'_*X)TR65 M@F@7KPD@>"7\MQ'W`>1$#%CHM06%HMJM$B>6E]"KI0M1).BM;F;11H454#CN1ANWIF90ZSUUM[V^NZTG@[K4UA1\+4P^OQ$KK[2*)B; M!&IYBRSQ^JBIOR2C(Z1T"B]1IC`5QXMTQ"P-1V&;5/6=C(0WZN?M0JNRM)DV M%>8C[5?I;I!)M4.\_/Q6Z[BPK9#ED]7-O^2YZ'P5H_`"1LN+?G_)+-.-T#M: M1C2^M"^%OJ?)T6+TY4D-D">A@X\9'4#AKBJ&@FU#"&\F"X(EM0?M44YLG"[H MKJ+9746OGGM4*%<]5"CNG*L?+E`>HJ'U[/+IPFX6>?P(1'`(.XQ!Z/REPB'- MQ_;;&02MRX)#'M$_/[^U.]T-!@'1+SB$?3.#"&/_B0PB!GF<\HWLH765'K!( MS]:.PQZUPZ<3D&$G)5!QVGD$]"NENJM_CL\__!U&":-XX04B"(F[2G)^@T6! MFZBL'>\C9)TTV>&AD-)D99TI;&F*;\"F M6/AIFGEV!$Y#JHLBO688$78P;IT'/.J3J1\DM[TEF&I3\J8#[P$-)8!PP;'M M""6+5"RM3?/ZP6_R-`NM@I`E#.;S@CRWZQ"?D.)'E5V$#AJ9M@7@)8]/;`!< M\:8ELW$MD' MMM0IXU,$E%X?O5[%[DU<8^#TU,G(Z`,:VE#MN<90=4>Z;NBF,YZ,K*/7JQPM M,2B[>Z!$IQ_)0M1%#)3[%)I)UYV[L]%[J(,")%A%,Z8K'_( M$CL))'2TX8&U2`*`L3I,MI010\#4)/9N>#Y;#CTZOZL@%7%1S",ED#`*5V12 M8`@$4$()^7`7B11*+K(>D484:A6YS)AUCWB@V0:_E*.M2W%5$WG0Y3E!QZ5L MS5-Z"OTO,;>2D3J/5X`8C\7%P?"O6"["3DA[:0BU6U5'&4DV`I^3Y+FAT;=: MO>RC&*7=*B]^/@\ZSCT'["+3$%ZP"[ZW:UH**T*!P7K#M-D4YH]*KGUO+_HD MX\LO)]+WZA&HT?6=J@:VMOM(B\`R&E6L\U9N_>)$"',2)C'/[_Z\>E*A98X\ M6/5\9].[@6./^B-WK+K:>**:KCU0^^.QJXXLPS$'^E`;]F1];K?3+36OV1>' MS5M:\2J*]3/I,_AZ8`P`?-,UX'^:BZ67MJD.!KII30Q83_.9ZB_K0OQH2BXG MV0_5MBW@+0E$9BKH(A_S)U,61`_"Q)U&(.G`J5QX\1>>DGP+(\KXIM?RZJ"2 M+@E!HB8)!KSKD4D2PV7I.HLP(HHR'@!^R(,[P0L8T7ZUS%*XTC$ZP56PN'X(L]X MA14NBA&SWV^C:"9&(*3SE5LR@_LG5Q^X#YY-PU)+'OEPWSJCT;G%Q_4P>7U]>7O@!>&/"HA M"JR:;TR2V2!L\PR2E-D$-YC_BM/@GO1GDJ%V0"+:)A"/;HUORB43=*X0]>D3G0HDKY.:65,&,CLN M8S4A5<5W4G([YKO,W?<>\NJQ73FJSY#6_/:0Y,-*-C.^X1J*V[.>,/U>.)P< MVE@-:QK&\^#]@FFN!7M6).%^?"QGF.!=(G=@<9'E>IC0W7\]#]$A>9;K,^@G MD8,K1C$5TSF,!YY$@N^.?HYBZ(?)CF\@P6OI@CJH>L&M=1U@=Z%LHCO4")-Q9 M.+`9<=X64CR\O_^?(OE>=&-_R<#S/DWD>]VN@^VCNUT\4]2Z9J]\_?'!Z%6I M4^DT?YGE,6*K^?'GRT^U&TGR3O1XA".O_TL^Y17'1Z7;EJM;FFX0WN?R%@TO M3.UVRK?['!'U0Z_>/L'C:KSR3+=-TS(K=WD^ALGIWJ7QPEO3?/,?/5LK7P[T MLK=G#+WDKA_.\!],I;CW`ISXF0Y;QA-],M9<4YTX#C#59-)57=<"SNH"=\8\2"7\WC65?#[(67L0NVCC==_7Q8*29(]4< M(0D=UU('$ZVO#FVGYP[*PER-,PXILJ,+-N_1NZO/63#/1 MHU?SU%%Z)"M'QS0-^3@LSDO0 M";:J/AH8KFI;W0'PIJ.IX"E.5+Q$2+,&AF4Y1IYT4LJSV0?^XUY<.8GB.??Q M2#\!R3G.>UG^]?>\B<2U>L>[QO))I*KYH[5;3FI7RK\.7??TH71P,55@V[*/ MN1N=`VZH%%ZJH'=&OV.0XWBW0HL[)ZP][KC;@5'-J2G;2YAC]HP-_(?CX=@$ MZ:VZ/V1M9D[/9?*(&L:JVC:7X,+^<&_ZQV]M>TY+Y"?#\N:''[3+#YJ!$Q!$RR3/LR:['JLMDT1TV*7,8:0M MB)YY%"\2D8-&+9^I:2V6)3^$X(70#>?;B^3*.;Z80Y92RAD54:WB1^;'>@_< M;UX0K#M4;2@_8JUOYO=L+3/;,G:[)0:GHI097V*W&U'\Y M@`N(C5FI\LV+TY#'/W+@:A4#DB%E_YDY]BRBYH`@H46=(*Q/LHRHPPVR@U@) MR1AR-6(J*L`V:V$B5A*=]D"TNH3G9">36K;Z@OSI[!'L@2*!^`,4%A4^>:F< MSKN)(V\FH@64;4\9>S,>BWJ!VQB['\$N2)J^ORO#'RK]"YA6&$RJPOC:M]0VW@G^N]3,Q518S'% M6^XH[5:4P*1W,?5V04G].T<_#I;D@J_;V%P^P M;A^"Z`9YV<.*1.!\G]ITS%D_`':+-J5:0UAH#_OJL;*-T8KCX<"5"%XAP/_' MWK7VMHTDV^\"]!^(X.Y%`I!>OA\[N`%(/8+L)A-CDKV+^32@1V M$=6E@>Y\]FW,(1\L-_LPZ#Q749RA:TF&J8*;/0"WU+%U3]*&NJK+AF/!_O2I`HC*JM5PK>'&H=_3K[_B`=W@CW.&!T-+.ATQ;#.J;K@W1ZEZH]&3*Y\&0_0;PU*]Q&OF6:< M5(+C=YB7Y7/`W\J18_7DMAZSR2ZA\II#,/\ATX_MC@<]@E^_\'E;.T%+V-Q* ME<5\=G"]PYE+`[K6([?*+_=Q;D[HK>&"D=*Y%#X/IZ7Y=#OU0PFZ7K!X@(?- MCO*XM$;WE0ZF.0C>6F6"UU/!@0<>*7+<0%,PU*HIQH6'W;PS#-@LI M<%!6DEC3R?6C8356&-E`]0:V%!XO'0\NF#\/(AYT7;8&K-.7?T%DY2+$?%5) MIE',[S=AXOP<'LXKJ[!:&F41F4QXSX:,'64[$^*CP=TBJ%7YW(<*-F],!"RL MC.JTXCN(0G9'!"MTIO%IIJ#W_P='J9*WAZ9NK=H4PF7@=R1D*9%Z6THSN8R% MB7$<8]1C"..H^#RR]*_"OK$T*+-G.&7PI:!\-%\3KH2B5$0!*6>50&>%&"(\ MYN+F,F+1#*XM^>.T"_'S79B7>^BEC.H0SW`BKBJ*4JB:'=^M13DF"'@(>$*GP'@4+Z#X+ MXU]5Q^AK82YU_<)CV3S+N/W#X@%NR8*[SL-"D7N(#RT6B=^X&L`CE<2SLET- MAM7+.UXYP5Q7.BX,\GY772LZY/A46@I9I_"DN]8`A`UZO[H#LE'A04'0428D MU.U;<-D'M-1HM1;HZFEWY;2V?+2=^?$MQAU=*H]W3+)@V7)-NV](QE#I27IO M8$ON4+6A$173S@Q=4PZ?/W6D2P2K?H>0RU!@0GSNK<%;6CPJ0N&%1[<"B$NK M*"#(5`&NAD'>$UM\GCPC3T*&P9>(;N/_><>!?^O0&2\"3+;8XA9;?#G8X@:` M6M7UH-9K?\:BR=GLK#"MBJ@8NFBH1X)W7N[(SP'8JI;HNR]P7JN,IN(PH>?- MB!WPQ'Z/X8&_RBCXA:`WWYN.)9KF/KP^FP&<'RY+DS8B@?NI7Z:!'2)`(9LP+9E-+D M(^I;HI`=TC&*].5L=!<&\[S.-&\)K[E85*+E9EV-ES55&F\H:K.3Z[2K&_'[ M^B#U\8NJ'+C`RYH#VNMW[^4ES?:8R\-7%WLIV^;17GK"<$XN>V=5\K1`+=$M MXX8-AY22>*CR/O(B;=.ZF\V%J]<]>S)1I9[9T@^G:3B*&*H[#MQJ"*9Q"`WCW4?% MM&5;+0>\I?_[5#.K@ML'/Z>$2SO=\'>L$&'!\#5-W;5,V9HQ;6`<\1:>/\%< MU^]W83C[E";S*7CDAT]M4F5'[_=E^)8.PY2'FF3WW*$T,*VA;+N69=@G*@UU MK#S`Z3R=)AG+]\TYC'*L&"6D/E"I,IZQ\\AJ[^6H+& MTO$=$8'2&.$($>?UZ792?Q:>W=%]78;,ML2;I[KTMY,?T(WA^::< M;=:)V:#$WVU9.PT^[&R4^D,R@2T7:>J:+'M%5Z^TO<^9KZ_<>7DG88&5!YHL MX;TC)4\(]VGG?U=_;JFT$+^ZHT)AA#2KM9TJU=[<"6$&X6E>]7:E M3A2VDGD+]$A_8.\/[E*ZMC(TL<:H)KN>I+NJ(WE&SY(&EF-:FC,<#M7>^;J4 MK#+[J%YC,9OE=2TXE>8(1'^+*6*W6&:34&()%A5`'!3Q]DHWO`9SI9T*.R<5 MX_`K26CG<&>[EJ/*.,M;RHO.+3PY:_8AY(!2@G MBZ\JH[5"4&>QVV#KTCZ:$NX[X MTG8\[7C>9'KL,]#.Y?K0[=2\E";-RSXHW@:KEZ*+LK/M4'%&8WDC4X(@\:W' MDZ;EFS[7Q*FL]BR-Z/J0(O8\(Z3=\-OQM.-Y"QO^+G4BU"MU=9'0Z*_\+7F^ M'U\DIISG29A._(LJ"J&8AZEJ<'SL7B.E)^K&T5/1W[3\-&T?3[&57UU^JF@; M^T4HSP`*L>+(M_0SN?XZ(PMXNU9R(DAVD>BDJQ MWGV45%4Q3;.")=I]1"NL/\E]^"7),B3&0;Q9@@64YV%0EI:&MK^-?_@_K\-T MB>62)J'9S)U$B5IEKCS`B'=2IL_Q`V,/:;(RJ3(HDR%7Y;/[<)8U"1]`.V42 M_LR!)2<<](XZH6@(1)2UJDZL[_M.+*Z4LUW#\A4,SK`,G7+.L<*XJ?R+CFZZTJJZWJJXZJ:*1M_.+)L_:'`2V44@VTK3Y.Z;A_@,AMU,@K#@&P+ M6\(T=KY89_^.@S#]3+QDT4,(-K5^#<=&FV@J^K*X#C76)WG8.)[PMYQTKFFB M41#9JYNR8V\E7ZL/8P.8U2TQCCDFI\H)?@HF<\\R^V[?'DBV,AA*8%*>Y`X& MMM0W-$OWU)[2Z\N28QH&3'B_9]BV;"JF]1I8C".QU6G\1ZK56Q5VA5.#_->&(BA> M@^Q`<.>W\`9!E66S3E7LCSAA$?XQIT*(`^%FGD5Q2=K;[;BX)?[3Q[>1PE<* ML'WYTA/>X_>7G_G`R-'*/W<[]'+^+.ZG76Z4@J,B(29)B)]U]+XA<<029)HTN`UJ_W? MS][>DIT7JEBEB%!$D!C6906;XF13.?-1P+EOTW`V3^,,]#.H+J?1++SG?-ZI M'R"7%&#?^5;$RH=6R(N>$N!&AA%#)N/Y`C=0>ZQ5C_\@(2 M(2>R9@1>>;D\+DE:PN)$F"3Q+=%4LY%?<>+"@B(-,7Z<98UQ,^4H011'3=PE M1V11D*(VCT+!M$1DQL73.[`LO=1363I-K76(J^$>;[$:#7KT4W@)=ZV0VCX+ MH2?LG/*?$*-?8>`^0"=NP_QST.?1*P4I;'7@]14=W*D^.M&6;4C>4'&EGFDY MMF<[@WZ_O\Z3/*UL-@&*AQ&2('Z!\TNP7)CH.'!@S;8'AB?+DF6IBJ3#`4-R M^ZHJV0.M;UL#3W9U]WSAP"U95`OH/5.@44L6U9)%M611SP:\M&11+5D4OJ$E MBVK)HHXDN98LBEILR:+:-)FS)(O:EB:S\SE\]^MJ.&G1)R>]9]WO>EIVWGU4 M3=V0'6VW&^IB3$LWTBPZDOU(7!97O$XQZC6C)*&9&P<#^.OTGCF63;M8!1G4 MLS-V'\VFJ`[F.L2S)%WTYFD*/QTGE.,9LJHYCBG!_RQ)]]RAY`T459(]RQQZ M*@RJ+Y]S*(?+L(S-",NAF>W1G6XG/_B=7YVVQE7/W<7):$,X;0CG8D(X+XIV M/FD:SXHM\-AL5:@O?U%3>M+<2)JR/I+VF_\HX-UM&H%_?R"B2! M1RSJV@5'T2IG?#P.9>#-"K=)$FQ3WC<7YM%%W=I/!UKH8E5^EJCM2?%W3.CB MD3'JSPZ?"5%^NKF@*)!MBYIIMW&T%\#-9$NTC!.(\-EQM.V1CWJ\!"$P;AS@ M/QA1>?`G&'5AT:;EU/;FQ8U4\]U'>+.F5T$N^PRI+HS?X*0#SX.TLFM884>+ M@X>+!CVEK^I]3[(]M0_C4C7)&9H]R=#U0:\G6YHU')PF7'0(;O`(?W3SY,52 M>J2@]&&38SZG[XM;YGGFHL*$1\I4##".5J::QN$,GO(GT5_T%!%RB=T.2Q.& M[]R&<9A2*B@&XV`G2Z(1NU*%%\"J0XG!BTJ#E#P)GY5IV;-$F+(HJX`9G/4$ M42$9C\,THV3K47)_CVETL&7B:V?1J-N9$>(-A)7\1HG'1 M//3W'E-B;Q;"C1__*3Q&F)-,?&'P$DJ\CF(08SE7@;\H,EKYX(0`>KU#]N9F M(WX*?W2=AE,_"G+\#B>C@Z7D&W0C91<1S5L#%17O#U39V89)VF5HFP+I&Y(T M>6[PD0A3AD-#&WJ:I)``'-.5/+FO2'W%M'N:9NA*[TB$*8?F1JF%REF8.0AG M?C1!NZ\4=L:@>;I47ZW;*3*P,1$=C:&D'Q=")#98$WK?(=A^Z#5VEVBZ>I9) MDNL.1A<48S\.XT;Q2QNC;^",G%E\_W*,EV_DVGR$&$SU-47AU M!I;G%:U=N7)3156U1=G<+[GR35PV7BG[I4,V8]`'FG=%-!5%5"]RWHTCS?NQ M;YAW`V!\0O:%L#&LP_B4L1S+CM?A':$6^,EI*B9+0_N&,W7B3(P:WO?0$*;5;AL8)Q4$86E5FPDN#A$;O-JK=C/OPY7DGL]US)D6Y-Z@X$IZ8ZA2';?MB1[H,AF MKR<;RM`&@>CO/AJJ8MA/5D5Y:EQ+PL$BSIR;X=>PB;0M2#)AZ)9B549>[_3N MZOXC3.\/5NMD-T6&_E\;O^^FQ=B]I]+R<]1$F=C?O"1\&[FJ=-/0MR7AKPYD M&T=5C]6:!BTOBTU[X3A)0_;<#_]GF'V-XB2%-2`G\G'CH-X*(J!FBZ_A[`[! M3SG[SREA#+MJ/=%]F3IH_D82JZ.*9!D*EH4^K"'(B,6($/`ACIMHGO1`>):I M68I>Q<%L&<%.S%[#*/;C4=.9O8QW'W5--633>)+;:\V`EM"023;[-CX]_]". MLZSC+#N:5@4[5GN\;CE!=K?C8!F=GF)ZGF=(KJ/`+*FJ)SF:TY/ZCN=8LCGH M#7K:P3$Z!X,M,ND(M&20)]KB%=>"ETKF&XY=1"029V68H?"0I0$_3`.\TF0L M*D1QP:W-GPA\X\-\8-_?3(!.\!/X1WI?587N_#-WO7OE[_Y M$D3CB#%DUEMPO_=J#0B6+HM/SKK(Z5$1,2O=#M3?T$> M2((D%N,Y=`A_R]%9(P:X%A:P\@J,'(,![O#KW%M$+;DG][/)_! M60(?I7)KT)DP1EH?>#O:]RQ#*AA_)MSY#Z%P$X9QWL>_&%<&M5$(O>"_R+"S M]'[.7,*`GO?@E,#K,JX0/%KST^)93%[%'J;NPN:.,X($XP3[-HE$T1=3J M55TK40"H$3XA9#E/#Z+M2!=G"3P0S.$GA+'FHP(IPIOX*#@3$O;Y]-6BN^1Z"(:)0@1GC&9_P=\,[@MB1V MX7PW,-DY:PRA(E$U^(R6UNO\DI5Z);R_">-P',T^K*P_XN;)16U=L3G0FG6Z MPC0)&_!O_2C.9G4K8"W6(=)PP"R^!AHXGB,IS[JV\Q:K':VT2B1/_A0&^Y/` MVJ!T_Z7!M)33>Q]-)M0DF4X-\BD*P1PUO=N9PZO2&;R)QEI!>>-KF1`6^.L< MPP9_$9U/%E8'MK[S53LO)[8^3SG,G`T%1L:@[6R6;A:@!6F4!=&(FH;99\MM ME=B+$?2P.6*,5RS4+B0/B!`OGE\GOD>0#I@FS072OL"[KXC&C1:BAS`W;%B1 MYOZ$DRS!3$0(<6?40DP6E6&DW4Y%BQE!4;;R&`R%KV.LMUF-K0R;6`AQR&:! MM4&3L4;,^18$N]TD*$J6(0];!&V-V/?*Q7V:9%$5-DP#VLYS=-G+4]5NQQ'2 M>/E8U^"&>*N^@B+YH[LY:!-.,F@6)\`B9X9;%7+ZP38$JX\_AA8BLBZD/45S M$]$;X(J9"'=P\(S(6JN^"2US>#1`:KA;Y):JNBI72[V`G;#T1T8E;5Q&G>IV ML$!$DK->"Q,XVPHC/TT7L#P^DI,$_;B%'0O#P?!C""TSMR0W/V9E]$4DYV(% M)7*2/S2E^^E\QDB_Z"%X)AJ#&@K)B'P%7!!@V2)7!9-'Z+NP4D1+J^2C7UGY M<34B/BTJY^"3\;&.Q.'CA&#N]_!834K\S?A0_>_8,HR&.`V[G8`B@F5_<;#0 M%1=GFEF(6'P85L=[LZCM0,28)X23"'8GMH+>P=MN7A__VP8I_J5AUMU/Z;*WY;C3?-'R(PD=6FJ3JI,,\ MA=D=$AVB!E?<6_#:D<$X8YXVV[%Q@K:YS,5FRCSG?+W%U>%/<+R1%I"',)E? MR/^.5E]90+AF+/<<*?;R)9Z>+IO''N+'I+U$D$E[._:,K#$I^?;`C$.LWH$V MN=%GY8Q\JR-XI(T&.I[!O/FDM\4V3T1_X>@N)L[*>^@G=U)F=PGL?T53=4,/ MHH#>61Q*R-AXT=IR3BGC*^T+'R!E)Z;*U_@2ISAS$0/ M((D=ZL5L"I-L*H?BPI(?1),YON!["$LA;0"#G[2J!2Q,62P-W\8#/T4G%^M/ MT3W%P<,P>3I@N7E2)]@;8-P6ZJLKKFI/N M5>NQ0#=@&T4@%1)]PE/@6,Z(TVY:[/3L>52\ZN=!>#-#94:665!X<"#0=R!E M)J_X)@27K]'%T)O4EY9O;\?\XH8CU->7+7%KY]E7&/`QZHI?T*RNKSO05O4Y MG"`;5(RGN57>.1FPD)1Y^5O$UEQ(_O,RZ9L!R3]<-8IGI&\W!J#_#'VFQO[# M?-G/:33)/F1W-$ MV79$Q=RV_YV3OMDP%EC:SP7@O!.@[P6JAX?D_3R;\\9/PO*I*J*J;O.+6_3N M$QA4T=&L/4WHC0-1&TL#>VS\AVZ*JF.)MGP95!;'%J>FB[JIB^8I\#3/QH,< M*O!>#^Q_R^]0>69L$U.CY7_YQ'Q MPPW_#WC='ZN@$/69DE"U=Q\E^4JV]LD0WS#0IV`'.8M*([.>%04$H3B:(V\# M'%2&L$'IO^"#V6]E8OA1$3'KL$!6#P8F#R3+]"Q)-_J.Y&J:(@U=579E`OYT0[9YJFO]*4FKZ"4%Z@87NWBKA8RU0LHF2AF"4P[DCHJR3L.PUFV?()BM)` M-TI#7*5E::IJ]'<-UA46_/LH MH^Q\4.-A>-*YZ6FF96B#GB0;F@>KLPK[NV':DCWH]3Q+&?3[I&A236K''7K^ET?V?^S]ZV]C1M)N]\%Z#\0@^Q!%A`5WB^; M->2/36O@&*JO3W30'S0?-`ESHL)?QYH]'@7: MR'OB!DM;.#_&+7?_QA]9&2E.`Z:U?I9=C:/*U7@2EU6X-%6"Y05\H9F4[B*, M3G-Z2K9$:&-<$*P8#(D9\,!Y..7L`<)#G]W"G[L=1-^&5PS%PU9RG&O9`O73 MX^&4H)>(@)=3'+J='W2K;RI5:@-B_V8SP@*&B7*3Y5]I`N$BQE:MYUF>4PNM M`MODX=@EK`N!G3$F-V5W+!5?^174=7Y[`( M$[/<\.'CP@T?V:&'34T4W93)6AU5^63`;E^%G)KT@]XS=0<=O)RD\6TH-QWAN&C-*83C M2DQ`3@)2HB2J\GM@AG7`@W&6!:^K07#V\,3/Z16@7BC&IU2O!38?(0+:?<2T M-FC-'13V.\3FJK.'[^Y9&!_"=#^P*FZ"T#4TR_-:Q22:&:\8'(+]@($N*4O/ MN"K/@45X@PEH>!-8FFL8:J!/?%4W!Z[C!V/=&.J;-;S-4U_-R(<_,'P<>_J2 M>^\B@H,<%4^H'?F!9IEN,%$GG@X[Y1B!Z@WL0!T9PX'M#^`A=W"4J>WG^"/J M0PWK]=J*44U.DFLM@M*-.M_J7CB8BV-%-#S`J7&PJ7#A(#++@XL\X@20DZOE M3C$ZB<[S)69A@7P3*1>R)"6T(R7YHLH':D]-7DRM%?1EU?#WZ`9$RV]]98`: M3/E#7LV`\V4B+LF.B6$X(6J.3%I9F-*Z#8.5+9T%:_,% M5/5"%(`Q92S@BY24";*XK@B`JG.X+('`)6;7))@5E$8W=1F!8DGZ,JZ\?D\D MEP)OYL;.0$G0.T#W]#6%.B6S&IQF9HKSCV+*$&IEVN:XX&Z'5[RZ MA`U3P\P*S$I:G4^WDZT?!F-MP*2HC8."Z=O0&ZP(S-TMHOP:,Y'A&U>L'HDJ M`AN3PKEP!#PQ@EV:EED.%*4)%DJ2H3)1*-@H%\>DK*([!UHY:7"X^:CU8!/. M_P>&)J.%\K9$TA\I7:"G;9M?MT.Z"B:BP9$\+GW\Q>?2/ALQ7ZXXY<28V]8Y MQ2V=ALN":FTL%Y26%NKH(U?)EJ5X#Z\;#"I=;QP&[S^. MH]P]#'Y:SMR]R#(T`<,B2^647>7'$'9[%LTI>TYD$]:K^WL];[`DHFW?PUO` M\Y8^U%?>M\Y812E,.Y=6)-[L=FI2R=RL>075>HDKX@JECQ$'7^&,=#/!N)4& M[%%^H[#2J\L!]GV^C&8]Y1RGL4P7K%0W02:E-M(YKY#G%.-7@5D*6P1N&'), M3'5L.ES#+;L4Y0>4(DR`S>Q&E8:@^U&%A!*2A:I\`%VJUO32G,(YO`^,2CX? M7,1$F&YEGB7R*>EVX)@H=YX2)KUR%^4K/GTOZ94[*4\6XPZD5T`\)L"'UXD/ MFT+4[W$%#9C=DNJFU3EP(F>.9]X6(?C7>$@( MTJ-PV0$\=5S**3S'(B@96!N8M!L)EV78[1#7I(Y:7)RMJ8N"`[%!1YUZT_8] MLT"?P%_=DCVGM6\NLN$DHIN&!@$/A6&*EN?5P2P2$)`8&0#-,8K(KTHS$X66 M9EO7(&JQ"+,/7:OZ9_6]'D4C?M`=%RG`=9O@7]14LBYI M)TFDK44;4.':JVK#?G[!MD\Q:$I2_)D%==`)?:OOTR%'G*12TQ7R84A@DF=T M%P]=RW.LH1I,7$NU+,U2?2L(5",(!H8?&*:CV5]\37._Z`C;()2H;?DR./(Q M*VW3K.HE'F#HZB+Z8XE<7M1HE]HAK0`MGPL7MVLLB3\3M;S1V)J,/4,=C9R1:@6:KGH#1U?'FC^8#%W3M5RLXVWAJ;+> M_6(Y&+?0I#KL!UGM7?55JM+@\%1>QO^E,03@JEWS_U#._LDXF%BZIZFZ9XY5 M:^`;JF\/'=496,[$'$T,?V"]X@(J85DCX:HB>/O7NP&F`&U+N7WYZCR^[LL=>'F=&\)-\]`7Z MEOOKE"<&5;$2]V]U39ANY\<&6=-8!ML:J1YOH0K;[;G&?NV3CJ9*Q?:]J_;+ M[!_3?=$UOV3GFK[J(CLNCW'?KN'^D^$V5+$ M;!/5WVZE`MWKZ?KQU"DX4/_45Y`H_T2=$BW;Z7GV,2?'[^PU6>O\U"10'V'B MC+ZI*5AKTG>GWR$,LC@3_5J.#N5K8+]'4W>`_VY.N).GO[)I65I'`I@01]N7 M3'=P`W7/-"2O])WS7W$)1@G64?^5"K4G03H+9M@P!#U5Z'@\VC5[[WXQX'G7 MD9/9=EK+2EM'Q!%&O\.?9^_3,DPO$'P?8,N+?Q71?)G\'L\?L?KVTDPM\#5O M8*J>-QBKEC^R5,\.;'5H#ET=SNPH&(E>7F>Z)O=VW&&.A\W%_Y7JY!UIXCW< M:?N06??MQ=[1WDT*3^M'(.F75#3 MXHL2JN.H.+B+WW",L:M9MCKV`A=X\FBB#ES3535C[/D3;^2/3>,U93LV&H0E MH_OE'DQ2X[2*K'>ZH5\&=7'`<@G*F7$ MV9X(F8ZQX5Q<*%)GN1N!3\PC`J\CT'X9$D`]0E!WRLE:"&]J^%JO&JQ)?\P) M;Q;->@PS+3#Y6>1ZQ47=U8*4-2ZIGV!V6-6WBJ:$D$QXX+;;"0N,[\_ZN+CK M>HCHJF['47VMGGW=)0F[YW4[8DH+T);Y'7PD3N'JQS.$0]Y<9@HV]LJC"N94 ME'WE3WZ.X$^EZ,:'?RFDGGP+&!6!F(C)E+])O3%NHY*>0KP#?[NWVF@0X955 M\ZY<;%?<]`VCCC:(X5M'4LAQB@V)&9>AW"9-WOSZ.YATY[M:S[<8,_*#9U@] MS[+O::KQ5A@))>0K32[:0[G(6^(8=_8`Y0L\E7(.N1&=$ES=A+?*KTEVCKFF M55III'R(L"<[B*8A_#>-$CIA9V%>@DXL@1O7VXEV.Y_'0VS_.9_+8FVP!`X! M/[4[@'X.VBU$8:567]I33+_)FW9_"J?L"-Q3E?V-F=GXPRU<5NIAATOCV'G, M^3>4(Y[%G$6+I&A]@WM(_6#91H6-4GZP+5.&1K6`[MNP42<$Y<]5XW2EZ9Q^ M$O";YU*3*J])A4>6.EO-\'C7B>0$\>-FIO04I9^#<*Z/.7=(2Y);(1NOLYC2 M[1BKQ)EH"'"N!YS%!7T-ORC0L+NOO8%>X:GAL@!7.*(GH/$R_`M_(X8J!>9T63!S*AG5CV=OO(7:O&A M\I5;W15@,+-N"T(<-=.,$)IB57RE^5&JJU(+^NKOF.+%HXCB+E]]Z'JG447W2];X6B:QZ&%UCS4[1LN_=J/`CF(5"M,E$?_Z%C MFVY>[5$?`I8X.'B8/>[&P[HPJ.XRI_A MM^A4:V_?T%O,Q"N1>!OB91Q>`IT!?H,>=2EF]AF3F<-\5E51:X7.)L'G=NRL M#B>T7QUF,T*94,2Z-4+P>=@.OKD6%B:^9]>KM%119JT0X?I65)S6VNTL!)PS MPP(&\R5,J*J;1]Y`;.N0EDVQO2KH!?$JL0P`L14R+R8B0G@R\G\=>(8D\AU4EC7`<5YJ*B&B?W;&LN M,O0+G@D9A@/?G%U4\;&ZBB%L=@6W$06BL#GGA@*)];E2?A1%0/Z^QG]Z=V\N MU3M9O7-P:C:=E?:J^W>UL&KL:49ZH-"I7 M]EXIIPW;TFQO75B;KD[+K=@3J`<$.DRCO(0OT5JE""A^MH(QP3]%51@D.P(. MFH5MGKQ\SYN-72G;)4*PO!18&8=]>9?.;^$4Y'$QBZORW(+=MHJ"$AZ;]TB` M&T15,:P!T#R_B7Q4].V;*0RI@4:X_!4@0?$Q526X`G'.)622-1I8#&H,W80.9*!(&T2V:U MFPB19C&,->7W&N:^R`J63!P^X@5AI=>ZZ=R)/=VIRLQC!`YAR?>K-T0GU8=S$Q!J&), MMU7638C-(<890Y@7>;9W MP!YO2$F">5R`Q$)C`@NFPH0TN7CB:3134(U5S'4 MVZ*2^#(^U/[]#;724J@*<[#I@)BH?+D./:?(>S5BV\_Q/"+?Y9 MNM7=3J.SG:[OG=.LE!B).QNK,$6%;L7AZNAF>*FK" MG^GTX@5/N28MS(QN8U9K3H@'C*BX=KQ%9[UD0.'Z"FY(T)QC.;4"U\F7E\4\ MXXVGERF64`5*YK%04LK+K(B:V;8O^BR>T3=KHX1+Q#85P'!QDIJRLG+6;CB_3R_'[.VE4H(Z/F:B^A\WP*+$7 M.^@,N?L.Y9N=#M\.'K?%(HF%,ZKM8$$_F1)\'BJ&`^ROIG]5Y@ZI#09YF\Z5 M@0'&"QA(&,PC4*[PJ%&M>])H"$4%6[A``!XYWH#?2@.+1DA*L]DSL=FHD2;5 M9M-3J*%A?7HAL$C5H@07_$C].*US2A8CB#>Y1Y-H8=#MB,K\-Z)0HA)RI40E M75;-&C8W>>IVLJ9^HBQ7V%SKUP=UP]SC0J#DPRNJ+'=."][P8"6RFW&+BGJ8 M71,6K."R[ZORCRTRS.!!^2_/%TNAQV`=DK2D1AWPC%I5.JSR&VH5%V0HZ?75 M:LY6!D6]87742!1)K.U>,!N2Z3()*T?GZG92PI58JD#>$9U;A=>Q%FM.N:(] MN5,7:EZ57<3/$5D8Q!DR3`@/YJ.%ZQS27-U1+;S>@ MUAL%OSD;)Q.TO'\OL."G0+Y]1[NZ&=)XPH8>CI!'!`<]7ARB*.V@2*K1%K(= M;P%$`\O#]0QGOZI(QX%,/!@)#-U].A(\*TAQ#]#47T+7;*GW&TCPX.UZ;%4] MHV=[;D_?"YGS1!CPPRQ'MS7,'3[@-X^;;8K!Y#;N*Y;,,>V/Z?H2/& M7A\,:;W'&7@V=/!3#-_*87!ZAN_V/.W[`%L_-3E-JVQ6 M6B+P#O&!\729E&W41=@`BK9V"9=@/5,L#U'#]2[C@LH8-'`]`>"*8*J3+)<( MS#7:*`:W6.:+K(B*]9)JS4:5:^MDQ"F%6#@*Q:!'JIDGM^<\S[*O[;<$MA*K M[+2!ZT3Q.)\IBS"G7V2BPWN8"H0F?(XC=Z>8^,_#ZOS3#^/F_)]XU_T1<&S5 M@D@A4:+I+E;",,U9=H4W8=KMM!E47"X%[DE@H>KASZ,DCJ[Y2)]'W&\:>\A. MP07=3AX77V4D^!82A@6! MMXH&QG^ZO3]CN;>54K9YEF8(83LI(-MZ_G&OVB)B_##62UM284(\G#(F>HW` MV`2Z16$)(HT7"(L/*Q9\;7NE89*Y`M8H``54SAXO0:-*?F[PGE+=IRWY*$&: M8@;!)Q++>-U!7%\UA-&4&`<%L&?TH4&D5()52Q,(&9%H#D%D+V*ZP*%M@ MR!M:0.Q42+M=?'NU(2<]?GOPJMON8&R/G=%0'?J#B6I9[D`=>):KCOWA0!\' MOJ<[SO,TUCQA[(Z'.9TP=B>,W0EC=\+8G3!VWS4:ZX2Q>XN[>L+8G3!V)XS= M"6-W2!*<,'8GC-T)8W?"V)TP=D?%S$X8NQ/&[H2Q.V'LC@,4=L+8O4V,W7K` MZY[@53O2-8J+:9)A)9J/<[D%[R<.R@^QIL1:!][#]Y\=!@/'G9@#=62YEFJY M0TL-K-%8'0,+&9DC;V!9^G-&PM0_/Y[]@QVS;>_M/J[:>K!JMQUD3>T&)XMO MTLS.\<=V^]JZ(1?WKT6M4Z6M4.3=4J2.R1STIZ'HIQ=OCG6^X7@?R?2XMO54 MIB2U0!)E3$5CUBF<_PN,.%5E$KEN(%4+(CM`Y3N0K/I$OY=H7>J+E<6#KLP104BY$ MP.@\NHA3JNR>S05N:@N%CJ[OE^7U=._[:W=F63W?\K^[9?M6S_6=[V[9KMES M]O1;'V-(NV%"PD?0<@LT8%0"6`(?^L>&%3]X1QX;@GNBCY[6#$& M1A65^BQ@ZK*67F*J\2,)T"Y'>'G3)V<_4/P&_VL`ORWYRT->;II]IGH"'CP%O>O;Q-%7? M7]>[`VFXHMPYKP()]T2MO2VO9]K/`'Y[NQ1TM)[E[V/\G"BX0D'?Z>GFB8*/ MH*!N:CW?V2^\\,KJ1+;GM+W>R,&^WXH[BAZX;?-?\\5WX2_M)O43Z-BZC]VS-0'*+3'IR.\S&1\O4=YV<,I>Q>Q*:" M=G8['YO"'SWEQ4&=#XN#;2KG8G@][556M'DH?C=X#[O7?CVD)6O^MW(#39CRC,'Y@I2T) MG3G$3@9)-/MI_&T1YQOO]9L%:_RH&W;/.U"1J$TG^,U23NO;)Y3:8PZ>NR^7 M/!T\&@5,Y<>5\7I3-=U:?J`HG>WD`7JSE5A+YA(M9O6#?!_V>_C0^I#KU M:Z7FTYW&QZ%I]X=H/0N>=B\N+VQNQ+*LHHSJ-IF>7<1!3_1U7TS7T;F_Z^%+W[-K<275!)9.RC1S1:V5UJUXS$CX2;7UD@``-;Z(5)U7R/ M^IB+7O5U8_*[.[.V.OR)/L_\;>R9VB.L^U4\^,$R$.I$8L%SJD3BLRJ1^)5U7CUT!VA!#VQ^/HLDAK[Q'MQ! M3&PD':;4W'@615?Z$4]1,T2PE4VX]E_JV[G M8[@-_!#%U+*91HKS`N_@K2*2*)*P*+%S,W&"$#N!1M@05H%9Y&64BYZQ$3(< M8*E)=A/EK3;P*W?\KG.'HH?J8"_+2V`\_V5B41$,Q=:HLY"0:OUNYV.J?`CA M146TH6;AB,UD\3]VSS'U2@2*5J$T/#9(KD@I08M'A+4DC M/1S=\,3HW0Y]4'2X1AZ-8^3151@3U$S,@1Z:4@@I@>UFU5JXF2 M\+_SL(G<%>KD?15%W'X7:[PO+^`B*NX&=6$#UQ9]<[&S;IXA34)LXWWW_N!) M[N&Q1**5N#?<*]BUY;V!56#KWI>$:Q%^"97!^3JEF2=GG11JDLR M4VQL/^710X[5TTT+[@U-J(>;CGW%X^L(1=M*\U^^5U7/8%7T#.YVFKH*=.7@ MK1^TON[2!^`GPUD=%XB11+RIJZ/QY>1;>1,6]+Y6C00'M6Z=V^MVVH/"OT`Q M1`J1')6JQV.O]+3@B5$R.HX'E@H%(V7Z*"*3AJ'M$#P'KJ/L\WH(,6 ME_%B16?L84>$9$G]M:^SNGLX=?F.\-B2E5OTE4\1?"BFTH=;9H0:RVUYI]F=VW@/0SIM=S``S',C69^ MSI*"9/.W^`JV'4[Z#Q@I05&+^X.-2=!TE[:Y=0QR[L^#YS[-4A6-0MP&/*9< M:73EV+3JCE9[>(_6*ZP_U%C6-W6][]`C6PFU^Q(%5W"MXO_2`!_G[],29H]] M\(*BB,KBX6V'EF`LTEMQD5E`\"__^CQZ!]K[%'8A*2AAM=V9R+)&EN8;8U6; M3$S56!/+,`QUI`>Z:AF^K@[&AJ..G$!W'',X MLB?><_9:.H!2@/13_EUQ[)J$BD3#UVCS/L=<_I3E^+(@X5U[$87%&:?D1&'7 M#+9%FD5LV40S%@[`?8B+S23923)^7F]%W&P%B]ZBI!?X6=(RIF%Q26*'?D"1 M?XW&:`DS#J?3;(FL"_AA!+_&R>&3U>^!2X6W_-N&I\J"?`;_$SH"V&/`HX04 M1`UA;6IM!0"];-.53IPH@>,4&7E:)K=@/L?S>3P%91X_4E-'01XOM/RM?K:: M3,BU4W:"T?HNR6]'IGFV(%T']@>8;`%FLC(!):N*3HP5J7%M(3H?41V!1>$*I^CT*V_0[X>_/L^RK^VW0F;*253`FTD< MGL<)+`&U*:1XG,]8R\0C(?P0H5!X\'-LJ>X@8';BDFW&BMYQ,$;173AFDXJ? M6NF)=RC6ZH]UD-_H+J:-1[JGC=R;?/@K/5P14O@MA5* M0[*'LLPWRAX;)H3614'$FC;GJV(QP=4-6"B_)MDY:W"5BO4A0I<#Z/1#^&\: M)72_S^!>@*6C!!=Y1,H96E_XG7R&[B1R)74[G\=#,';#^5P)>`K(!09@K*%S M2/FQX27#GS\'@^:?HY__#BNU^M*>P@5%^PK5RAQU?N10C;M!!":`1Y"O@YR7 MV.H.E\9V#7KP2F8/BRQ.B:TA*5K?8(?8#Y9MD#Y+KA#;,ND?PC(#DVHW\V,' MOK#C)6]SAO?I-`>C+QI%_/_O4Z!MOHQFOTO\Z_G43-OP7>`/GFIIAJU:UL!3 M?7L4E/,P>V:Y4%^HX\<2J(4O>)]>D;FL$B\8!*ZM>:8Z'(\=U?)M'<2,YZK>6->_H`.RH=PS$X=W!@[>\A]_D=4)[Y([&-05(;;3"S(&C^]ZF09<+\WR-??_ M_K3+"J2U_IK1+X%IYVEC"1]KWJK&M1O2 M8#@$A26,OM/M7,5)@B]OJ,@&_TQ9LO?H\.?Q^9(F`3H2(5NFT^75DKU8LPBL MI[CD<(=F*]6P(7VJ-2.RT!IW)#7IS?*<2LKQQ'2K;S8CK+C?A,^+UIZ@B89V M9Q[!H>*PW=GM-U!QWJ=I=DUL$D@-`K:/``T%%#"XZNRC[7:"I(Q!B6JK7_1Z M2P'K*Q]3GH+ARY&[*[1"$7^!3E\R?\FGO#(EVLV2]:-YGEVM+`9(^4=V'5V= M1WFW4U/HY4_DL=X.I&>QG$[!4)TOT2=!*F:E:QJ,*)DMD;^3H[VH'/`$J6&# M%FY7DF'04X!5P/0&A9_^1.]&TGVC,7ITR\0E@EDNY^&T9'>\^`8JS$F"_R_B M'NS;F%W%*=C_.-8U.EE8\RG`8+[!<#R?HVR!9C\*1&%PSS*ER"B(`L_1+8[$2WQQ%21G"?VEK"14#U/\`%F-\@5]' M'MKFE/1"M\-OM#CF!A1"KSV^A`M@Y$@=H(./X@KAIT'+9[?(HWF4YW6D"N45 M2C,Z-]&,<0T_&#V!=C@=E#5E<)X13I(^+/)`"-Q,C]P%!Y+S2DKV<(A07KUU0+UB$($0<-$ MA%T(T<2^2>+C:/D4R,;$WV17I8AZI^CHQ@_#$21)?(X^<6`M*WH',N-I20P7 MF/LRE\6!T+)8NI`GHT?J3I:C"$#@1XR>U@6*=?2@I$@F5K&:00J8P50`;I)* M[\7/S8&;DM=5B!E@PC(770&Z8NQ.Z'#HZ<8/PC&Y\UO"`]I<6%`U<"U^ M2=K!##$JWU=^JT1>F@$IX:SDY!Z;`I\YCY0+D(\I.Z\0]8O>J[!@YA'1J%>- MD,%SA2U@%8H6(&MC(@(H9S$X$&2Z.+K(Q#":Z,CD@$*^-G46<@91M.UH(=C`7.HZ*M M4"4$<7OU;8-5*1)AZ*`UAPS^=)OA+:HT3DDEK[8[E"CF$T>A>F'X,(.:(F*#6<^MT#`3.-0Q MK*;F6Y*'%AB8$EZQZUG86=4_[WBY%8-!REVATP8W-XWPS(:H1UT2*5O@CG-$ MPE;[7S/?..6S&-4HZNIJ'(%HNJO0^XO.ZGU*-YA#R(,S.KY,\$ MY`]\1_TG\%JQUXCP%R[R$>P>7Q<^MO!?'!FD1RU-\N@"MRK'2[8`-3R>5G$+ M/(+S.+_J*>2T`WF6Y:#;IRH5(;4K9K=16ZBNA'SX-DC^5Z2=/8$M6Q&I M'4]F\Q,UGX@MIS#/21 M->;X&`*D:>SF=F5PZ"]:,FM=S/3ACB))<+7+M"W)9QDAZ++U+)2V@$1HX3T$ M5[;0F_28:(-1V@2X=G$L2R[H3Q$6IVU"A&=YEL*/TT@*CQ_<(3VT)X&F6ZXZ MULV!:NE^H/H#PU?MR<08#QW/UT;V*T,3,1WE6&N;DBCSB90BXAL! M>NAT26%9O`VR[;]&8"QQW**PY`_`*XF1`L6"K\47*2DZ*]N#1SM&%!$>ZI!P M24*>XIO$3QI0V.<[I>\=B-V`)36RKJP1M\&2VNIMK\0VWV8 M%Z9C*,O%C-1;>)NA,1=@Z)%I(W).D,V0)GU^R_I!\'G06)8@;MD0920HV=4A MNI9A5Q!S!8N9,N>^'WHD:27WL:2]&(W$H(;87H0<>6"P!>GL]WB*'DTI%/F$ MD;-1,!DYP[&E>H/Q6+7\"4;.`HRAFD//G`039S)\G9$S6XZB`4R5( MP`RH0"2*"%J9+/+H.LZ6!:5U2`H^>R3B%''C>.]Z MR#8P%TE%!D9)$Q'1@1(Y>#YDS(:5VQ??2.C^DM>CY0V&][/;,&'$7RK60#D2 M/,N><`K,HYS>(9!E7<-+23*,#Z)G\):_6>?=U:XH\LSE\>PB4J3?-8K?Z62O MVJ,?IV6&&C`<;'^KH[_&J?T1E3=9_I5]#!5H;1VPQMR%0&_#+%_T>\KLI_.? MPI]6@'`MY[_\IQ7??TC&8SR+0X:]5I>%(@AG(C!`UX2-_%;.&TAUQP2(26%(DJU0XFLJT@5;CA, M5(5%@-B^CD-8TN7M(LJ3./V*4AHM=NE)?*RO_`5W-8R!T*U5;(;0<;)@#;9# MU4/*Z]D968=AO`5>=%:B0HSCH5RG!$D8"^,CC')DQQ48_J#/E1E,^UX-X4&2 M7M84PN(2GT`%H_K_3Z@&/1XRM(!/;L59#2T[\$!)4'U_"(J"Y1BJ9[B::@PG MOCT:VL;$F+"BH/4UHUKP'1.6UA1LZ(OENZZI?;,]S?3\ MM1R/@6[!BZ:J#PU=M&4U/>_A7/HD_LQO^`!26&XH"RS?];0&3F6:Z@CQQ^I MEC9QU4"S)JH>!!-].-%=PS9P[6(+';.!RNVZJ#M.ZOOT.H.#_B>(M0>#V[[8 MFN7;[C<;-M`V'W8V<6VPKV>Z-MIP/.59KL`H,3;*4#?.%V3('\'Z0,#07QZS M,-MSC6\V_-DT'X+A&[J6YUA#-9BX%JQ=PS,=!*H1!`/##PS3T>PO/JX=/@%2 M[MTO\/\2#'*7Q>U$#^Z)]'0$6<>"OO]C\G!J6`TUM!T(LK*ZW4](55F`GJF` M`@0%>#2!=-/RGO#$F%]_J(9C6;8EW:_6 M2E:R6^OH8/%G%M0.[C/0`-^GPW`1EV$BH,=,S\<3PG-T_PD)87_Q\%#H#7[Z MP6O=GU1TPLY7$>Z?T,I%[?HS)\/S:?S45(QZ%);_N2EKO?O%=W13WX^PCZ', M47#^YR$N\#+/W8&5'8#W'UJ9>A8"H?I`_,TW'Z10D0Y:TXT/W>:TE'])%0_D MWU.ZQ(A[\$=#/LPW5\(=@8KC62/5<:ZP& M0-+1T`DL9^C6)@8,2'K7$Q%AETRH1Q/*U#7;>A"A1H8;.)HZL<=`*#-PU8'C M351+=P:Z-P[LX:;6V;SS5:M&SC-:9>1Q+M73#>:JE MFKA4N`&^Y?K.;LME_P/GEM6\-6<91>]]G#/+8:WRX>O73<=W@`/HAF$_+B]O M!*3T`S]0O0D&EG1[J/K:0%--=^*;GF9H0W?`OA80,TZ_9@6[K_*%2.-J^G.0 MQD#2P"G1^]Y#25.K1&D9S^)DB5['S]$4$VQB,#V^<>1CDF=7>.*6I2C*,@X) MD%140P>$JGL$X>"Q[8I>EKGJ\[LD9XB.4?)45=W][;GMV)HD9-472$@D[5LFC?+$%U MR]#V=CGM1%"S)JB)!#6`OQK?`4%7Y>CA"&K5!"5=$JZ^XSXI07]'%`_UP:.7 MT/6O/YP^IN9JJ&<8CK/FS0[.9VEAUG8&K6O;(5P/3U-5)8%B!Z0(1-*U1 MH\$&5C53E4W@35-]CL68FJT_:#'$;@Q:C+G[8@3H)HUNPH23\LEY+]G\7,[^ MA==E8LCA/S5&Z+[IKIF&5'B@BN>.,54``YS[KLW4<6FZ9N@6Z;FNHR/#,WUS M;6F3@3G6AIJF&HXVA*7!J@+#M55W`DJL[=MP-^5HRG]:-MRVV4I+`]TER_^" M:PD/_)&5M;=EDN5_-M6!/\Z;@/K+KA0.YYE?QXWVGKVT\O?H2PH3?`X8SSK- M7GBAFKRE]\WU,1OZ5UQ>9LMR2%7`GV+-8]`W@^$`5NIZOFHYL%Q_'&BJKEF! M87K>>*P[S9K-AV^NO)+'4N37##V.8;&/#?LD--$?3Y-F+07NF9R#%&9>R]J$F/%5+K[.2S M*CEY3Z?FRJKO]VAL]>A,K(D;./98-?!KUM`8@S(ZU%1[-/0'0R,8:H%9WQA@ MJ>U@\IZ+W(5"<.*N@9IG23A]D+PX%&'&YMB<3-R!ZOC&1+7I3;0_,V[V0__8U\FS&TUV\.GL3@ZJ MXM7WG!H3ML?"[F<65=VS1JT<-'5@=B>+S62Q=',=4[7_';(-RW9M7]6,`1AT MGN>J_E`?J=K(<;6A!>9>X-626#=UQ[#M[9QEVRK;-*I+)CTD?.X+`?*DA=V, M+Q@?AD][IJ5)%>PVS'RM5I_X/1NTE!H(SW]L$GN/;J4^KM1TX3MFJU;?/0LY MK-/_L8O=+:!!?FW-\O7](AJKO@AX/)X&Z6R$[HQ](`\[K')7A_6.NPL\\Q=5 MZVLR='#[:K8=:`+F<;KKK#D)?T3EQ_F?X3<8<&4L&O^HR6,1-E:_Z^`_:,&K M%*Q2%WCHJCSD\3$"N!RZWZ;%YJD__(@\7-`CJCX$*?4K:\Z*W`WVJ.,*:/G0P0V MUZPY8$_"N,]$/*"=:?NN[S>4V[J`U5KH M!=PN<2B/;FT@,BS3LQQ)+VQ-^`YE=UP5Q3NV]>C(`AU+]S1[@Z9;37M?QO`: ME0&3=25KG^N^DPX@3L;Q[3VLV/4=S['E>\IS;:_@UQQH<)9G\_CXI)J-S,;[ M_^U=64_C2!#^*R/>,W';[2,H('&L1F@7&+&L]G$4$@/6)@[C)$#^_79UFZ2= M"^IF&B+,?)]K+\]5MYT5;*': M]!;EUSNX[QR>P))SW.M3&C#;I(=)%:_*+P5V<#LC,-\ M0U3^S3`>9JD(J@L!)B!M!+YM:\J\]NX7%M-AOR^^\4,5FA7(GF7*S%*5.("^ M!Z[#N!XVF4N45296K"#3L^?BXL._?=]'T7$<]4^.QLDDW!7CX.A;$Z/BAW%*BPP6YE-[G[:3Z(887'CLN56 MG@'X)*1%#LV60;>TWUQ)3@:\"65C@:Q$@B< MK798&!J\N[#Y7D>PL>*!X_JE.AH.TLPG)[K[.QH.0Y/CJS&DX'G6MBPY>H+U M.O%S;=!R=6QR@/IR/?O0B=1[;L?Q$0?6W'BK#G^7/F[O>2KP)JC3QZP MYLSG>FI^4:PYNFPY@LN;H0HCU&A>_H:LO*FN.+A`DJ[`@\.BQYCLNRO+*+5ESW_4"RR;$FN/C MS58M-8I@S?&-BR=)`WFRM'/6TW/WXV%;"9D;#] M,D^E53DPF,F' MK3*82191=7BO)UI@!BJ#UEKNMT;8H:-5S=E9[3VNC&87:3M8/LQ8\9@9VU$I MM(SMJ!AVM&P'@=G9E/Y,2K-[873\5_C4Z:L6#9I>_YR*SU=Q/'Q53I"KN(N[ M&G(:P*9]:N]Y`YP`&)AMR.0GA=D\G"%M+''70A M#WO0OVMZ+]9LHTY7A8A,]3/9I_+B.0H?_Y`]?*-7@?UCU`T3W.4":S`WAT&T M&XRCX+JQ,AXI8.5#)VL&0O&42,;IZ(OSR8-LQXK[&+*2][X;JTU6":Y9C(O\ M"C(71PVU3`U54J@=J,SJ^73U`.61YT150-4EKI\*S(/W9@73+L.'<2UU0!7[ MKJ\.I,V0ZHF]+)U?7^S7%DRLF3;H'2A(:L,&3D,MOR6A<78;&QP--U5Y'(U/ ML<*@&:=BM>`R7L7*@J?Z"58!/"T3;IQ$W7$]S9K>0Y,D:K/EB:LN5SE=&\"\>=*`Y['UO(>L(H6YA7&4:MIGT]$;2X0Y3+S8E@ MK;=\O.7Z0,A;+E$0[SKQT\)JYKKS'@TF@UHA-0_:XA9^@-M62*T/VCH;O'6F M/_K#AYHM4DR$7?5`HQ4T2F)ZLO'0QGU?>/Y"'A7`C!M>HP+&?5^4^YZN#ACW M/;;[GC#VQGU?N/N>H#88=V&%03/NPFK!9=R%%03/.)Z^()K&\?0E8#2.IVHB M2(NG(S`]EIP<9CO,V)QM53V*81W+2$_?/27C@PD9E`T*LN-2V M@+P-OQ8,B4*7)ICZ4C_W6QIH\$)6H1 M7683EKF_5[EHB,R.@RXV9L=!$A:SXZ"%#"4;BR[S4KL:X[[;;@$$?4P*`\>X M[\B!0^EM@2ZS);;ZS+1?V1QP`3V04`,N`LN7ZP?/\QQX*3@MHFXQ,=FC\/<$ M%A"OXL]RE2S'V/V$ZP M%%H0ZHU<"022R<*;Z-]A\I_88")3`,(@"-5G6ZG^)(Z4#D2C(;<%QO_\?3E# MGI,D/$W/'8MS[>;'03487+\PT@AJ-8R6!E&'\US_^W&\?`LPC7`FQP": M*+^$Y+\6;J@7O0K=FD\@7'-W`JZ9D M/N;RQ>VF=N\K17\1PRS-'1Q<,VU*"<6'_P%02P,$%`````@`AH`.06N-6N'C M#@``ML(``!4`'`!I;&EU+3(P,3(P-C,P7V-A;"YX;6Q55`D``SNO*E`[KRI0 M=7@+``$$)0X```0Y`0``[5U;;^,V%GXOT/^@];[L`G4<9]II)YBT<)))$"`9 M&TZFT]V7@I'HF`@M>DDIE_WU>TC)EF2+,F5)0RG=E\E$X>5\1X?GQD/JXV\O M"^H\82X(\T]ZPX/#GH-]EWG$?SCI?;GMCV[/KJYZO_WZ_7G#]<3#%'`7;NT`OSV>+5.4/4#2D*8%CGFOB/]TC@'QSY MK^?`HS].I]?.T<'0<>9!L#P>#)Z?GP^P]X!XGZG!#URV&#C]_FKBWR,2CYWW M!\.?#]ZG_C)EH>\=.S^F'IUQ',WL`4W'SM'A\*A_^$M_.+P;_G@\/#H^.OIW MNC5;OG+R,`^('ZQ!A-?[54[XD3.*IWCF*!J.@]G?0():%D]]'A M^W>'LO_?SYD;+K`?K'XBW_OD!R1XO?)GC"\4]3U'CO]E>I6!0>@#]G%`7*&D M)XAE<2#;#HR&'50E?@H]_[P-0.SD'./9!?'AE1%$)TP0.<4914*0&<'>'A@, M!_Z6*":(XWU>1XG1@[D&'O8N.%NDW,[Q[)S0,,#>9QQ<,R$F MF*LU7PE?S:34*:R!=,`?B`L^*I%NXE<2S$<4$#$.2JP!<=UGPAH!GS&0-1Z0 M>XK/\7U0/T"C"6I=@>"4/LCI1D+@0%1V)%@_,'Y81ZFL!+"Q5+.)N[8.09O M:`$BTY9JR&'&<:*U;",IE@$\!K`=XBDSPW($_B^%2VWR0QU0]IB MVD@*S`..%$8#[LE^<]9J)[T0>/LZ)>(QTH@NS,LC0AJPF65GJR>._0PN,>B$ M=19G'8@*9<[&LR28V0-?F=&;QG/)8!;%5^ZG-`9^"4XI"%NMZ';-U316F'/) M!**7G(5+`?X\Q#5`D21%&?80?)+T#0S*A/3-+<*0_=F>&(X93N0KQY8 MX,!ZZG9PX@Y!4&.##_'$37/AC%&*[IEO`"@F<44VCBJ=R?RORKP'2"7E6OQISF2K2TG%<- M2%,]%#6O>5.!O0SVF]>W!A/&J-UDTTM6?6700UOL>[+P)7HJIZVY?BJNYHA<:^*KT+1?T!H.9#B,L`T$*LG M_:C$;1C78/T]?OQG'`\(D%4IG&C\<`BW5/L8O(DJ?F, M`S/J<[NT`T.L1R:(!^"KE(63W]L2,AYB"*S0/6@O(RR:]E:H7^=")XAX5WZ\ MN:.C7=/:"N7QMG`^H>EM7AMT[9"!3!L;5,JJ*!DOP(]4Q<8H.$.=XAN']>U/\A/UPAS72-+9!]V;4#88E*O2!-W_) MF/=,J$Y]&'6U@RDNU`**M+2GFMB@,64P8/%MQWH:NG=VLXRE6.Y;8B55.&#D M-N:UM$&QJMV-5QE$+(4TY[>U0?6$QWINIPK/:VF)XB6X0I]>9'R\0S;RV]JA MFBTQ#UXG5&Z30.P(JF`I8S:]_BOL8@/#%`>(^-C[A+@/]D.`7QTN0A45@+4D M+M$A,>AH`X^Q1B_2X:FP?L2SI"/NK@:$_V[%]-DS37&+@0@743*A3R"H7_6? M<;;8\K57DS&=F^O(JB&NCM6]/SSL.<]85OJIW^&W)2>,`Y:3WE'/"040QY91 MJ-%6=,6+*`'[\UL`:^;U):!_>0N@-48T0?FA:R@W#%0:K&%$F(`?OB'PQNFI M!/[1FX:?SC`FF-^](NP0\[]*;W M`9_7*@'?(=.ESQ;DZ;#-,#V!?/@&(>NV'A+4'3+39JAUB=,$7F@1*\';):9GBW]RT2L!V*E4!#]ZY>-I!<@MZ0MR2,_>C<#XEDH5!LBOM80<'E10^< MS;19^70+.UO`4C-(KJGK*J*35"`,R5$J[<;PSH[MQ'.*9XS'5_K_=./9 M1Y]_^/`S!C,`+]8(\(XAVHZQRKO>;V1['`&BXI3B*7A=>IVN:VVI;$FIE)@4 M?852II6M8J1(KT7\6]%44)B4V]Q*H0P.$M'6EB+8G*;VBF&$1AQ5V[@G@,E ME*E"A&*I+NYC!X5BHDY`UG^V4IYC)!!MD(5;3*FLR@!CRQ&%MSOR%L0G(H@. M@1<+A6%GJRDWP^`^N]F[MZ_>R2VSRBS:T]E=,^NH0YMM.+ M&BPSLB#JZV1-4&ZL74Z_=73/M23R7Q6>N8GU+J9)U02>P; MB3]-G5#+K5`IS#LV#3M9.:1->V5]]<(\2"=/H!@!-PWZ.WDLQ8@#NPHL.GDV MI2![FEGOZ1BOD]7=AD!S)$%S&J?EZGPSU9E9RYNIQDZ>N2E"F)]BKW:VQF99 M6;D/1G6+W)95\&U_SJDUMZ=,,,BHC$\Y1@*?X^BGKD:NS!"V;H@!D_)$X*V= MOGX1&,A:J]_X7OSXDLGMX*H`]/YCVKFE!=:#2R+5"5Y5RLG08"SJ8;^(Y4T4 MMF46QY6_3+Y:6N M<"^_L=44X#YIDLR.?0F%V\GZFH88E&MQ.[G3WQ"#V]H([>75C[1IYBHVCF>;U[6EOK$Y@KC#0H"S(7Z4C>$A9ZLS5O?EVC_XXX)Q87?66\G MR>L;OVV4#*XGOY!E^7/LR:\FZ#>UR-M/6\KG( M;1;GWE2?A=?)JG!CK!O+I&.UX8G2F;!`9D813=WQF]K*B#ZB@CV5^DK(&<_B M>Q6`33(SMKK'P;H.O94'BO`#<4>4$ID&_DJ"^8A"/R:3P.U4_&<,I`H"7'#" MS_%]T$XBMTXL65"D7-A[:U]E14UF9"\:+6&->31,V+5*;[53ND3C*NW9$S'@( M7'UI3"6C85IU0U/K='Y*1N),WV?@R-TSID_X!@+PN8&JW&=0R[;`@.0I7B`B M=[[E[?<"1.A?&/%:F)$_"A7SD>W=SS#&: M0>BQ`;&V8=O_QB7==S"]KG1PW]$Z@OR9U8<;QFH9:GUR8TI_K&:E%@L2 M75%IQ2YC[?N')Z*"2>RL/6&>9B"3(4+]>+% M'3O'(#<+"+DN$.'J+".Y8H%+%ZP(W&3-.L2NEW+M@7#%_ MNPK.-MF*K/$RKE6<8A$`]X/X^WWQONUK.ZC<8MY(OOH''"W$5HKUE>^%P-'7 M*1&/D:J0U=;1KG>;*%9'".[8^G-PZVM;A,INC&?)3G'K*+QD0)7B+/=3RQ&F M.X60Y+%U]$87^R%ZR5FX%%=^G!C,KXSH`J#"@H*ND[UZT%'R[Z+2V;81?\8H M1.LLNN)0EA=$'RY)=D%.C==]#="$L[>;&E?YJ#RHY2[,^G-;:]U$13TO?4L:'EWY]J:7Q<2")N0?`\,O_ M`%!+`P04````"`"&@`Y!1WAWZ!8L``![3`,`%0`<`&EL:74M,C`Q,C`V,S!? M9&5F+GAM;%54"0`#.Z\J4#NO*E!U>`L``00E#@``!#D!``#M/5USX[B1[ZG* M?_`Y+W=5\7@\L[O)3NTD)7]-N6';.VOOP8HB:0$ M@``%"B"7^[`S8P-@=P/H[V[\]/>W67BT0'&"2?3Y^.S=^^,C%/DDP-'SY^.? M'TY&#Q3L[/'LNT]G'SY]^/!_Y=%DOHSQ\TMZ M]-_^_\#@]]^?P(RS"JI_/KJ)_'='HS`\FM"AR=$$)2A>H.#=:J5PA>01T#-* M/A^7\'I[BL-W)'X^A;4_GJX''O_Q#T?YX$]O":Y,>/VX'GYV^L^OMP_^"YIY M)SA*4B_R*Q/I8KRI9S_^^.,I^VUY-,`1I)OA9;"^/\U_F8].\*>$??.6^(R0 M"N@<"4?0?YVLAYW0'YW`?GP\>_>6!,=_HQ_\*28AFJ#I$8/X4[JDX1=G8O02Q(\Q2AH@(/BPH?$XMZ+49/MT%@]?:&+>*%YO(`#D!G: M#_K5&F9@\_%):>F'%T#_A80!<,JK7S,XJZ,H&`,YX@LRF\.O4)3@!3*!A=ZG MK"-KX-3I?Z^]$[5`M`E MOGII"K0#JMUBH%]`*1@$[`)[X9Z\>H^O&43U`3]'P(9\+TI'O@]*"07DGH38 MQR@QCVN#SQE$]B9:P.$A\7(O'(I5#()V3U)8%`0$W,P9B1Y2XO]"K^S""^'G MR=6;'V8!"JYC,KOP0C\+&7'&TTL<9BD*[E!Z2Y+D'L7LSN^%GV%03![6E&KK MS]@'C193I?(;3E]&(6!$8F!B+1S7)A\TB/`%@;,6I_@I1)?H*36/H-('C-Y` M4$J?Z>=&28+29,^+N+58BX":)[W:%TRR&(_>ZPN2P+=F!#;]-Q2,(WK$J6T( MYBXZ]Q*\WY:H?L/H'9G-<$JU`BHYX4!3D8*B=N27]L=,(NK-<>J%C!^W@%GM MZ@91.0\]_Y<''U13E-S'(/Q!^2$!"N$F9+,Y_5KR2"X1:$,S.#+7'H[_X849 M&D^_>7$,NL-^AW3_KQLDQ2-)F:2=@R[.Z$POSP2!@*$REL1L0\ZI!ZH\:"_\ M&W[2J""'+XP9J>$:35"2PC:`[I"?/C_%"]!]]Y3<*E\PC=(.T4;TP#RCG&&T MH)XT^Z91.1ED0-OE!">_Y!S1A^_&.2`MR$S=KYFQ8^]`)0:>L/'B;`S1A(FS M\;0P9AK@I[-ZV_A\(?`51MAW#8C&)7]ZVV<85OSDGBA5]BDLT3 MT.?!K@&(*"A,L&>@N^2V.4B$MHFQ-S!M4TMJNK=#$\5/NH'Y^@<6*+#YM!N4 M>/3`J+%!A]6'VZ;"!0E#[XG0N[A`S%L'4BA!);G;-K-H!D'K_!0]M8ZYZ!MM MX[9MK;>-I\KW',"YA:NN_M7V[[G0V&__@FM]NG6^3PV-2B")CFV;".I?=0;_ M-D2?YK$DTK^I[1PPO#XZ/5PF64-K-PE)X& M>':Z&G-*)[0(#WR*Y@:0Z"1`4R\+4SWH=J(--=B5-KJS`#)<,10'-&,M_2IP2?#NCGKT/O>;TY=^^1S$FP37\+.&`*1Y[:#@IC=2@+$8>#L;2L:85D)6.S7[4/#&!KU=E$5C`-.]?<'@F=YP;2F\`9X]]O_ MHJ4(KIUQ!X.OR&%B:FTRSE*:D!ZP4(T(6-FD0T%^N5)F!#!>EK65]J&YQB&* M+V@R%$N?$P!5'74HV";H&23/AU=@>UCYTM^C9"_-OC]XPCP%OCV@? MIL?8HZ?X83E[(B$'HNKO-_`4FMLHKD(&:M]ZF94&J&:\K.9,8S)3$$;K3Q(> MKSNBB0OQY^.S]^_?O8?_8#13:C]1"PX%GX_3.$/%#TF4@K9Y%3++#[1E]$S_ M9YP'EMNBP90_L0Y&JK%H3Y-W[,TJ.3F.VI547 MJ'WH/&H"!:A`\6-O4-S1F@LDO^L9DA43ID#S^\ZCN24["M1^Z#QJ?$6BP/`O M/<%P1UTO4/QKYU$4^SL*+'_L/)9:.=5`<4EM[N.-(WT9(8-%4=VYMN.KB\]-IU3_C&![1@J+%ZIX$6*C-M8*5.'E.A(MDABT,5LJO=`NV MA]F`]1)-$9SD8((6*,IJM!7!X+[$5)I3<3OK%=2@O-`>#N(70H)7'(J$G=)4 M.SBM&B4`1$+82T/Z%9%I3K>2R@7<:#?_4T#+VFDNXE(C*I6G6\9-SO42-M0,QZ+:VX,HE\*&-M`3Q'`R] MJS>:SUQS-OAC[4!-YBA.E_7%B889`=.12W&$;U% M6U-1T4T.%G*1^WBHN[[&;^%RY%,=.3F#=3GTJ8ZCFN'H<@!4'5>!.N5R\%/W M)CH0VE3&1F!$E)%2=#!NXE M!YO`71K9*I!W5XCN@[QL=(&[NZ+4T*$7A`0*"K@K8>L=T#R-8MOC6V#JKMVF MC:DH-:=`UEW#30]94;RXD,.=D%L*F'+C%06:[IIW>FA*C^T'2X)XI\2LWL%; ME355MVH/*\ST"++MORCXDKM6CQIFZF*YP-F2%52;="Z/"CB<>:ZRF3KZ$C>$ MZ7+I8#,T=_/$7*X=;(:C,//7Y0K"9JBJ!%-=+BALAK74FE&L+72R=J3ZHI;= M-%*`91PSL`/&*8J7@KC13)69EA-C\ZJP49:^P-'XK=A),28[,YS`X"9),G7H M5Z.=@%S<2D5I2E^2?EN`YM\?AF18KB:7/XS'ZD?S7Z#(1^H9:I+I]G'39-&* MD^WCI474LFN`)_/=.NFS6DY;6''=RK7C\463\5*0M/8Q M&IR59EUZJG*U&PXA?8QW)6XWW$)-,5W+Y&YXA)IBR6^`XK0;2!]5F8+O@]]]Z)MK`M5,LN/F3(".J^P4H5^S/,8&E.L0T5IMF*]NC"`"U*C4Z!^U6S--%HRUU:F(L906* M$.+J*%O]EW*^EM-O#9,09,'P(12=$PCN47'=!$2LCK'3)2"%*5IX$ M<=\?[E`[_7X2Y,4^+>J_!$A"POIIR#F,?(X=+!@110=D\VN;L-5,H,IE+,0\WMVG`Q>\$@39]LM3E&8V=&%V+:QBC3T`G0A1CX M'C2J#6O8#XK__KIU*-MDVTUR^,Z'+E1`-T1YRS-DO0JZ+4QK8DE=:.?5"&^) M;Z4+S;QJ#?QJ,:+4TNM"1R\M?%4MA"[T^])"O"YQHPO-O[00YGCE[#*ZER_4ES MK6096<]J-8:61$IVH>NP)I+E.%`7&D.JH:=@MW2A$:0:L@?-/>M"#TD=LG&2 M:[K0)-+4R>A3CS*]'#GK?5?MY10&SR"_(;`Z_HE19((NU1_P><5\KAU;MC>C5'!LQYU'PGVREC3P2 M`7AL*YX\L)TIZ8'NC/E/$.Q*@E/T@.(%]FD1*2;!!/GD.3\;LA8YK7_655I^ M\^+8BU)I1Q?]=2RWYI*>^=UQ>M#B$&<,AO<_?'S/(*`_*2_[")1(0')1C420 MP:0T9:C7RADMO6XD@N/'!50^MI-0#ZW/.I9O7NW?(&4_W*%V4VSAY5C3KJV+GG#NG-J<(<.R/QF6G7P1--?Q+K,8[E2N[>97[6HV#\D2 MH;RE2Q;[+Z`KTVEV6K.87Z'7MFO&B%:3'8(+V:T"+=`#\V:M5S#NN%F M;LT]O"=*QPK9:3W>Y$Z[[%HV3(RZZ]`%;[/4*A$W(UNKA5U(HE%&D>,KZ$(: MC3)^-;Y`ZPDV)G$5V3'V*RGZEB4O;Z*K9?%4XD#\G78)7\[^F45W:,';P[0W M::Z@U5N&L$.Q0BLJ$N4_ZF%G&`)6SC2 M*W<'9P_^FM=]T8,5!:L'G,N'C!;8@#3)XKJNHWLO:XL6"C>-7V4D(43S-6U0 MX1*!9>5C!@%M]E%J@B'`43:C+T;(\.P!'ZS>MJ6OL.:;:.3[)*.LVUM*[*#Z M>6YA`SH'`J'4!*'25&=P`@,GN,7>$PX94]7!:7NJ&SA=KI)NY(\NU<]S!)L, MT?L^02%]U._>BRFE+[(X9H:G*FJR1=S`DVH[$7Q-YPB6Y[B!Q49+65G.-1J? MQ@*.X$?]R`474]^JG8ENX',?H[F'@_757S>_6#G,I:]9-5S,YB,CU*DCQ*8T M9'`[;W(7>*8(QQ@34%5C`;?QJWLO0W\AA_`M#.V&^\E;P&W\FNVG;"&'\.6X M"O3PY"W@-G[-]M,UCVA'2E2]Y3IR4X!(?H8"Y&=;AGO'T/@;-+:55&CZ2X:8VV1V\\GR]GZ,`Q7"N`#:\H"K; MNH].->-'5H-G;'G;M+DC*:IQV0B'6RMCWJ&E*.C.'SPD-?2H%#B;S_,(O1>N M0RHWT93$L]S9+A>5JK.-M#I9)8\F>6S]FL0;C9F7X*0TQ5Z^09LQX'+&@C36 MTH7BLT,12L08NU"T=B@:Z;CP[-?!U=/-5&AZDPE>RZ*L=]13H(J^HU9^1GBA MH"Y4MIBFPZX[N`O5+J:I(`_1=*$/,1=%64O[*7J71>>#=X+>ZDA5&#OKBFC^)"I5@GL M!N^/[KJ(]L%[IZ"Y0-A==5R1YZMFFA0HNZM;JN_Q?O'E@A:6]$176D98V62] MW*BJ#54N(M%M_''@_AC%P=OH&U^]%!!(X*#>8N!.`=VW3;N3$@ULM,^X"+TD M&4]9GQ7I(T><@5TN%A>DQ5VM]AZV+(O9\[J?36",/W-KAKL!^]3;'N1U]":SY3`.-[9FN8'1+CV\LO?.UTWJ$RU[OM1G& MIB8K6S['%2QDN=KB\4/QCQ#*4FA;7H7/&VG_1;T\]"I]I%0RP79I2A%"OB!@ M><0I!N)6X14BI;>*"^$CGP_FV4LJ?`2%&4?BXZ:PD0KA1B()@">:SSI*)MA MM>2EK'>KO#>X,]YB1KC0MJBX,F1[93^IMV]966H/P-2I[^4-K%?(7,):\@R, M2:2=>`Q&X8ZJ:M.;J@R1A6R]"$$815-2L>OVMO^Q-6TR"=]7<3>G0QM'%<6H M"X5_^IO+LS:Z4+YGY+;O>'NZ4("GC;G,/NM"(F,#A#4-.NN)B\H1HUH/C+O! M([,XUBMSN@^J=`1AB<6XPOBCX_IWK ME4;?-",A*!0H,1`;%$2W:-R5Y0;"!]=_3H#FO/B6<*R1.%MY]9MH0;"/'E&\ MX_&6C[73;ENEQ:L+#5W7,#QZ;WG5)TV"R6/M84A>J>RK@5XVL\NQW_Y&7;]Z M;WB6S:2>SNH8*]YF+WI&$E]F\7MKT$DI6!YAQ3?LA2BA[R3BA,I4FEARC82= M!D6CC?!QJ2#;T<7+7%UQ9OM0\N*4JK,&I[-!]6^'+50<,>5;:1^A>N.4PT;* M^&QQ:NN&YH[WM,'UWOB(5>Y;#SVI#4DF5"U=]JCNB:M0A+GL3-WG2HA-+Y>= MJJ8PKIIX+CM3#=UAJ=%EW;=:ZX#2U)HZ[%ML@"E'7W'\C>;"\;1NC[5LGFMN MWWX7:/D;W`ITI1:(='Q;$`FM#>%8.\]VK("YA@.9O*#@"R&!^#D2[F"K<-\A M\<,WI2%689QXKU]!`XBQ%]:2MC+6:6_7(6I.I//F M1V,\M[B:\S9'8T09&[1N8*@I877"TETET[*[SIHR>4]2VD'-"ZDA3R(6BBV5 M7U^]^6$&GV&-;[S0IVE3`,YX>HG#+$4!'$Z:.7:/8I9Z8N7Q<``_H-#@!7I` M/DUH!(V_`CB9S;-T!?@Z"VP-\FA&;06![#:SM@T-94_(SY?\!201GS:_V$$* MBLP6X\N[0YL[;X:D]7NUTWJ$BZ5:Q%(BW"5Z2J4Q4/Y8RU!KU/O4S1KR&Y0M MOGT$&.FRHRS-$F]**"]$H0%]Z*A5B+P/E@/68C&TSU9L?1!([,?L4&GU1,> MTIM8'6.W[.D`FD^E'6*M^'# MUXIV[J[_V0'"'$01[$R6Q4,:>REZQOXH##'-^?F&TY=1"/,(?7;$F>9_YUD" M6DR2L'6W&ZQ!-=!ONFUJ"MZ5US8_J8-35ARW!HK^YW M-&/PCJ)@@I*4-2\15/T*1CH0C;KV<,S:N!?T$\DPE9EV*G*?TILH`6Y+69`D M',X9:!_>$E7SO](K?1]C7]@-5WV^D5B2\'-W&94?J\?_>*=><:;]/:C3SD6C M[4->&Q,7#N\P[);B^%5P9+HQ;^1@Q+EHQ-WRVMFP,$')DR[89;6YKF"U?J>F M4(?.21R35^HGTD!0NHPKN*ZJ@#>077AS^$VZU,!3N$0?^T\()/_]$J[E3121 M1?[2'>R].(]$/'CHA=&]7AA:$&K+8\%Y^T;B7XJ'Y\5'C3O.;H:+V`:IEK&* M]!_K?@6UA)3]T'0[?Z3&)!`CV']OH`9I],1Q<1K]O-1C.ZSAG/2>G,E;.1^QO(E";GZF6D7?WZG(7)3/^-]I*(T6W M>(&";>*4WDH!LP.4L]_RC`:^FZ[!0I;QO?=H^X/D2RQ^-5(TVD[?H2I5[U": MY^6"-DD;H;SBPN&TTX9(86KW(W6B[L&;!*5M.B@V&M-;X&`PBQL?*T\>M)I] MFNLV.5=%CUWU'>ZAPW<_`M8R$"?051 M\J+@[6VRJ/MTF"!ZV`.:5'(-]]4+_X4\4=JMB96-G%D]0.AWKTD6CZ+@\07% MR)NF_-Q>$\NZO^,4[D?XO+X9)5^M(YB_$G-XPUJ.82U^)*-FDM-V\2'L'!U) MO3%OZH5G7ZT:77(9E4[.6SR'H)JJ7J;L[Q[_55&=:6*65-FN#.71#V&".*Z%., MSH3S+EXPFEZ](9_U*1Q/I]A'L?R]`#+(.==JD/B0=29)4>+[(\ZTPP0GX9>UW M!(,-O:R"Z/F*GMEQV]1_@@++NTJ2T2U`D\A>>>$-M+&36Y!,F&A)U1Q^P:J&TCI.P+:%,KE]#6)J6S"T2KT*Q5F^HO8@9WV3:9Y=Q,@YT[E M@)$E[>%%LO3"`\W;&%:;!:WBU,)V55>UTF4&L738>R\6Z*F2@1V#UY+^5`;D M,?:BQ/-9L>7YLOP;6:,D]06,W`_@[>C5"_/73.C9+5FG8GM+89:99+D,%`D0 M06)!NS7"3CUGG=ZK6>]L59Z\X>K_A5UGXY&(-2PV[YL M!5JV`@E]3S95MQ8K#7$$MED/PZYZ!%)TBKD<26V`L(K'U.48:0.4&QB/+D=% M#T&!JJGF#KX)'&WVY2FW.3ZMNWWOC&Z]3)_J?7N6F91 M53%==5NRN(NRHC^W0-A2AT_E]EOR$(.["0T&$10;UMWIHE:/91/?F,N=UNJ] MDY5&GK(U2,I"7P/!S?1"N+54]4W29*A;?]U\W6,>+1'"Q#?S^@^B_T7X/NL MM^OZV=CQ-/\2^P+QSD"O0GCNC,YC8.H=#^XG"D-7',93FV@&1E!P293S)LJGJ)+X\YQ$ M19OK\72KYSD7X@;+V("?<0H#".3KF,2`+EC^,*BFL8\3M#D&7,&C/MG*K2R@ M`UUK'#^PYR!8O_RU=!3=3H69EC'*S\HH2U]`3?Q-J,_(9CB!0?T#;](IIN_` MSA>`_:$$Q0M$W:3LD$<^-ZM)?Q%#L!<_G,O00$HV#1(Z^7ABYB^ M*T*/TOFR&'+OY5ERJYV0MJ M)4^MQ"\J'F]FW^ER6R^X"=21^O'F('HA80!?N`(E+EW>2AOC2H:W!(^XZ:U@ MJ)5SECTEZ->,)ETLX']R[L(=ZP#4C_`]V=T0C'8$_$[]V-4 MD^!X=XX_T"0,H#E(7AS?'F/RRZPK4.VWRZ.,?OV5U'][,\9>=HLX-EH4C-1H MC9M$AP_N9AG+T512+0LT;:55JB7QU,:.*VE+LD!G1Y)W3"'L>@6;1G"Z>']W MAPL7Q]C=A.\&&);X[0;#C[W:PXH\*W"TE/_;]A.U'VQ5:/2L&%%1:-0:UAP> M6A&F+B$JD15[XNF$B!`\9E)O^1<:G<@J[V%MJ0YQ=`-.Q5%PCPOOC_=N0,KE MDEI3^*X#5R[7TIK"M1+DJ>0 M6E*@VFW=KG'>8D&`/FAV:H5]A6^\'[I<@Q+O@@3=UNOT*A$*K+NMCNG7*A28 M]T`AT^D)4"!N24=3?/!9GMY7R:T01UZL1U2,(2MK9>1PDQ_MO10E&EKOYV,< M54ERR0K9[UP(>4ICN_*TT)J-[5J`UP"R3D1Y%9)(:O-.)=CN)ERH61+6NA2= M@Y'[RX,/MQ8E5'3BZ/DK"5`X`KDY8S""%GF)4M;X$EU[.&8Z1,GQT>%*9T./ M*Z^)4J+9^N7!LNZY!;OV=-=PHTTC&^#$IKF&RS]("*HR=7LWW*FM!5S!;X*3 M7ZYCA&XBN,$H236QXT[O?A7_[[#*9TCG&W*_;#HGU)E3W[*AZD5HWW*B=`1M MW]*CU)5!Z[E2!W'/N-^G]9&D7EA.`;@@P(J03Q&@B4Z,`#MY`E::M](\@IKR MT^H8,XV?V!,I*,_^V;A90R\25^+53>ER>ZP.*;1Y<_]2)HKLR57^4"N%O_X+ M"K(0K5)L9#DZB2A)1_;BKKGUK5"'"[,(5?Y@=^!6R+<2&6$&%W:2'L*S5_#X M**!,]=2#YUE:H8G@AEF/]`J?GC0GTRK\PQQM>^A]:IGV`NW*NK5N@B)[:!2E)]($ M-H7+?KN#4HBCT[CLX3LH;6I]";K^0&MN(X9!?AD`[0E*TAA3)U^>@.6G>`%@ M]R4X[HJ?8_`O.&"7#G:Z&MCCM?>?%0S1_?/V%ACAB!V)F;L81AXA9%SW\!B-F^VO;+O?3Z0Q%E;5%ESO[',:N M:VD'UO9V+\*CSA!XV_'3BP"K.>HV4!I=+L3HWOE4<+;W(J/$&8)SHFPN]Z6U M[QBRH'"XW3RW8UMBTK/B(Z+8= MMIM**&4J11O'FPA(._O=EJ"B>`%[RS]"/T<%SFF1[]3"^+\-,"].C1!1:T5_'/6RW.$2E2>2Z M@_OZAZ+(B5WJG9E?RO?<3(E8TC?5P-[:U<7'@[I ML08[D;E63%.I[G.=HIV*#XK]DCXKLFF9=)#\W7HHK%'ZJ1['IVT:M[&5';^>"A^/[.IN=7I_1&W75&_3G%2W6-V+[V9YR\J;UJ)C+0K(G6+&O! M

L`U#5>1-%H1R"77W?A M>+M/%@R=BYSKZ^3&HP@]R\A6O`X\MU_E0:5NGF,]M-PX@/7!2Y6F*UPMQGID M=J@/<(TF`HYOO<^8&U2I\@_WWYXZ"%'JWN:R]US54&KCH+1RK#"DUI?=Z^J$ M>IJVY'GM=54"EZHMQNQZ7:"P%S'U'>&]KCV07_>F3L."9.X]`=\NR8QF6/6Z M**,=X=TTF-KK8HL]3BPW`[+7)1!BZ=)&8FTO:A;V;'9;DV.FFYK>X5=_'7`V M'?K-WS,U&\I:O<%-%&1P+)?T_3TXQ1>$N4WS;=03;B?16*4"KM,-"M@)]D@A/PRQ(^!8/[DJF^1V4!`^`;#M`$P3W/T%?O M/R2^@*M#9BA>&?F@>XG*!E2G=S\+7W#CU[;\EYPI,7:3)"A)J#!]!,D(VFP: MDR#S^3FY6O,/[5VMYQ%ED2&ZD3UV@:H1J,%!*?0)=TLM]4Z'.J>Q[J=5CL;( M99"[D4G)YHJ$UN8<NK+GO`0G MX^G(]TD&&$7/-LIG=X'@ZPZ[X_JBCKFBLIA*05T=KSH#@3/0*KS2"K#JH'[R MI0.&X85GI!J7J.Y,CQ5#-8)P6&5WE!_^/>OJ6^EBH?J%P,8P32^.2B^JP^?. M0^H+[K#0$MBT=1ASS-BZ*8,P'83I($P'8=J",%5C68-<=4VNPC;-2>*%7V*2 MS9.;R`\SVG6+[AZARE"&@C&0+&]09E3P-F>'>\/,9Z![+SM8SH.P'X3](.Q[ M+^S-,>)!(7!-(7C`SQ&>8M^+TL(CB3FWO!")%;?(@P@<1 M/HCPWHAP598Q".IN"NKU#VS8Z1=>\D*S/N&/JU\SO/!""C>#:%DGC=3FVDEY MG,UP0L]?LLKISZ%2Q$MQMI4T1"^.X`PE]RAF&>EJ&-7-ZHM7I#E=-Y4RX^GF M'M]$"F]JQT0XW`[L-)V>Q(J75CA\,#S6Q2<^ M`AX-\E:1O4LF&`F>TO4K]48LLKVAOT$ M<'/[*U8G.M&<0PE+L1+:B:89BCB*C(1.=+E0/*T*BE@GNE$HH5OK)>A$-P@E M5!4-]TYT=%"3-6H>NT[T7:A/5],T$CO4WG-P@9=SC`W7)#]LMQ5/1X M'`$@`0XSVE3W`?D9G$#8Q*LWFE."@FLXW[1_2I:R9)+Q=%L*U4:WS7_(+KTV MVN-%%L?KJZY.A9KI@\-D<)@,#I/>.$S4V49__"9MB!;K+I9!!=Q2`2]("!R7 MT!S3!6V4=HM]:G:7^JOM7;0@"#$U^S(GU-1LH;Z$U7NFSPXZS*####J,<5=- M0V9K79L9Y/5VO2%ZVE\B&RHC%(#"9X*BT8,<'N3P((<'.=Q[.5S+-@=AZYJP MO8E24(\PX$B;7*9FZ_?=$E_[Y`+7$XG/CU5F#@)Y$,B#0!X$>Z%0$[T\()0RMIW@\9:Q\V5IP]JR>]0+1D$]R"X+;3FJ&5E@]QV36X7 M$GH\I9670)/\[684PI#@@B0@VVGEY;D'A_G>6[)9MI\9!0RL%@[ MCF+@]BK)^?(>5'_-E,-#PF*7ZGQH1WZ*%W`L-,FFM=B@=@UJUZ!V]4;MLL3( MK2MK+1!0CR#D%V?R/!7@XLL8I:F#J\E)#7O0>0:= M9]!YVLGI5&&HUE44AP7T3Z?T$T^@Z\`__A]02P,$%`````@`AH`.01!3[S9Y M5@``3[P$`!4`'`!I;&EU+3(P,3(P-C,P7VQA8BYX;6Q55`D``SNO*E`[KRI0 M=7@+``$$)0X```0Y`0``Y7UK<^2VDN7WC=C_@/5.Q-P;(74766_/W-DHO;S: M5;<4DFS/KF/#0;&@$L1*)5^)? M_\?WUSUX@V'D!?[??K`^37X`T'>#K>?O_O;#SP^GFX?SZ^L?_L>__=?_\J__ M[?047%[\M+D'M_[>\R&X/OT"X]#[#O[=A7L8.C$$C\[WP`]>W\&-\P3W$;CQ M_#^>G`B>`/SG%@0^^/>S^QM@?[(`>(GCPX^?/W_[]NT3W.Z<\#0@MG M<'J:MOD+U>Y'L/AD+3\M"K^Y#X[^]D6/;I9'5J M68_6[$?+_M&V_V_QZ>#P'GJ[EQC\Q?TK>G@R/T5O6"68)^#:=S^!S7X/[O&C M$;B'$0S?X/93(FF?@`3(EG[TMQ\*N+X_A?M/0;C[C&1//ZOV9_)8^'7D_1D3* M3>`2TT@H"+A/X'^=IH^=XA^=(@M/K4_?H^T/_X8;_-^R$J:@?/E/UR`^Q7Y84A-]CZ&^Q9/I3_+[`4%0\ MMC$1BL4&;DG@'EL[")F0B:QG)WHB`E.5L:]^AOLX`W%*O==*P2<__GWCNLCQ MX^C.>7>>]O#\&(;0C].6"+Z__=#P\.=,;_QX2?,01L$Q=&$K4V`IK33X??^$ M7WC=H\=QK('^Z<\//P!O^[C@K)+H`Y4#@O,)BQ[EA.ZJ5+HKPUHDB<^NP$*'X?XM/2A MGL/@M=%3TK8#*?"?-?+A'KK0>\,:?86Q'"N8KVC@!DL/26=:V3.KPI!<&D#B MS"!*7X2$+H^ALX7`27&&F4P3>"-R/Q9[N!8Q@T/W<(^[S3LGC#T8M:43^VVM MS&*J).>"UFRUGO))ED@&B6C3"-<;>+FKRED',!'0ORGZ`Y+_;A81A3XLYB3? M:)KH&1[A]L9SGKR])T5(SO-J*<#EX]+&4O$;E;BB,`0!C'D"WQ]@F&[ MCYF\HY\M5!'9H<3"6C=Q!OQ&1?X_H\C3'F:50G<)A02A03.%RGXH0:2"4?30 MZ3^.4?R*^KSH,>"H^/#BA)!,?I\'K[B+)W.P]_#O1R_R8O@`PS?/A7H%,,9!H M!JAJH*`;(,KI"C#FF)S$J(8F>X MCB(TM,!_XE6O\R"*HS[.S!-I6ISCZ"F9-]OVO'T,PTT"VB9(&P6D58.#TP!V M(H'G+O3>\*KU8>^X$+<)@F=P0`X/T4!V"R+FAP[,'CSMG![]OXSRI>N_=L#WJR$(OH&?=PW,G6Y>8KB MT'&YT^EC-*4KG`RDOV2:;\^SY>ERQ,G4(&O45!&`-<&_Q+J`5!EP]@ZP.C@H M90J!7"/P6ZJ3MBD;O>:UJ^:-`[Q*EYAWCVU*5NK03U!C1VR]@+8<^.1A'WT! M%YO\&-'0%V1F=C+-?C0FM@U,=F[X&_)3MHN0WMX[DK@W64PG).KAG_R^>26; MU#8^&M-%,5Z?O$!_5+Q2].3`,6<;N$=L*^))\FK(^;:]GDYFOT^);U,QP/'Q M+`H5!+"D4?C.BJ0#H;&*:#9*T'"CUT"02/`Y1PF0%X-GQ\5K@>\@W4Y)MN'J MB!L2=,&T;[)!][PF@NZG7?#V>0L]FM*@OU0S&?0CVCCFT-7>V56^4/WW"G*& M6J.2J?1R:4\+_DWR8_RZ6J?NI;TMI_W8OLMU"^RQ;(!:\N_7((R]?Y#8?_M\ MC7H!?^<][>$FBB!_OD[\DLJ<6*B)]%KU>I$Z?2X.W#Z#7""@$C6EIH.AM&LH MT>C7RP2.@^\-AD^!*H06G11$L1^1WRDB-6$A0HIMI52VV3`#):7?G/>?]L$3 M9R,!YR'UJ6A%`SG76$UFDTF:A2()@(H8=Y.`(`/M`<)2"Z(I\>R!Q*XBT9AB MPS)*/7RN[L_HO3W"H'":XG'.(D8ET[H MH_%L=`=#LMJ(XLF1O^%T$-DJN_\A%)9=<5JLTUU'A59!WBQ(VP6X85!H&:<2 M:=MX'P'==0!H\YI2"M66H]UR@+ME#P4M-WA]188AT^T`+WB_.7LRZP53(Y+) MKO@%`M?9N\=]EJT0K='O\707F14[((-&6"FM/?N0M"PE`(-]J`\8K<[>V0(V MWSWNV&3$%C].9!/!D,VFEVMKV'AW]@YXHG[#BNF:^#?#U+;(U'S[?)``)\/D M`<->XT?Y@,'PQO/A=0Q?1XI\N?B/$^8RG66W*ZZLY;`Q[;<;4D0#Z_`QPU]$ZHZ#!^N'A\O%!O_L*]VC5(>ISYX8Z#*5GE#MSNZ($ MT\FZ[,NCEEB0B\(=$!2"L4O?-B8HB\HIU.!J]VFI2%U]5I>/M]LW:TWGEL7R M=4/B=P]0=#]>R?'U[MP5N127`2/LG7V#H;.#=^B+O3@1O`OI^4@R2+Y]IF<9 MR#^JN7/;MY5O;)!63*"B02H;$.&%"9C@.3T\2%M0O!MB%.26 M%/);%<@;ME",`I_&C\!'PF.R?:UV(!(^/^-C46@T?TBM<\!MZ]N$T9K:^>Z, M=C;4TB=_<\+M(VI%M'19>D9E'UQL6+8ZR6R>[H3';P/\NMYEO*X@;&D0RGI; MEK.4>MD:5AT^?>9$7G3[G)3=\_SJSG?^1R]#C MX;V@V#D4U-_?(073=$2GIW-=J.CM;-Q://X8>3Z,HHU+2W0@ZS6MR@I?4T&AS[+H..SHN1,`AH!%3]=!I!?RB!U9TB/= M[S;%1NI?PBVN$^4>HSAX12II6^IIXE.VL",TS>#4OO;?`L^%CS"LS>:)G]5) M[:(BLA5_UK,5B]J)*$!DZ:-V5T0,:H^/2)[:76'EW7=&YH/S3FK;\"<`E-.8 MQ1TFC6MFT)4I7^V#;U\10O17I!.,2-DW?WOE^8[OEDK`8=7W070,8<-FJMYB M%>?7?725/4$P6\T+S,0M@J1)D+5),O*LU6)1R+Q=[7NZ5!J,5M0_'@Y[4J+6 MV1/N4WED_I.-YT5E1VN#NWBVF`=.G98J,@;U5?G%%B*#N=R&LL&DO+;A1L M%`AMI#*X].93-;+T,[V6L/+BP>?+[]`EQ]ANGY]1>A4*;P,3O:$R)/#5D-TK MO9XF&\")+)`)`XDTS=>`#830%B#42L!FSRO1J\$:6LBS=Z+H]IE.\<3R.!1Q@>N,Y5HP,:NT?N3JR!N MPWMO]Q(+=BCSGU?/A;H2DBZTGB[7%4JDMZ/1!\98JD^()F?(JY MPG<]!F4X)C&&.3(="/,-W>QI%8(7R_3Z(0%_3.A=^F)LXI`Y/8[(#1MYU+D/ MXBVIL!JY_'[PZ$");II@SI9+O:A\L45&*\FS61,+A>:IT*U.0"X[V5&D>"EF M:+P-H4(-W(9UFJ$Q%V\CPX7'4X2Z5VS:4#-?OI&VSC#Q(]@C_0,L_`UN_.T- M&B;Z$=S@UG=D/CR?T^5M:^HA2'E\Z:*EI"^NYE8:;XJMD+6"I!U0:*BPW*(X MYHQM`ZMN@TVC#31N!E-CE>3B9M0`W'DNV.SW'KDZEER4N-G'GHMZI6O?_:0O M8/6)!7D`ZVQ(+4.+X/75BR(\IWQ)KZR@&]LD-W)*OJURR"&GDG2QW$7&YTPN M2`2GVSC-V<$J6?7;0=[U: MA1&9-U23CJV&Y!C86MNS`M&26RG)YNFB-(V\Z@_/KL(C!Q>*TL!?O@8Q!*N_ M:B>8V`MKI!(8QS`B-:?S'8680;?.29IEV].%!`/-2%G'MP23K(VQR`".-N2H M/2PWT(`;W\5""^3@8CG.TQ[^?`A\6C\H(A6I"[6$+N!3=0-D9S'J!]NM=93= MJSNQ9NE0FUQM0QL!:2O@B)H!>3MX[J]8H`DWI7K0/:HM+($M?J[8XE:1+9K& MVZ,:A.;MU!*X_$KXAFODHQ&V6W**+0>\HO%VYU!0&&UW,Z..6$86X0?P!2K' M\&A&E)3TV-6T7S@C;1D=SUI;HT=`&\\:@T:TUB:1#&EW6?%!?/RLPC[))OZPIIC5K)NNGZ_6Z',C(=K%R M'$NE%Q9D51^`&P.VQ8?]!L^H+X.;DFMI[0FO3X-E&KR40[)A-;13#O:ZV^.\4L0 M>O^`U;V&,F_HH5E5#LK4IK/F$SYB"/$-HTQ$AGSN!&*(V`C&\4,BBJF&& MGI"LM7(;WB=S,%=!2.8H?+%21?>2KVB,4*Q])%,(U=XU%6/1T6)8]?DDHD]?1'6(XU* MA-)1I2_,6@Q)Q@%:JH.U(1HK)G"-H7E((+RPI/J8GM2_S;T,]FS.&B"/=]M( MFPR_-1!&+_I/DT^3B95/R8)38$TF)Q/Z7WU^Z5_`='&R7%@GJ\6,;#[%_YRL MT7^+\NB:_++81SLQ^%]''X+IY`1@/R(/7$"7+%6`J45^BOY$(@[T6L;]NR$C M#/[U%JR/H8>!/JY[3$^CWGO1'VTVE$N\JI2IS?K(SIHN%]FJ9$$HP%)-VS$^ M+&C"]&M_>T0]PSO%F^P4SYO12RYY?RT33M).1I#PIN%B/,$+.@EWT_+"N,5B MRJ>9_BOQAL%G=\2GC5$UYQ/RZ$;_57A5E1[Q)A[9;TH?ULD:HH'TI;OK*9\Q M1)(I9&D-BTL4/BQM'"FYF)`?N1D&FF+)]\=F6X/IP"ZHS?RPQ\5M!*B??FFA MG9QS+::+23894]QDGN^L3N8N`L"8-54].3,2?LLH_$U3-R,9P:X8`1?`A"$^ M!7J6[+JG1PX.%>;U)&<@K&6ZUF1P/E!/X"E)KO_"G*U90!#`B9D)?CH_!*^EJD`7]=1OPY^ M6LD/I(QD`/4:-INSGM5'KU:%P6?V9,HAE.Z-YSU!V2Q0!M%$M`F=!UTS%%,7Z0U]E20&D(DD4=R*,6UC!YR1?'M M\SU\@[Y@R:_XC%+B%!J6G;Z8VW9*DRC&8ZOD?5V,Z`C!SB"@9"OD0U#G\PQ' M*7MX%6EW?XZ@^VD7O'W>0H^Z,OI+U8/1CWX_/R(>^?$52MB<_?^!3GCI;R_J M%]H*'U7@SZ+VI7QBMEZNIJE;4T&`2@)8%+C$J[#*;WT="I;=!=;8?B_C7MC] M&XV@(ZKCK$U^\9CWM,)(SU%!=HRZ2NN+D70O"`R`S;B#1X%[%7D$$7QOFN=T##/.!T\OIW.@Z`C)TP-R#3TW?77(W?4]]HW]U8UN>K\PJ%-R5R']?& MDUP'R?FYM37C=%18E.;K$8?`QJ+*23,X/62I>QR?+15SZ*>+:";/:Y"?S=*6KU%51@1B;L"!;X&9\? M7?<"#T4-N@0L7GBM/J64$J6F90\H6NDADO1]O:NO/5#8)10&+,!R7*;LX76X M!GAWLCPF]XW2A_7Y>J*!]+DB:\)V>9`(,L+U.X`RG0$5MQ(0H0A>)Q\>G>^; M*()QA+>9DKFUS7X??&/4$&KSI@:F"-21]+#)Q*KV%$@HH%)!)A9D.CXU.E^91V*;#+,H ME6W+.-L[[A]HO(?`1'CIR_-W7X(MLDX4'5\/I#S-8W`!\0#0\V%V3B*OQR^J M*C5&,\J7NX;'(.7;B\G,GEG)VEB^J^D4$#5.$SU`H@@@FH""*GCQ)%.F>$"I M<#^(MN)7FHUJ58Q*E`#-)GWDF/16G4D;%NWTVM76Z*QJ5@#'BYOYC+_!+ZRC/%9L1V)-FDM,\ MIR!O"A3:,B!FCV*/:DPN6T./+62#[2@&J0?301Q$<9QL'288<;"=>8>.<_P; MC?N$O:Y2-4;!CBK+^_R4%11%=V4;'205F*L6,X57K!L>0Q78BQ%2QW`OU2&V M9X1B1=P^'V/P`%PZD=XKZ+:0I#/0RJLI[_TS9G"ME%TP.IZ.8Y5Z#*W8Q/2P M.8Y96*%R&&=1'AW;AP]F1&QIYX&C8%H+%M>RHR$YKV_7(R1V%ZLO/G;66=[_ MYXQ@V5"-U^38J<1BU4!:MM>F9B^SXZH2D]6#[$A.ICCF]@Y6C`#<[X,,'HUC M]'%Q9T#7NF6#+>=8UD&)E@ M]E%RJPYA1";TJ<^AWE`4"<)WV9A7?5QG7*OH(N^**V;L2L09$9IZ0*N''T7` MY.-+#W2L&"*'3WF(X#"+&098%M&R23?3Z?;Y/'@]0#^BMS?`O1/#+:XQ&)&3 M\F=.!+=WSCM9GF@L<-93JLK-OOU4E:U//%G7%PYOGT&Q19`T"4B;M`0%(*V" MM%D3RJNILQ<]%8GW'YQ2,Y2LM<&[K7:0B->ZTW@8!I5V(P]@XX'SAML#Q+,^ M_NZ+$V,?V?C;&^_O1P^E+^\]QE3=Q>K+0SKK+-_MK1GY2M8L2-HE$Y59RR:/ MO)18K!9=:_;:E.QE]IA,BL=K!@I6[\/,G`TOD/=`"YJA/J! MY*@*W-[Z#Z@];_="ZK:@GL&3G"!O*TQ?Y&VIJ305YA-&O*6-))# M!\H`J^`Y^\(=7YYPR7WYW]\_>X)U'H]OG"VQ]1IOT5 MQC=!%-W!D*3;DO%TG#8UAMU1`,D3C'4>+].I?&U?02V0Z@6PFX."9OA\4Z(; M0,H!K!U`W7LRY#8@E&LW>"WBMS#W5=7ZWD4IH=<@Z M(UAH%^0-@[1EDZ=>U)BLVETT&(W&,ZG^KX/4QP8P7Q`3[1&)'\EE3UV/C;>XA:\MPXN2ETX\;>&Y[>EX_; MTJ(T1VE9/>5IP3KI2.,*;8LL).6MI14FDO9,B;]CV(4=;1.K;'1:I55L'<,T MG$@ZA,OHB)IM`PDO1K8R]>`1,71BN//VX07OMNK\2V MAV2=\;*[VO)<8)U]S%H&:=/@&VH;)(VC%,(U.Z%58[AZ?*V9[=>JV4S/9=58 MCA5^1W,YY0&Y?QQCQN>>GV;@!Y%+YM'F`W((_7M0?M=79KAJW&RUWE5J.-55A2.A6 M9[YZ\![3]11'[V'"&B-^#_!]-!W3.`21L_\I#(Z'"'4T^^/6\W<8%RD3=83; M9(-BX$<%M,WG-/J)57M0HY>NDK7-Y]8BW_Y`&@2T19`U"8IM@KQ14&"C$08D^$HDXS^RN>;*(MF#&.'@F_5<)?D*X!?$-2-9(%[$$]0$UBU('I>?+3 MUH[=$YP(NI]VP=OG+?1H;H/^4DUIT(\RE:Y0>'3V=S#T`I1\N>#6,Z(O/[HQ/)3M$CE>E"-Z=+ M?WOAQ-4;+/G/*69&J7'I2&I5AR9)$H'D`"Q('Q,ZX[';XE'I^4Q7JKI\';HZ M7W]$8@5?A?Q:L6?C-N4=H)KNX+?U>7%;W6TIW55Z;-$AJHZ:H=,Q.7_IA+[G M[[+S0/A4J[M!I*&GA3CSLTUO*9Q:;U!%N5 M/,.TS=Z.")[T2A0IGJW=)DC]A(;D@*M+S\I&Q"J8*C\:S$[6K&T7^YG`5G(> MZ[UIS;GI+8WLK*@B6:MNNE[/N*RD(@U8#AX0:X6$S%/FZ8%UW)1)]./XJ(AV M+$L-LGY[^7K8!^\0/L#PS7-A7M&ON/7D9S^$;K#S+9&-VJ@)(="B5YRSMHRKJ4=^,%>$J29DN=#>6 MVH5EO<:T/J0QQ0O5>BU*HG')3F[13BZ2KVW=>KP(EZUNCV1\+?E4"H6<`?KF M(Z=[\0YWR`4N'V[OBGI??L=_K4Z/=9>C,N=JJYSD\&"ZLA;5Z$+/DJ5M`-P( MN`0/X!;B:';[3.)9E/Z0.YT3;@8^LCUP%.K4E:E:!"]IS$F.N_4:&*]_<. M")$5SQ1"E!P<]<=I-^'4/\X14ZX^:!$89.RV>)3Y M-L^52C[.A*[,U_-JUG1T>7N,(WS>R_-W_&\E>DDM"P2:2(?%Y:I,B6+A]&2J MIB!6&T$&@FISH)Y(8E5('@G?K#"IR4:J:'6!\D>O.BJI_5HI56B;TIZR+I/B M-_JZKE2G@_:VI/;J_+GL%&7/+>!3Y:-7WAZ&Y[@T51#RDYSR4TH]MM2T]*>? M6B7')4)`*D67^W:&8K>"HLZ7F?0]W'M[HZ,=?G5?NF+/ZF%+? M+KCR[NY@['9@U/DWVX7*#LZ`K66MF"CSJ[>%]_`-^D?X MQ?F/(#P_1G'P"L,[B+ZW'SL[[M8/V==5KO)*ZB2[!75NVR7>8,D@$0V(;)`* M![ET3Y?HA;4+K>FM+]RTMIK:QE19N_OU(AR6'P(>X MG@IC6"!^5B7K6`I([ARR9NLT[R)20"9&T]!A,%!V:U#*F"-RKA)-N#889L7P M.R*:E^U2^-7!US/$U6H,PD>5KPVR]9!.%_[B[(]P M$T7'5W(3690&E@OOS=LB9>_KY>=:OZYP+DQ6)]E*))-%RV[:KAY;G$UK91[3Z/@(P]<.GYV\9@C]L"Z2 MKK>RY,JL81JI?@GV*(ON'UMR6HUPNWM"^KCO^,@_?,CFFLI'MP+*\9-C)%(;>>]$?5R&$ MUS[R!!C%+?G)?%TS.UDZR9Z_GD_G0FYBV0`+!ZETPZC9%SPA)A9R^HQ1>BG* M4%-YY:Z^VT1-KIVT$O/L_(5:^5\EG1Y)I]E;*N5S[?/5YZ/%/3PX:4H#LE\:D2+'S8Y MCO!='4P6*22YG#B;VO7<]_899()!07)2YU,S?X=";5=0!QS41I!2QF^9C&RT MEA8Z>KX7PQOO#6ZO\55M.^]ICW,!&$<;USV^'E%V7E[@X3E%>T$JB=I:.]D= MLA-[G;"6-`%(&R!O!-!60*&9TNI?/PH3,QRSKUPPQ&8WSZ/X<;?/K[`$#K/ M,7OWUA!B56_U&D!GR4U'Z^DL.3HBCAPS)/1IY\VKWDBFV5^?X MFEMK,[ZUQ%O5%)N,!-?\52WYV=!1)MO^-I0MS<_1L.Z/J'GNHF5':<;F8IF* MDL.0R6QM]XP/I+F/D'%ULDV:9].]6_!AR%Z.[ND-)]]-)KGOMZ3Y(F]#*/X5\B[>K3A)3-(BS21 M[6S64SEV(I%Z+O(=#N8BAWG*';\AF2?@$2ME*",+KBE)O=1,9G'LYP@^'_4 M8UK%)IKY1LT<_10&D<0Z8NEI/:PJJB![/_MT/640*9$$B"CMS.F*JT@6?+FC MWETX8L?B$*0&70-$AB#R<@]X^T\Z1\_G$[RCDAU`1V>S' M6B3[5+$T>G7SK0\*`O%"%A6IARV#H;0SE`C4ELAR]GA;F\-%IXI!4FY8Y%&S M40994/HI\/S=.=8_Q`VY^R`ZAI"WO5OJ%=4+00WZ2):>6DW2JD%$'D@$@ERB MVN6:`5%9(E0:-Z8/C9/0__8`0^0J>`.Z$^.FR:+;C??WH[?5625`DFC9>HF, M7;3TI[@WOPN#9X\W25)\0F5?F3-4H]6@:C#>Z]]-WB%N%^]0JHC>J%(<41$2Z)&X/-20HD7%?IZLS:R:=-D MG>RCIB)I>HB%@EPJR,7J21"'A4NZ"8(3NR\:7&4X@Y%Q-@6!87$N.N)4%2[D MN5B,(I(V,C.XG,'G((3TN4?G.XR^>'Z`BP&E9SXW_K8LA98!_@+CEP#]Y@T] M0HZO=':@X30P*MP-!DNV8L`BO;)$+FX"JB!(GB8J@E3'_.`VWO%4$YC4L::J M@H*NI@8I+1]#)MJ!)_H5/&KB&.MF=@0?*,BI<<)24)MUXO%JVB'VH.D/9(A$M:I'?7F9I1#F`ADFB> M?[RTJX$1[4*(R([Z`P*>6:%*PVVN\U<8WSZC>"?E/`TBM-%>K)=L'<#LJ$R- MZ47Y1:ZC%O""`FK#!&H/9P6[8`628FR+!AAYZ/@&PZ=`#VY+%O@)\-&G#YX- M3:_DJ,X/;A(6-3V>]4EUNDDV-/KUZ]QG5GHA=X>@:'HN-+KADJJRTK'3Q&C1 M.4/J;EU]L>4A=F*(1W&;)WQSHLM;]^$]K3P&U%203=KMV:3$ZTP0^"T5I:EV MUP#`[`[`U'*/ZVAU/K$MH8\CB+S)OO8SZ$/^VBCO:>43V5F MYS4249IJZPP`C!302=X#ST%H6"K+];(Z0=AFT$H06G*KJ7(D]W$=%*GH(!EN M5_/*HBI)^X@H`\I`#@'.+H,SA!L$SM"Z$3P`M+_7_L;UPV.N$*= M\\ZX?DO^/;5\$2LC7>[7RHE#)(%4)+CV02H4)%*U\66R>&%5XU@F2Y/K(+IO/I4H9GN6!]*=V@F%/H9 M5W=1.=)5;&,,[\(CW-YXSA.^=L"#@CTLS:_JYEU%']FJNZO97,P[+!<4!!O4 MQ?6`G/9R!!VDPQ+=*:.T>S9RCF48,SAW`9]A&,+M/7R#_E&^HZN^IY5M%66D M+S"SI@*JI4)!(M44GO4`2^?54UPA'Y<^DG'\4T@*#M\Y M(:;_^1$IZPOF_]H(T4L\@6:R)UG1($?$PB.DRV9)&R!I!"2M&)-U#F4*DG_F MZ1E=3@\3\`.#^9GN.F9?'(Z=Y^/GGXTBZ)-OBWF MJ]"`AI`W?H%AGI'(]WZU%_62M:*-=%FBI6B42*069D'-Z0W[X"5=XA7<(M_< M@QV^=LW8F5">=S;0CF4<,^AV%\*#XVW3,6VR1+_QMT1G85&:CL*TTE)&0]F[ M2Y:V:,TB:2F?V$GWI.!-EI3'0Y2X&9#"0]N&T#HU0SK)2KK7@,!WZ:#+@%HX M_6@AYKZT50>IGG/MHZ3%V>-+SF^?+U\/^^"=;$K;A9#L3JLX@]P[JNOG-"DD MY82+B;5>6+2`3B(08(GX/$`N$V1"U1;3&1*B58-XJQ"BN)C.D#CI?>@Y+B<5 M<@*\!#V^RU5;01U9[F45=:2,HR=-*)=L;:[#U>9-I0E`HSJR8\?9)$O,J\6( MC:A=-1)DFPE9;VG2>7[Z@5'_&V1R02K8#,;UA5REG)/4`O=UU3P?&B"IC*&]J'D;THD" M"=<:FB()*8.1##/X'[3TE-KX4&Q:>M/./%L>2BK3)`*TC9X[PUB58$`^#(5$ M8/E,Q>=K<'6Z]QT:43=\&?*(!L?&[4JZ@VU9JXI7X[>U]6*=]*?K*4[T`L@\ M#SVC1$69X-1%3V%Y=`9WH.F79%TWSRYO/!]>Q_"U.HO:_+SZ:1>^,I(>L5K. MUNF42R*L-#K"\@`1.,[H2##?,@PV2Q^VIHF680#:G0$JFF-I)EAA?J7!)F-Q M_I%QBD/\K`%H%;//CCKY4R'U::G[(TD%VFMV^?;%P=].<_9-Z9JI6=U<**H@.P=+%-K4B4$ M$@,R.9JIT!42X0$&\BH"HIP++'=B$J&&6Q<+:/ES6G4FG0,5?#3FXXJYP-)! MMKZCO9KE=*""TOL,K@6SU&H8T1>875HZH)7!=--"Y%]59G#Q#S(O=X/W7YX' MKZ\>:6;SW6-.P;,>4ST;Q]!!\IJYR7*27!)(9(!<"/@-BU$\!]<3B*4:B'CF MK2<:NR4:)?-M`E9D4VT\W&/0\B)X=3P94B0/:J8FU4+2"Q9+BTM.*D@O/=N# MX1!T3#"M*-H>$8>D`D0Z:%IF"8^H!?0ZTDNBS>7W@T>+2%^@?-?B9#_,1Q6F ME:SV97>P3=(3>M1K4.#TC&8EIZ"6 MR^DD]77T/J`"M"1D/4'8+4",[<\"1\%NS$.J):3GY^`W_O8A#MP_7H+]%GTD M>JT:+Q@UO:8RU#?H(KLJL5RE5,@%DK.<19')U8AZUEJ&1%I8?RG40B"'-Z." MX'\&6_CLN7IO>99UTE(?(6,K$QG74,M$^G6#&-BRBHQ&0,\+0S MN]Z<7=]7]PS^#B\NKZ_/K1Y-I*:I%`/]5H5A[.L]9S1W0U2!6^`[JT#ED*'EM8=V(NKVFK@B:"0'0>] M&;XOWRE57]#*A7:QUYI8Z4TS#$Z8U-'T@$=/<]0)HK4*5K/#B9EB0&_AP]OG M\Q!NO?C*<;%V[YM77!K]]AA',@?4YQ8P@J./$CD0 MOT#@TH_]G+2H-\:TH&@YW,B:SIC(4Y^9;'Q<=WR17GJ=+*WTKBM>2-$Q?3DD MN&0ND[#HJ_,*-4YERKI9(V'T3G+6%9)JT(CZE9=B`1$99IS&DYB&8]O M8G2C%4VA-TU@F-N_I%_33-^B+K*#H^5Z)J9KDMCIV5,U!EH[0QO4T)[(P-5) M29:7-E&P9BAC*,L+\YW[_7XFG6UY\X!_4:P/Z:%",V\X^DEFY+E^_HY-$P:R'-2D#9A M#BF',`+AZ*]!^`>&Z"9WK#P)$W&=S&QRZ2:B"DUF"F]9A7J:G]?,R!;57W#% MP0;Z:2EL,R@\<>>GK[Z-M.,U44EOG9N;((K.`Q_?&@1]UX-18QK)?T$E<[A: MR):'L;*9%20*E&29D#L.@L_NB$\9=QJ=KT0>L4V,8(^PRV$_K),U+:+Q9#D3 M,49K/],;%IO?\
VU?^7Y M#J*9O]NXL?=&=J1Q/E0+`0HI(*^5[-&22;HW`]_?0(I&I\+!V3O`XO'5:5D# M(&]!SY[C<2RP2"W@DK+9J06>WL%SAMP1(E?%O_:.721G2^N9S=R&/?P.;\ M\?H7C:MV)S5*7EB'ITU2P!^@G.T$JZP-1R*4'LK`%3N^J> M%BAWU4>,VO-)25**VNAN6N#4$NSE6WF6,YNUW;IID2`C6=RR1YK/U_..;#:UFQ[( M*,QN^O;N\G[S`;II"?_O1G03NFE:OA>O+/$=H_",6IKF#E(IE6K-2]:67)`,D0L8ME-;,E5YP2B6@?`+K0(7I MJD[3]_O8^0<2(%''B/313!*,)5 MOQ]A%$?7?AP&VZ,+MY6/TOY]U5F$G27H^]YN* MT#/([86D.+C-\$`!'E5],]>)BCTS&[H1/M\P@.4_KY,#+8=PZVE:AK7.!>WC MU$'`V65P*3&TCDT;74W($.UCT=OR$%FP7,%Z4@<[6LZ=H['.:C&M\F+T!0SI M;J(;G$5VZ@I[8]I9!+X9G81X<8`'?9`!7":<7':4E5$,H<-*B05/JQZ<\561 MBY#V>FDMZ%`L=W-Z;U5>,QA)4SOJ&@:5I0>5>#@U##3>]6+!\[/G0A`='%?+ MI(PDF;*A4(,U1N!VQ#P>*7A0+Z.C-H<-I_9B,662.1KWY*0DD3N`87%X9#!M M^-L!DJ`BIR25D:`1*L.U"!]$:/,&= MY_L88/`,$%&\@+G@H:AC%#*HT#7R[:&E<\3[,/!R0AQ]11"%^P38SZKL#%D* M2$[M36P[V5I*MYY0,2"7HZGKZPNIL)O&(6*T]F\B;RKU:US8VDCPX.QQ!_L& M_:,H,60]JIH"E?9E+^);3DH,(%)`(D9C\M<344X`[9[/<:&:X[/0ZO#[.^>= M),A707B.T^4HPI.[G._$>5BA[[,UD/05VYHFI3)2,0#)`05!>MR_/RBZ8RQ_ M%QP<3TLB).=6138(P.ODPV.P.-O\?6WAU=^AM1" M@`;>-&LE>R9L9:\J7'H,0"((EI:2=Y,8/K?E7>P=FL5'22EH8BC3!EZX)+M$K/:*2985VY??')J=H M\,M-M\DIZ(LZ0K!E(2CC`<--2IY>!:K3EX67\%0>TN#/K:Z+5HR[Z#J(O[,?.CG<^ M4NI5E3R0T$>VY,W22L<@J5!`)S93L0#+!;E@39P9&#*]$\YUPR.^UC&%&B)Y M6LG4PD=+%).UCG[BW7@H8]N2-13Z"XBL\HNS/\J13_"Z-@+R=9*ML+R86FP2 M%D2#7#8@PDT@XC#0D^D"_PUE]AX^+7?(S!#A5D[`OF"'0]:0.51M]FH^71ML MJ)^RPG+LS$>U4;'-4MYD,IM.V;336Z2]+Z0:G2KPS*$-OXP[UP;ZZ7#GA+?A M0XSG=@A+41?[\.*$OJB2"`D&MR&@HFF7A=-(0*2; MP*PAD#=W70=DAC=>?ZV'=DT>S">BT&3ZJ4ETB3;'^"4(O7_PYU[%+VFC8E43 MV>MH)BM./T8%@ERB";3K@[*9;A&%[`@AZZ$=SSOY=&.:RA2:74?1L17%DA5QH>JD4]D+FZA4,(\I-"ILO&OQG8MO:294 M0159OYNM.9..":L*(LVA5D>VF3^; M+M)Z4U4J&3-'V!I.,V/^:?)I,K'RH14X!8N3R62"_ZMG@/\"YB?SY)?((]&_ M*H_2GHW\KD!"X,3@?QU]"*:3$X`]C#QP`5TR&0&F%OFI]2_`V>U"LM>#,TV) M]X+_DSW+6JW*-8?MDC.6VB[T`O"7T,OCJ'_-8@]%\^O>,'V*@@? M8?CJ^22RW#YO4+R!C#U_'86H/B?56D,YYUJOURN+GJ`B+8"D"4#;`+01LL6V MT`P.SEE#:H]7C6H'JZT=;L>V@_A4UJC&L'-C^-0(]&P6_A>(`YPK!*^H`1>7 M9,-',^$W`%\/^^"=9PTE)[@ZQX/L;%P9?P$SB#_A8-B(@3[;!U0JYUS`R;[,C3/8@R;*XOI*(1[;ESK-W] M,(#`#Q%.4VWE/7\R0#!%K0+2[`>(I%TLU#^.CFNA$8)H%S-)A=#X!>(S?P?' M?\]\Q^59QMP`6HTS_<)GR=I:@^<(*6E9ZD<)HUVR"'N@6/JQ9.4BE8"\U M!^I?'A`E8`3.`'N1T8!-TIV84%ZI:&]@)S']QV"3>A\"'!>DCED2)KY;T!YM&6Y\O-;&6:SQR2 MTGT^/^.TZMK'APR]-[CQM^3'9TX$MWA0"_V(GFQ"7YQ;'F$H\=J)WEYGV5L* MYXMI4RA(]LZ1UD'6/"EV0GX%B`:@J`*IAZ*KRI`&"S*""EWF@Y"&#W!`.%]P ML5849+0,#,;B7'.XZ6AZW0&I>"V>A*N5'M<4,(HZR%\!/&$%@-(MD_J)W!49 M@YC%A+WQTDD=K&0Y'H]E-;MH8@V[=A*_MJ3P%;7LX>HA>])\8F7KO_QJ8/J* M3@X%D5#IRON.-[22:J8GP&=C4DB:1K^K$$=LB6'6`]Z_>]&U[P=O]`(AU.?Q M2XSS'U8^>\_31,Y'5I/I:IU,RF-)H"`*)XV*9]>'`&-QP>BL,CX(-+O5=U(S M9]U$FWPJ6F@!'1W@/3*XJ$Y?_GN%75O6J.Q`9CU/YGO)FUJK\W72W9;1757? M5'.)8D=4AJ?-8X7U5XI/J/;:%@$-EV6PSUJ_JL[ MYD(7>F]XW!/=!7O/?7^$W^.S/7\!3_""2O_F:B%[TF4^2<-T+@I06>`W+`T0 M<;K\?Q!\:16]X(@++N%*%!';89"1!FX##62HF3Q_A\8W/OHKG=1O M8$4'`:I')*VTD[QE9S5;)Z,4*ATXF7AP*,D')PFIU(Y<1@-M%4#GXD%9OOXX M,JX1;!DC:!L"=>)S-BQJ;S0]W?8>%WFZ<\+X75@-FO&@TFZZVKID-K>>I(5= M$A&`R-!<&;H?'+L=''4=,L^5RATQ$[INWW\,'3]R7#*!_(UH'D%>@":N MB+62K M7D>(-ZM&F^0"$V=/-[&R9"$S3*2K-@(A(D-VD2H2"7FFP/ M5YT"#PG3T@RS*=,=$JM=Q$HO$-68S,JRKI#!2AE#3]<=083\9>-O+^`;W`=D MW3"IU\'M%$3O*.V@!8K(=DCK69;74FED?;L@+RTBHZL''@BC7<*(*S-M*DVW@GDTD2X./3>6N7B!_:Q:8M45D+XE=)FMCJ12C+A[H3Z'BK$CN?#[:43^IZ_BS8N&G4=R=CS`CY[KL?;LBCQHE*2-&DCF_3, MLVT?B4B0R@0%H2"1JHL]0Z)-5Q+7P\IWJ!_A/?0#78^F=F0W;O2])Y2 MJC0H([NV-,VG%(A$4!"I?R5Z%+@V!ZY>-DDZ99E8,E;1R#'^&EKR:_6,D5S\ ML2QK;96(,=))RB!V]A*>WTKM!5;[$4L&(7W=`-?F+$45T.ETU,T3&A\Y+G_< M47E,@^.F;4LG#I-5V8'!;ZD(O5&\$Y)BT/[1!'>N>@S+K4M`=;CW@[.'T7GP M^NI%$5[BW?C;*\@-R[RG%3H[1P79Z+>8)9.X1`XH""*SN5B4'M=XW)S M03JIT.!=14:(\&LC1D)3_@G9ZE.JB9`W+3NU,K.G10*D6:ZV@Z\]8!!__PGZ M,/9<$,,HUGQW$L=E:EY>0:O%N]T7N#WNX>WSQH^]K;<_XGH/#]`]AFB8`*/+ M[^[^N(5;?'H=%WXXQDGEN'2(GE[]^2@HO#!P(RJY-:CFTI>A+Y)\+&V>%'@L M*`!R#4"J`BT$45`"OY3-:V4W[J(A.E9%4UZGSYYVR9Z!A#V?J_8,VMI36;P9 MA<2E<#7\=_O8T:YA!G"$ACYDU&MYFFRUG,W'C'RZ)R?U&I:6$0AB7-/)V9,A M#[(576['Q37>4$Z"3Q55(J"S=_%:0A(!+[#2Z'>XM.9-$$6XOB[_+O>/%P%% MLZ@C?3Z]D?#L&'D^C**-BUP@\I+]W85_R65VDF*T1#$YW22I9,\7LWJ,2IL` MQ3;PJ8?"OTU)O88W1RVY8IKC!!?AEK2'^L#1C@?LL-#"LGI)7ZSA=QY$\540 MY@7^[AQRW]DF#''A`'(><;,G:I%@QJX$B*4@K+A8$P$IGR&IU$5+^%$(4':> M?+UFY%FEDJ"X"7+/0+%H:*(L*&H+]@1YO:,9[.3>O01A[_R#Z M)IN<6X9I>4E:@JRT>K*[>%=+1HA,6P'%9K+M_N8%M5&L0L>1#AY')E$]$8_L M@JSAH$@4.M[N)3Z]0=D0[@L\O8M/W=G`#B'MK*HW`%QYOA?#&S1.W5[[,?JV M^-:'#:D(VC(`R$O2$@"DU9.]162^7-<#`&T%D&9`W@Z@#1D8`48Q"QWO'5]? MG?`=#_=JAC"#[JU]GTWW=B85E!R`+\3X[.S^.TMJ2Q,L::/6[YL8GAJ,4.!;!B)]\^'=Z-PJ_I@R]WWMOR'R!^'[^3$,T=]:#H,:7M`89SCXA*^9.#-&,7+^RAZZ2%A&+QG9,ZH;-_;>O/B] M)35;"=-"U#8:RE9@7JX7==IREV'2M@RD\5C&H9TPV>:25!3#Y4MJ%2?2ALQ@ M?1=BL&-`:[,:&1$**S)G[_4%FV].N)7;J-)7ODEQ0U9IZ!Q.DTG`ZA8D,@EY^W* MDO46)QP>MEV`?0)V"6Z$/Y_*)0'4G'6DZLI"HP%0580'D$"U"!LF#`>#:1=A MGM8^H[[Y0"FBY9.`S0;1TRECMZ_\VEX/%J%#G12]3Z8%%N0"/G ML2_"R;Y+RZ#0=,S)#(5/U.YXAC(^KDG2>)!H)_-I5`W,931\#,[@=10=X?;G M`SZW!T/7B^#M\^TQCF+'WWK^CKS%/E>C6@<#!_2#`I0>0$WF[0;[W/#(&.G' M`7A">0S1%V"%0:HQ?JB@,Y4P3F78/O,!VC[)6#W68P#..%_D5MD7Z3V=H.VS M%/LX]!\,WY(B$8>L_!=,6C)YAF&4<-YF]F'X#_BA1@-TNVR48,*].H4^=';' M;>/7[]"7)@$;C=O,'1V,(W6=Z'GK MY73,")BJ"!(=\U22:/GA0^-0G^`_1\"4B0`CA='&#_41@^M5$#Y#+S[BN1]_ M>_G]X(5$0G3MWQ&_&8D`S>U^H(#:"$;VJN[58K`Q>1I*"[J1K?H%[<"U#^ZX MP4'>XL3:Q\Q5"_;^[,,=OL?R(]A]A>U^[J!@MH?;ST28G@5\Y=0>,E[*?9(_ M9:34D)SVT^G/%&$'R*+LR6SPH;Q4]/USIKC*/IG]GRYPJTZ"^W_*CQCPR?KG MV'EPI9$/%)++FLN>IYS/[*%C+%5DJ&165[CL;DYZ?QY^_6.'/3;?AHQC#!M_ M_,!4B;WDEQ=HT'7E>.$OSOXX5N[95HL/&]H:H9+=:#3ZZK\:^>BI)G@!8 M7X`5!D3C/T.('/2SD!B:2CQU$ML]8X.]\0SV,>.J=+@8+_#*?;F/&)D+FP9& M76JOM_.!HFM->=G;"Z;+P7/'XE:D$9?:Z1+,I;\=,SSVLNL,V[4@06+U:""K M/,1.&!MKEWG-+D]PY_GX/L`_Q]H:-V0-&?_9G^"#1_C[8+^_"D+\R_$]M]C8 MQXSU!02R1]\GV5V-HP3\W[!*(-'IHQT<&\S`A$ M^]]G52FXK")_OJZJ@$YV"_]\^+GN%KT6*&C\X?/Z$;Y,:;H;V7`GT>O_R:(R M(W1H"-#5[Z]HL$3WJ9/"ZKD%0%HVII#*3:S5RXA"2O^65$I!R5N+6( M.-Z'T%9C@DY]W2?'K*^"\.J(=[KA,\%X3V'%+4=KYB-4BFC`($>HU6PZM5H4 M@^#DAE07D"I#2N-0=4"JC_EU'@8T:.]D6Y=!AR_3,*!5N948/(%)C*V_(!GJ M>I58D#&^D3,2W$MIZ,TT2+^-OR6E*YU7>!&\.EZ[,MH]FS)I5J&#_I(EOM:+ M-E5I&NZMHG]B=X*UI)[&VAP4<*O/*PY"]A:7$T6#+J-I_=^%.$W'$^QH2II>=4QZQBX[([969V<>ZNM,JM>>]55S1DE]0E M7:<_<_9XU@?\Q?.3VU'^JGV75%=<9#_36;:%21*:TD#$8DDM7-3P#[/TXNU\ M[]ES43C9N&YP]&,D_B[8>ZX'HQO.'2EMWE2^0"*EEN19DM72GB1K'KE8D,L% MJ>#Q[S+A+V`,#M@R`G##`L/@J.TA4*M90VC%V7Q90-YDXX>6TGWTTA^6OF54 M2"$JR?G9S,(5J/&R5"RL6,W$I: MQA="U>#W^`PU_@5(1$HCV0(SJ\E,EH!(-""R=:VK#0Y]AH!':_414$$S*&4\:G*W$G6$=M#*ELN_'[WX'<\$!CZ> M^Y-A#/,=':QA*2*[`K?*%D4SYE!Q()=G!GGZHJ3KC"VP*>>0R`F9/.*:1"N7 M>%-6@@=UL*;E#,5D.9_6.AD#KL_M!<=N!T8IBD/'Y1[E$;VB@P\,/23S$\O.MAYFKH1/PB!Q@,A#03:1J)LE/4%6^!*T M`*F<.P)79+*(9QK-?+KR?,=W/6=_%T0>6:*5YA7_53W\XNHCF\:LZ\D:XEDF M%J1R3>+;(*#KO&L-6@/_&EV7PT.QR33SD0S:7H+]%OD`S3_E"2EX5P\C^0K) MEM%?VDL&)8MRT_&409PLDY5G,GF;2SNA!^)Q72>Z'TKQFO-`V"P6 MMJ0P`I)']_7J6&8>"!^=@2=R8@_?KWE`[@[#$&Y!1%"[1_0/1',W1Z^MTH$T MY?)UYB8S#1<%Z-;9+Y!1YYOSD!:^%S60=!1KOK:+)$]VJO]&A:C>3-('A*46 MA`2%NR(I5"`)R-9ML".2]-*2Q8$R%VMX]228U9R7FR35'E2::%9;ERWJ55@` MJXW9-&XC[X6'L8]5Q+ALW612ZFSE?SQ:J0:U>9<*/M-,@PR/@< M'QN91"[>'UZ-X[+PU*7H8F*5DW6!0-D=M[,E\6N]T\\4^+8>F^B/B=[;Z3D?U1\7(HYMA:>I?.8>?!$88 MCL#7/BZFZ[U!7)ZL85J:]:P6"C,4D?.-Y7)FER:I,TFTT)_&R>J>F"P]F"1X MW!,8(3)J<`8N7P_[X!W"$Y2:A-!%;@X<'Q?4\:/C/L8GK9+*XTBH7G8+2%6F M-\\VVO)F7'$5;B^.(3[91:D].=HO0M3&*QW-:EQP_`J_D5]UBH7Y MRZ:$ODPCV3.:]L*2C71(-OV]B6&M$W!"WKO0>W-B$K7<;$MH98_,"?`A^7GP MC'Z,3>,&44R.M/[3=#X[64^6QI2%:N7MTKPNV];,:,<0Q^\X%4WSVX0Y1<+@/UL8D*W,*^7;V<&D: M\ZUE$*5_-83:+1/3R7QE-V?DE,J&)N3=80^9CYO*Z2XI.,.B MPZPB')_V$$4"P=I!^0GE*P:EYB5W3T\G\_2ZN>1U76L#G;6WU&G?L`K0&8)= MA*!O2I_IX?E$?AV>EL[P^!3!OQ]Q:9PW]`>3CN)G579V+`5DJU%,UY/,N1,I M@(C1Y.2#@;)9H+3V02*?*O4Y7.@&4('#GLRI'3V:=&H:_\Y"%\=F0I-DF\K99242K+[ M:A>S=%]Q06Y>*@P41.L_L3,\=+L&?9OMP253"RZVQ#.VA)>WI/=H3SN/+M-3 MWH`ZR)KM>FZ@9?TYA02L-2Y[+:]E)Z4'\]WYVBG5"XS="HPJ?G"=J,@$-N[N M/A]!]],N>/N\A1YU=_27JI>C'_W^&#KXJ//#^^M34/TF]=\K\.I:HY(.L%Q. MDD%,\C:@KZMUXU[:VW+:C^VW7+?`_LH&.,A$\*\.OD`POOQ^\$(2_B^;:]MI?)\/>>)*+E3,< M6[P8A+*O;U2POOHG0I)D4\I\_#JRJ$0;X8QR^1F%V5.I8=E=M^MYQ>7U3AQW MQF`7,.A,D9@>4DR/Z@B'[')N?<'J8^T931U-IH#D7,YRE5[^F#JII6D)L@^` M$LN0!)WKD'UPV*4/H;O[J#E\M>0Y"D(D$1*86I@X!T&(!O%($4(K'0Z"T2R@]BM+S M<1E+'[HD=?SFQ2^U/$(WJHN5$4.J;B0P#>N>.6$K]\U0W*QG.7R5B%>>@W/L6-#,O>T87[U(% MY#^S56:=K9EU70"4.?;-Q@Z M.TA/^]X^DQ,UM\'T-TN.E(,A; M.@%/Q#*XF,:6;QEEDTF]F%*:=>INZ6&ZXR#\`R?8M,*8H$MF/:>\6V8H(;E7 M>[9<+).NF0H!:5$U31UT3RB6^@ M?Z-_H;^@&`;1/_X_4$L#!!0````(`(:`#D'#3=LJ;2X``(SF`P`5`!P`:6QI M=2TR,#$R,#8S,%]P&UL550)``,[KRI0.Z\J4'5X"P`!!"4.```$.0$` M`.U]6W/;N);N^U3-?_!D7LZI&L>)LZ=G=E?W3,FWE.LXELMV[^PY+UTT"=G8 MH4@U+[+=OWX60$DD)0`$2%"@0/1#)[%Q6?@(+*P[?OGOMWEXM$1)BN/HUP^? M/W[Z<(0B/PYP]/SKA]\>CBBO[MB/P_ M.((?_?WL_N;H]./GHZ.7+%O\?'+R^OKZ$07/7G(#WSWPH: M?S[ZZ>/G__CX4^4W]W$>!3\?_:7RH_,$%3,'0-3/1Z>?/I\>?_K/X\^?'S__ MY>?/IS^?GO[_:NMX\9[@YY?LZ/_X_Q<:?_KW8^CQN;;8?SNZCOR/1Y,P/+HG M3=.C>UA@LD3!Q]5(X6J11X!HE/[ZH;*NMZ3=<,/__Q/1T7C MG]]27.OP^F7=_//)W[_=//@O:.X=XRC-O,BO=22#L;I^_NM?_WI"?UNT3O'/ M*1WE)O8I-!($'G%;D'\=KYL=DQ\=`\)?/G]\2X,/_T4F_"6)0W2/9D>4AI^S M]P7Z]4.*YXL0?5C]["5!LU\_X!#G!.[33S]]^43Z_^M%[.=SV#OK/[THN(PR MG+U?1[,XF5/J/QR1\7^[OZXM`X?/*$(9]E.Z>[+59CPA;4^DACWI2OP]]/S] M`?8](G-,9UPZ]?GZVX?G7OIR%<:OZ744X`3Y6;>E[0[7F>(+G/IA MG.8)FB[(50_RP3&"@),YCZ.' M+/9_D".[]$+X>7KYYH=Y@(*K))Z?>Z&?AQ2P"AWF&@EN4W<1I>H<2>N8[ MK4\S*3HW:T8D\&?L@XR*B9CX'6;@:=+,8CY_H\3F&N>0P? M_4\43".RQ8FV!PHL.O-2W.V3R,ZA]8S,YS@C4@&Y.6%#DRL%%/Q>[B_ER70N MU%O@S`LI/^YA98VC:US*6>CY/T#EAZ'2NP0N?Q!^X@"%XXS>M`N0Q2G.Y/#<([A@R!T; M)_2#G!&;4K51I_6WG%+K10XS3"G4<(SN49K!9P#9H=A]?H:7(/MVO+EE9M"] MI!W0)F3#/*."8?0@GK2;4^L]&>2`[?L]3G\4'-&'>9."D![N3-79].BQMR`2 M`T_86'$VBFA*K[/IK%1F6JQ/9?2^U_,UAEDHKDE4X1CH+3L+8;-I75W37'VO M%>9PZR2Z&;PXW0-QB=B>D;+:'JW@\FDE,. M8^7K'QA`8#/U,)!X]$"I,8'#:N*^43B/P]![BLE97")JK8-;*$65>[=O9M&. M@M[Y*7KJ?>6\.?I>V[:VWO8;P)I[..KRL_9_SKG*?O\'7&GJWOD^431J MCB32MF\0Y&<=S/K[N/H4Y]Z#U+QV7,VJ:N<]"J%)0&U_U/)/%=,[[YWVZDUH M[D3+P+'J83?IH:A_SEM1[(FRWS^_E9APM>I%)>Z+A'W5E@^-4120R)?BIV1> MS0$\E`J@`VBJ31V2L*$.-./7^_>.Z)J-`ZPXE.`ZNX&3^G]U5X#;?-V_]#[SRZ=MKMC;XR>H0*%.DTSTAP M;T"-Y#QB19WV1?E%//=PQ*5Q]>M]47.%0Y2:E^TW:-G3*ZK M*+OUYMRCL=VL?^INT+,7%G-/WC"+`6^WZ)^FQ\0CN_CA??X4APR*ZK_?T%.5 M-B=)G38O\=<#P5]W1,UZ0/NJQ^R\XW$BILR2>MY%1UM3$+$9X1/S) M",$2/CUP^F'HSR%5<:+PM5G M!"?9^WX-2_TV*U'Y/&I4MK2,$I;34+XX>%BZ0`G07QQ`;*6NA.C? M1PW1UDUMRC,.BC,TO5/MNT[JQ__OHI-2^^\=[)] M5Y?BEK&GH7%[2U1WNN^1C_"24'.+,CGJF5V&L8:53_O.2PA#45T.N[>AE24Y MG%WL/>$02ZV%T]X(]9NX_#L/!]?1*M&(1SNGM1'*5RF*;$*K*8IE:P4F&$GV"[F0E:+U9"X3U:HBAOD%8XC6WQR;9'<3M>&<2@HD0" M;,2O<1R\XI!WV4EU-;.F58D+H(A+>Z6)71[=]KA51"[@1KN1NQPL&[L-<2T- M5Z5T=\-K$W.]@@->X/=U@S5\0(EV?M=2!(2HX"PM`410OGWI;"+ MB37DD$\D8Z\?U\GE.;!\AZV,>\E4AT-+&>C55PQ\FP13^CH5%Z M&5;,!NXNU=7HFEBALIQ&9NB4E,P&(HLI2U\R\M8>_1=BRQ5Q83188VR-0I`' M1GSEV!J&((^/G!IN:S""/$XAX[H$SDX)J0MP MHM8E;G;*29H.*L?36*+71GP:+K^7]XFQ1,UM)U2)DIV&$V64>)&&)5!V6D[4 M@.*%SI1"EO6RA01*3+=O"5$+^\H2)4^Q72`)#]MI&U%K^+R;[ZO;56!8\H"= MFJ\<*O)20XF7G9JPB@>U+G/6O92V*X1LK^SHLLN:X1`=1'N3R^2=S%O6M]U0 M(UN+>+2#:#<6W-8J'NWPX68&V5K+HQU,,H%:MI;V:(>8T!S2JLJ'BD@]V(S8 M^@NO9I-C@)9I0LD.*&\L7ZXLIN7GRW![&D[W*2H63/+L!;;'G^67Y*]DI\<@ M5G"=IKD\]:O6@Z"<7V!2JHLMJ4QVI=34YW*LI>1 M_38>=;1VKSC[+3UM45I?H/8;>=HBQ*YZ9ZUE1QTFD19@:S57-;RD+"VV)U4I M0R5BXW:&![6$:)>'VQD4U!(>3ME2RZ5+YX5W7GB;O/!F_3C7$?P:&2EB.H^3 M#/])UT?HJ.?5XCY&5I$`.7=) M/./6F:FV,%,$CW!@@MH5W%Q%3D\.6W2Z0,4[L3RP)3H.O*`Z/4-YY15DMC96X?O!"E*QL(OX`ILZF9PJ4I\A*?U*:Z`$K"F);!$W,8<1\S MJZ`@\C;(YM(>S;!Q2&I!@A"(Z)%\).G`1S'-''-C.\ M;+@B)3N[V#Q[BM1^1_CYA9@^E_#)G]%M/G]"R71&5;V*AU'.8-QR,),>(D5[ M^':LB_*U:.A-.8;N:;`B,HA)Q%L8V'D5I@) M3(/=RB(/_W9KM&W5D_Z%1@[;:R,K826K6-M>.5D)M*8H+]O+*"N!Q3"BVUI. MN30:8T>7?+_1K^X9'+&]C%S*6;>+N!NR[) MQ-N.E^R64V++^1%\;%ESS#]T=W*^-NR=R245]O+]LL!M=>HX6X5_VW9 MF]S`1+F2_@=LAM.U);O6BK9K)\F&9'>J%WT0E=DE[X9ZD&6W)R)LV4K2?DW; M'XJ0@ZMM\(;M#TBX+&B7!:V0!4W/2[WN;Q10"]MY/`<27D`^PDMD,%F:7YC(M1L$OPC7PGACS&'//HIGKP4!01ZP)U^^GL$7R7%&7I`R1+[ MI+H,CH-[Y,?/$1U%5)RS]VF'BN5W+TF\*!/6DE0?QW`17N&>WVVG1BT.<4YI M^/33ET^4`O*3ZK"/@$0*$@B1:3F!RU)=7()YP6C)<8LCV'Y,0L5M7;H64Y-@ M(F@^7:M>7$UXC)E-S:0HU!]%$%+-:6PD^%RR".]`RNZVI?;W4[.A_5ML*67P M"+D^+J%"J=AQ\SL=O"4(^[HT$1&=NX^=<&C=:7A@]!KC*D!((6-?Y`EPMT+; M*)C>Y7P1QN\(%;4V\\1_`5WE+O2XU6':CC:XE=^B5_JK5@LM.P]H751IY'X" MM64VC#6T5;?\F%M]39C25/3`G4>BVIQJ6Y\AU0QDTV&R_752H1;-KVV]5F1L M#Z64AH=A8;(]F%(:FP;KL^TE]J5QXED+;$WV=5F#/#^;R#!0SM]9H*L(AJ32O`#IU`+G8W,;8W#L*]PL9%L@?:%AF1:L@__Y5-EK5O M8]98\W4T\?TX)ZS;>Q=EQ"DS_.$J(/R2Q,-,HQU$FDG M@ME4MF"USS!6L9%25F:LYN=P90<8R/J(>Z?D8O*?:J?C,-9SEZ"%AX/UT5_7 M@%SYL=:UT"77*#68R?>"B865NYI*$^<-V@2JLE01AC+&055A@&&OK^GI6_6! M!K3>4M%N^3U9`PQ[?>V^IVB@`:V782I06R=K@&&OK]WW')JE]T#*Y7CO:]^E M_T>.$P2P`I#9.\EK)<6.B=&2/M?#68+"`&;*`<4^0@$U,ZQ]K]/970*26T9R M=WTD6IM^&HPA]!C97N!@7R#S MK@;;"R/L"U\5`ZBMM19T!P5L$A`;&:OMM>+5S>OBOL.3K;G4"YQW:&GZ`&3RW5WL/)#7VS/8N\!P)W(E&[/ MPXT/PYU(F$[Y\`,&T"5B;>VD]I[=>F5*GE78UAJH_>$G\J387@JU3S3;^&^Z MO>@W%KQ5HE^Z/?HW_#<2VT=6U':P@N=8KJ#B`4O<>B!5">GI5(/Q<#>IHDV7 M5YWQU,Y*<'I`:_G0[JF=*>Q]8-KPS/.IG5JU'B3[<0>5V-NIC>O!OF-^9`FR M71J[]CM+.A"T1'3,+\.WP;U$SDXUM1-R0KFU1,Y.A;,3FJ[*8S-I%@H9:3Z)IV*1V]A\ M*+1?OBUP82&]@+OML$RMGL.944W9/LF0I[6V&TP:VE(9Q3W&280"W3B]W M46JCF%CI]O.^$]_/YSG-KKA`,^QCWE:3Z&@D^Q>19(:S.K),Z4>FA]$\ZZHD M+A`Y^.V-IO1Q]8V:@BWZ6K8^UZE;':H"*KB.;37GN`#VK:/7I+(T[9>Z0#U& MM%@JQ2:WF*=:V_X6LY2^(O56M9V1>\KXR(A>ME>S4-]4+%W(]IH4RBA)67YL MKRJAC)I(:Y7+*1@56(HJ'D]A,L`;*;2@)SC8" M?WZ30:D69<2PV^R//QGUXS_@YPB#W$WR"8L2%""5W\4A2.(HU>#(Y[AJ28@% M36&`"==_WL,78SEKN6VU.(VKHU]'RQC[Z!$E.\XH<5LS3TC)/%LRA$=*UC0\ M>F]%?1@2%UHP@S",7XD0U4"]J*?F0`WU`R$7J=%AW$,.U;`W2.*;]X;G^5SH M9JFW,>+J\J)G)'"DE+\W1IT0P6H+(XXI+T3I>3R?XS0E&78D\!AQWP?@M=;" MHX0<9$=MK7(AR9[]4\D*DI#M-0"O5?>[86-0EX')5A79.:^VE)4=)EVSF%=Y MY"B0J%\(52RV[EQ;K6LMV'V]5#BOC)ME7JB..''O=EL=4"WQ:M#8;75$Z4*K M;E6PU0&EB6<);02V^J,4!>?1^51:X,,0K:QUI;2`1^FT[M-;8-08OJX,_J[% MQLT85\Y4N-O\D"V`''0VBRS7+;1A"-OW11'77L%M:^:YWA4Q5SC"Z0L*OL9Q MP'^&F-G8*-VWB/_@=:6)41KOO==O(.XFV`L;H:VU';2]W)PMC?(,,9Z^CESAUJM\[?&:(M#6JWHMP:)LN-N6OUPBT))7?7CU+!D4)'86?8& M%PW8<6%4;[J+89P,[AUB3(TC&D=5*0AV^>:'.4Q#R_)ZH4_"_8&P"AWF& M`N`W)%OB#B4T_-A$I9`)D!\0:O`2/2"?Y+B`#EPC/)XO\FQ%^#I[84WR9$ZT M9XY8J&=L$$O1\K/WMD#",(1^ISQ`!'D:<3:AQ\.-K?>'`GK6C1V,[&62@K` M!7K*A"$M[+:&J5;('6_JI3D@3^_E(F>!ZVG.0S;C#3&0C[-WIE0TFN99FGE1 M0)+,N86@>$V-A)KYH)CF(9K..K)UX5OU>BQ.NAF7VI&+>Q0LYQGZX4^8&NKH9S67A2$T?DZ^H=S+[*_M>%L!_-] M#/F\S.:+P[66H6?L3\(0DZC<[SA[F830+R;O*0^F]/M9GL+725/Z<&Z*5Y@( MC>G"+KJSC%O`*)EGW&5D9Z#4:Z#45)AW]0ST59Q4LE4XNYC3V*Q!DW&T4KC= MRG_)F2PEAS%Y::4WDD4W*,THU55.565."T'$#QQY>&$OAQ9XL<3=F1Z MFJEX])1=1W!-Y>1R%\0[,1J:I[>":O%7(I/<)=CG/ITCWU^/'L6;[C8G-NOI MK(@C9.E)I(:R6FJT",M>$G!5`:22G]0]1 MZ[]AU82E`005/SEGK\KU'`WV;O".KE#V%@%C\,S[][A6%Y'4;RDK`S^ZO.#_/B-746^?5;DXWS+[W'R MH]C&./-"_F=DMC.I(/.E_'IE$YYT9+L!H4&B;:I7S6>5)7"?QPJ<4-NWU7BL M:6.)Y0W;0PX[@L<003M%((*:\A1;A)F4,Z<@AX?)O>VMA M:#!=\Q$<06P&RR2^N;`$YBU;7UQU\2JN*+S>HO"?K0XIN88)HF?";XMZR=I+ MEM:'EZUHF`'I?(-Y,D\ADOTSR(@B&U_;S&0X?7> M>22U+OV:T">QFQ95:VVFY&<=U5N4%2DAH$*2NH&O.`PYRY#J>O@.;M[3/YN` MP6T<)&O\J@VP-YKYKQ9)=QZ`A-[$T*XXV"'K!1QD+]\6 MR-\RJ)&?1:E83)7JUS>%7*&TL<^P=*J40>(;/:`Q$5?P<'UPO]!'B]+2\?(6O:L&B%DWJLX3R91\/B"$N3-,G8RF(YA MA__%"=V/,+VZ@4$\VH&L_#76MVX8:V"KYK]ZVM!IT!8C@Q6ANM[SNSR#?GTN8/I;(9]E(@?^A3TT%[Y3@U`V2IX+4?5 M8ZV=+\*85O>>/(/40_YR2?8;3=%'L)\#%O42O2RTO5_#'8V]\!$E\^F,`0$+ MJ<8^6BB[(95BRHW$,(=PF_4Q/_.;"!H:J7M'*(%K$2?T5)&:1+S"L55.8TU/0B,R/Z*GNEVVU0R`KV)=9`$K7N@)A4] M3LQJ:.)+;E%R3R^EE=6)9\06]]%3!9((A=]!+(3[\38&*0T5-^15G)!;`4>K M:"+A-:(^B!G:R*`%6#(V M1UO#`EK`U4*!M#408!_HU54]6X,`]H5D5;NTU?._QUW)AM/.RLER<(KM^;86 MHFRQY43V9=NK3"O`)&/8V%_UQB'#)6EW+\&R\QT4L0-I=#%+\K#PC3;6%WAO M!J>-8=CZVN_RL(DXF+V1;\W>C]HC,*)8JY)KVVFN4'>X\$[EV*((B_=)'K+8 M_S&8L,%)$\\+7PGCW%%7O-PX#NG3."!KTG>%IK-B)OH/9E270F\3KLWST$O3Z8QN&*$KEM'0(+VK MSSQ-[DEBGL#SRF\_&.IE8&?VT+*[F1.4FCK?6RS740^-(('&47%*R(DA#V%2W&(8$_33,Z9A`<4X.E=`!JQ.#/))XN,4;;8!DP7*=S9R M)DOJ0&*8)@_T%4SZX-Z:3_/.ID1/PRLJ]LHDSUY`:/F3>[.*>@QB!LN2T50,7\FM?4!=6OS!=R;]HRV91<7Q.KJI_J"[S$`:BD M]W"EP67F$\WUF7<12G4UOZ8;_$>.@T(ZI;]`P%_I=2VU+D%W\VM3%%TD.YM? MEZ0`T]!I*.L0FC<$'89"?S-_:^IE9B6QCU"07B7Q?"U6U12E.M''H*"%1W--HZPL*PM/%/4Q\^8*D M,XD5R/30@RLY_&=>B@)0$(C'>>5!2,A;C&0KG;V73>Z\(N3PU4N"VLOMZ6-\ MA@HV6#<:5+@*[<6N_[YO&HQ\>W)STZ?<*S9:@4V4WU[/=R?#;3TESQ%'FMOK MH^@E#@.8X1*$N.S]1E2-5=2$WKX#P)PFAK99_E3BO[(203)$OXGYB[,M@.@ M^A'F$YT-3NN!4"[T%?#;:]FU*SM`/8J/M6?9#772`#::-S9EI]K''N M:BNML[_&S7-OVICTX//]BF7F3H/ MMY4K\3Q<988-W_Y3\B*[\I!<`N\6VVDT6S`N]YJP9"M`LC:+*CZRWJ`2,PMY M=2?,=CU-MB:%Z\)J[[[2Y3#.JV-9>[;_B*F'Y;4[O;'-,;N2A$6Q.\E3?< M_L,1;,W2['(A-V6/6%W13@4S;KRVK07NE!'B^*-+?)S>(!L/6&(V>M5!*4^F MQ&V\:H-$S%<)TWAUAM;!R"5X8]<8Y#*52_^1TQ%:5%XHX1NOOJ"6$E4B-EXQ M7SWAJD1MY(*^2GF1$K11R/[<`E("U[&UU. MD"#FCY/QY\ M.%$H)=(/CIZ_Q0$*)R#ZS"F=H+QJM-M*9'KEJ)/JF M.>1J)7HRI3;H5,!;/[1=5=NV:%?N/K2UD0K8+=9$NPUM+7^+0^`SQ(O9\DMM M#3"4]=WC],=5@M!U!$<9I9GBZIC=#[\2SP@S="B^%M:!^79 MHPN]5KC)70"V)%K;(H:+Q6XA`X\M,'O<#X8![#M89\ M`@").J@2NBQ0MCE:!>_A?C-352,LA_04$>HE6TLBC<.>7%.[,T7/WC M&T&'23-OJ>S&PZ%;(G2=9SS1./`@\>#NO?(VBP+"5&^]>4--K3ZFTF>:^DK- M,X)*E3N-3#K%F/)&S1'6RX>U6C;7+4S5/H>^V\36;^#L@=N.;]T2R.A4[EZ1 MY+!B:Z/F]@*F#OEL!(%#VJ389NSMM5+N0P:NO$K.T8)M]<_L%5V&!&^K)V>O MN#9:W?;G]S%JB*;K+XXP@':/0-#'Q)U31,O[&5X"Z9J#YZ3FE#/@J@WE[*)Z M[:+.'CD`.Y:SZ\F1/5W[JVG-!/(]BZ(=NN'ASG/@:'U'),D#!:MQVBH$Q13J_9[RGO;UXKT32P>[O1=(A?H=!3>M[`6Y,< M(DX59;G7.VAW'H>6PCR_GQXZ7O=Q&`(;(K_L'[3J9`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`8^><.]^QOGD%&B+K,5CFRM[[JTL,AV=97<4)M MC+I1:IKNH+"3,<;27Y*'PS?UK_>2VM9,A3&DGYK7^+2]QBTIKO)2]NJA5!&H M_4RX+[Z_\]&+HP-7-6A%M.[>54X,C.NWGENR?>5I!GE21U.7\SHBFQ`O&XH] M<]L.+N>`*W9P+^J6HQE9.?O]/?:ZF&T'0'6#18W7>B"4BP\[M[VK9FN-TZD? M(ZU+"G))05T..?;O\]>C+ONM0VE2_2 MHU/1UC=-S7X(=2O_Z-\?:,>BVMJ@.Z6C+5'R%(\3<*WA8"[ES$09!V7_=J=4 MLM%^IA9AHBZU2_DN[B-R>?2Y6!T?56D(5=Q?AH4A>,5^U@8CSE@<`XT^70%. MNSNI;[7>:*[.=13D<)+>[W'Z`P[>>4S])47FH88L'4Y,G+^0' MI.PV,A$?4$.$H+1S7VP%"`@Z#()^4:@SI['FG"?E/2>7[=1^6%LR.SIDXE`" MON,`W2/@@CGZYOTC3LX!SWB.DI5E#41X7IJ-;/?#SUKA[.ZU$>QKP73I'DQ3 ME*9$OGD$8064HBR)@]QG1]LK]3=YMS;SPXW\K(9)*938Z927`T[]0-KN?Q!? M8(V1"=;ZR9IQD=EY]OH3=0L=0D1'$(K'$F$VK)XAT-OJA1MP6*(!3?(VSE#Z M&%_AR(M\[(4/,,O*SN.E.)W.)KX?YX!']&RBOL,N$6P!=K>=+3K!4.1F77DA MJ^W5I(4S&AJE5YA@7&]D@LY'X`)G(7G0@JUJ\]LY%CP`69!_+*I2"X,9VJX\ ML,_?>,.9N7"(=I*].D(C^V-"LW=A?U!RW=<8.`=5@)*H5*\V"+:7\LS+31S; M7M.*&>:\IBY.GG/RG)/GG#S72IZ38TI.M'.BG1/MG&BG(-H!'UG$J1=^3>)\ MD5Y'?IB3TKJ$O<1$8?,@ M+DDY^V%W5NMD4B>3.IG4R:0*,ND#?H[P#/M>E)6.B[LXQ#Z&'C98'2V6MN2^ M'4>JD>OLI$@G13HI^D.AC M^./RCQPOO9#032EZ;Q*(Y/J:R3&;SW&:8OH6<W+ZB27)=D;R-Y45X2P1Y* M[U!"LY;E5M34RQ;;<'M<-Q4@IK/-.;Z.@,'E\W)3<]"5ZVMB5=<1<"OTZ+W) M;1-N#=>Q)'L7=-`2Q43&K]V+"=RI>>2C M>?,5U&(`0^]7(9"LR"UY@98HC!>$M-JEP@6_N:>9%='DO_NBQ`@1IF0W4U,_ M9S=Q=A-G-QF$BB=G-Y%@!:,QF0B!DM9&;,U05-U7?$'%^@*>4@CQ16/K"VM* MXL-3>SI5PK0&'RFQU/IZE5)0-=I;K*\7*063I/G$^IJ/^@H1AW\<\/RDMAEURY?R)D`(0$.<_*ZV@/R<]B% M\!$OWTA8,`JNX(R0$L!YL<.FLVW1KC'^2_]$9O':J)'G>9*L.8$\"@W=G3W7 MV7.=/7<0`H%D')PT8W!FW;XNGM%8@)T&XS08I\'HT&#.XQ!NX9ADN2W)4Q4W MV"=FW,H+%YT3HSD!'.UF9@1RM!O(EJ`UR]0Q)X([$=R)X"V,W2W9Z6B$<2Q$TE6=N&QQB=O.?D M/2?O.7E/0=Z[A@FC9PP0D.?.,KV5$H-U%1@%Z.1HR6A4[A; M7!2K4T&<"N)4$*4HUOD<9_2O)#6:/M\``Y$LO(%$*BA2R!8C%`=Q<0V#U+>< M+.YD<2>+=RB&I`M0;:_$QZ=\-B/-5)^"SNYTS_S M0H`3/;P@E-'G>$&K;Q(HI+L[R=A)QDYV=+*CGA+%C:2^SF?<=269?D5U'=1YO M)W@ZP=,)G@=Q0TIF\G=EM$X>=?*HDT>=/+H_>=0N`Z=ELM@F(K_Z8[\+O4@Q>VJ?M)A%G4WMQ,_P$K:%(FQ*@SG) MWTG^3O(?A"RBFCRU5U8]&GU!$GPUCNV2UYRVY;0MIVTI):]%Y)W*I%"Q5=9TH(R=VUE[FT0PBY8UXN9(#K];TO'<46H#DC44DFH7_]6\DVV-@( MVY#&U_&7!*S=U?[22EJMQ?M?G^8>6A(A*6>7C?;):0,1YG"7LNEEX_.HV1EU M^_W&K[]\_]W[?S6;J'?]H3-$`^911E"_^8DH09_0[P[QB,"*H#%^XHS/5VCD MS,@<_X@>L"0NX@S]?C6\16!X::E")AD02L23N M24A)&A$1*)#)RT9,JL?S$RZF+:#;;OW^Z3901>/[[U``>_'T(#R:P-!/(ISS M%F528>:0&`IP]-6"H9NUIN.=I%!"MMKOWKUKF=88M"^;4XP7:_@)E@\&.FQH M!1IM-\_;22RU6A"9B69:LO&H1_T$:]2;$D84=:3Q`HUT^O;\-(;".&/^/%L% MKA(MW5L+@)H`101UXJC[\5(X&L95:[2XMM^T@L88M`,.J<0J"2Z)/*#$[S73]9+"B;\/`K/-#. M>"&X1\9@#:0_?![V;7RJ,,RT-&SKFCN^YC3ZCYG;8XJJ51]Z$7/3=P-1][*1 M"W+-5\292R:442-!^[2-FBA"CW\$4BB@A6+$WK>V*6P3]R$^#M@OYK.#/SVP@8-BXVF-Q0!A&/8N^>2\-- MU\-2AIZF+3<$A#]R(M@->`Y66Q."S]W!W77O;M2[1E>=V\Y=MX=&'WN]\:@V MW<&FN\<"0&::"/8*V]%@[S'FZYS&1*\2O/Q0&S>?<6$-Q.G=@G,$-&MSWAIUQ?W!7C[N)I\/<`7BX MZ/(Y2#ZX(G+,U\N>M6KE%994#B8=QVP8*9O&[%<$RV[.=WK/0J7C M<>D+`E\,`<0GZ#ZFS]J$I4SX@8,!NIPY1+"-DL?D25UYW/F:RZ#[:%C-VS[= M-N]@H1-S0!)]@@T[!'BS4;VE$.9="/2UH4L9&E2\X!)['P3W%Q!)'<_7&5.M M>:Y'H0_\!8KG3);UA(,[L;M*>]M5XH31AG+M(J5<9$2G#+:Q#F9J$YSON4<= M"AB%'"$G*;NYS[;-':.*-F111+RFS=[GGX0>NQ\Z2P#+ZECJP>B8=(3"; M&I"RX:`<9;M3G*><0NECG"EU],$'U8<0Z)&J&7P#37!ASD1JSR@W9Y"'TK;? MA6NW[NMMZ\*R8DF$H@\>09ID;,AW4IBZ[H0L5.ICHI">LK(QL0P+:(3!: M)1A0ITFO=#W+/5X9K,+[N8/ZL+O%S^FE'"`U#2T4[P[%5HQU9"@[/<#*F*E@ MASRD\FOY22$'(;OA4QF]/G-]J<0*:7K19+#II3;Y,^[GHP='W->O25K=X"R5 M^=NSOT>OHD_U"L08PV+\F/X0$K1[0RJYM]<;`K*U+SS;EK"`(^2G9O>" M5,XOM3VL[?XW;1&*A(&"-.T^D$KQ);8+M?U?=-]0P"N.TY/=5U()PUQ[B-J' MQW9+4S>G5- M%*9US4Y.3[`N^'*Y0@D*=E]()1;W+1QK7SB.+_39$MCG8K5MXDV#W7*IO.`: ML39%,5/B&VQ)Z>[WI/NA*#N#>"S[L;'0TFU]3S82J^ M(^J62WE/A)F/M^UY9.IVITAE!=>]HZ#["J0(93FHO*QC\HZ/VZ*3]"U6S\)R]SYQ\X;\,#;O'I-*).4H"ZDG@2#X1 M.Z#7Y_.Y?"`7CM7FYZGK+?:K<;+I7FRTCPU`8ZQ$"Y MAF`^)+LI<^3JZD%XI/4=UFL@DS'IS#F$N;\T`WJ>TR_Z`V?$%,6G%FXYT>QV M3N7C`K+(T$5KPL@LS0+234T[+-2O35UP0MU9=)-SI6RG'O#' M\H(@Y6VV.OG,OA?!;N=41BV9=*_M>AR[7GG8^3IR9O!4W@OJZ)0H=XD'\Z4_ M7VCNY)B#2HF80P2]P53\ACV?#"9?L,Y?IY=?AQ.T^T4JNV8Z;(8]HK!+9/I$ ML4Z1XFC=+=+](M.QWI%'7=?.4\QYQER9',SZ4$//P$,"6UJ=?>'"#%5S]!$' MVO:8DE3L;I)*Y9E>DBKML2#I?>*01/L/"T?CV>_):"\$7.AU*9"LB&Q%(82UVA55_*D M&7,(#@@9@E^OR7PC40XR[[#,VW>$H#M]DZL[ZU6@N[HU76;>/=HBGI)K6LT- MK>+:3UW[F4L)VUA:$^^T^MMO#V$A=F-I038XNRO'B>UNUP,,HY\4M`^U18P'EPG?.'R.:8LB_>`G>=F?4D$GI)[7S@SB.@Z_4>BPI[!I"^E M3USS1<9E*H`4"@N2+D*(E[.3OGC,7#'C!S=5Z/_#I+/M!DD(HGB\][2@01_WIM^X7/G@#Q8R6&2I MX\A8_D*60.9R^(DPHZ+G+VCJH-C0Q`4=(S2YSPN=KF;A[?_ZM8)$)5%""26P MXVX@`]27X)@2F7J0"PN=!Z<:DH:V&O@*TU= MWYP&`2O\"8<;+HQ,9@.8)7%>W&I*/@:[2.A9'QUV0BZRYY1R",%*ZJA<>;552X>2K)*>?.'Q%2$C(I;4(9OKCN*6^LP$&!/FEK^2S\VR9L#NN#D=#T-%3"O/03RN M.U@?$(7%JF1B,6A[P)X>V-!`'NAQ4G%KN37+ZU-EZ"9UFKX7LDIGZP&S^D%G M*HAIZ3TI_4MF&0>;>8"K=70;'<.8X__,\YN=$`<6!1PS#=Q[6A`];8>[#:,> M_8Q)HG<;FJ^D2'G`JQ2P=C-L[DS+)UL(^C?+Y:J+V4I76_@/1K.[)%2F0`AV MT;Z`*20=-'8`5"E6W.CJ8G"A)7%3:9^T.?Y+L+CAOH"%YWA&!,$3E9#X*-0. MGCG6P_39)HY5D,;2X\2B##3P1+[8@ M6V?%C7%NL`/RJ%4'IJ68>#:@Z@HC4TN3'>U5C(F1'7]_2K.#M_Q2-KPU40KT([L#R<;V_)"N!4FHN7GQ)?%F<%P^*UB%3@<-HQ_,J65Z M7DVW56HJ3?V&5^9(LD%5:?BD^$R-F5T0U1TH?5.^3Y?9M0Z[02KE9C[@P[R3 M9G^KH4I,AY4(F_?&MZZV.85O7'BF&$I>OV=I=6>;JJ@XF6PPM.KDN!G MYO39K$S4CNR%?+[")@=V2$`Q0````(`(:`#D%`Q0````(`(:`#D%KC5KAXPX``+;"```5 M`!@```````$```"D@3F&``!I;&EU+3(P,3(P-C,P7V-A;"YX;6Q55`4``SNO M*E!U>`L``00E#@``!#D!``!02P$"'@,4````"`"&@`Y!1WAWZ!8L``![3`,` M%0`8```````!````I(%KE0``:6QI=2TR,#$R,#8S,%]D968N>&UL550%``,[ MKRI0=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`AH`.01!3[S9Y5@``3[P$ M`!4`&````````0```*2!T,$``&EL:74M,C`Q,C`V,S!?;&%B+GAM;%54!0`# M.Z\J4'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`(:`#D'#3=LJ;2X``(SF M`P`5`!@```````$```"D@9@8`0!I;&EU+3(P,3(P-C,P7W!R92YX;6Q55`4` M`SNO*E!U>`L``00E#@``!#D!``!02P$"'@,4````"`"&@`Y!5Y;6;3H/```. MH0``$0`8```````!````I(%41P$`:6QI=2TR,#$R,#8S,"YX`L``00E#@``!#D!``!02P4&``````8`!@`:`@``V58!```` ` end XML 41 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6

Significant Accounting Policies (Policies)
6 Months Ended

Jun. 30, 2012

Revenue Recognition

Revenue Recognition

Revenue from genetic testing services is recognized when there is persuasive evidence of an arrangement, service has been rendered, the sales price is determinable and collectability is reasonably assured. Service is deemed to be rendered when the results have been reported to the individual who ordered the test. To the extent that tests have been prepaid but results have not yet been reported, recognition of all related revenue is deferred. As of June 30, 2012 and December 31, 2011, the Company has deferred genetic test revenue of $970,943 and $824,845, respectively.

Sales Commissions

Sales Commission

The Company accounts for sales commissions due to Amway Global under the Merchant Channel and Partner Agreement in accordance with SEC Staff Accounting Bulletin (“SAB”) 104. Commissions are recorded as an expense at the time they become due which is at the point of sale. Commissions were $452,000 and $543,000 for the six months ended June 30, 2012 and 2011.

Accounts Receivable

Accounts Receivable

Accounts receivable is stated at estimated net realizable value, which is generally the invoiced amount less any estimated discount related to payment terms. The Company offers its commercial genetic test customers a 2% cash discount if payment is made by bank wire transfer within 10 days of the invoice date.

Inventory

Inventory

Inventory is carried at lower of cost or market and no inventory reserve is deemed necessary at June 30, 2012. As the Company does not manufacture any products, no overhead costs are included in inventory. When a kit is sold, the corresponding cost of the kit is recorded as cost of goods sold and removed from inventory.

Inventory consisted of the following at June 30, 2012 and December 31, 2011:

June 30, 2012 December 31, 2011

Raw materials $ 83,895 $ 100,433

Finished goods 4,473 7,325

Total inventory $ 88,368 $ 107,758

Income Taxes

Income Taxes

The Company accounts for income taxes in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, Income Taxes, which requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the financial statements or tax returns. The measurement of current and deferred tax liabilities and assets is based on provisions of the enacted tax law; the effects of future changes in tax laws or rates are not anticipated. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized.

Significant management judgment is required in determining the Company’s provision (benefit) for income taxes, its deferred tax assets and liabilities and any valuation allowance recorded against deferred tax assets. The Company has recorded a full valuation allowance against its deferred tax assets of approximately $30.5 million as of June 30, 2012, due to uncertainties related to its ability to utilize these assets. The valuation allowance is based on management’s estimates of taxable income by jurisdiction in which the Company operates and the period over which the deferred tax assets will be recoverable. In the event that actual results differ from these estimates or management adjusts these estimates in future periods, the Company may need to adjust its valuation allowance, which could materially impact its financial position and results of operations.

The Company files a combined Massachusetts tax return with certain Alticor affiliated entities, referred to herein as “the unitary group”. Massachusetts law requires corporations with net operating loss carryforwards to go back to each year in which the loss was generated and recompute the loss as if it occurred on a consolidated basis. The Company was required to include data from the newly formed unitary group as if the unitary group was in place during the loss years. As a result, the losses generated by the Company were eliminated through this required computation. The combined filing has had no impact on the Company's financial statements.

The Company reviews its recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. The Company reviews all material tax positions for all years open to statute to determine whether it is more likely than not that the positions taken would be sustained based on the technical merits of those positions. The Company did not recognize any adjustments for uncertain tax positions as of and during the three and six months ended June 30, 2012 and 2011, respectively.

Research and Development

Research and Development

Research and development costs are expensed as incurred.

Basic and Diluted Net Loss per Common Share

Basic and Diluted Net Loss per Common Share

The Company applies the provisions of FASB ASC 260, Earnings per Share, which establishes standards for computing and presenting earnings per share. Basic and diluted net loss per share was determined by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is the same as basic net loss per share for all the periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the loss in each period. Potential common stock equivalents excluded from the calculation of diluted net loss per share consists of stock options, warrants, convertible preferred stock and convertible debt as set forth in the table below:

As of June 30,

2012 2011

Options outstanding 2,100,267 2,217,267

Warrants outstanding 2,587,158 2,150,000

Convertible preferred stock 39,089,161 28,160,200

Convertible debt 2,521,222 1,937,200

Total 46,297,808 34,464,667

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The Company, using available market information, has determined the estimated fair values of financial instruments. The stated values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to the nature of these instruments. The fair value of our convertible debt is inherently difficult to determine as a result of the Company’s financial condition and history of operating losses. For financial reporting purposes, the Company has estimated the fair value of its debt as the difference between the book value of its assets less liabilities to third parties other than the debt holder.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company maintains its cash and cash equivalents with domestic financial institutions that the Company believes to be of high credit standing. Cash and cash equivalents are available on demand and at times may be in excess of FDIC insurance limits. The Company believes that, as of June 30, 2012, its concentration of credit risk related to cash and cash equivalents was not significant.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Please see the discussion of “Recent Accounting Pronouncements” in Note 4, Significant Accounting Policies contained in the Notes to Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. No new updates or other guidance issued to date by the FASB in 2012 are expected to have a material impact on the Company’s financial statements.

X

- Definition

Recent accounting pronouncements , Policy

+ References

No definition available.

+ Details

Name: iliu_RecentAccountingPronouncementsPolicyTextBlock

Namespace Prefix: iliu_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 8, 9, 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Technical Practice Aid (TPA)

-Number 2110

-Paragraph 6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122427

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for commissions incurred in relation to revenue generating activities or operations.

+ References

No definition available.

+ Details

Name: us-gaap_CommissionsExpensePolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 6, 8-16, 60

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2144384

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for determining the fair value of financial instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2155942

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 8, 10, 12, 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 48

-Paragraph 20

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32247-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 4

-Paragraph 11

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 6-34, 43, 47, 49

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32280-109318

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-URI http://asc.fasb.org/subtopic&trid=2144749

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2144681

+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2126999

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 206

-Paragraph b

-Subparagraph i, ii

-Chapter 2

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Paragraph 3, 5-10, 15, 16, 17

-Chapter 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 81-1

-Paragraph 69-75

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6386783&loc=d3e4556-108314

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 9

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6386783&loc=d3e4492-108314

+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2196772

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 01-6

-Paragraph 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3-5

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 114

-Paragraph 20

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 92-5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 20

-URI http://asc.fasb.org/subtopic&trid=2196816

+ Details

Name: us-gaap_ReceivablesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 8, 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 6

-Paragraph 5, 6, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 42

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2127266

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 22

-Paragraph 8, 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18823-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6

Commitments and Contingencies
6 Months Ended

Jun. 30, 2012

Commitments and Contingencies

Note 8—Commitments and Contingencies

Employment Agreements

On February 14, 2011, the Company entered into an employment agreement with Lewis H. Bender, its Chief Executive Officer. The agreement replaced and superseded the employment agreement between the Company and Mr. Bender that expired by its terms on January 22, 2011. The agreement has an initial term of one year and is automatically renewable for successive one year periods unless at least 90 days prior notice is given by either the Company or Mr. Bender. The agreement automatically renewed for a one year period on February 14, 2012. The agreement also provides that Mr. Bender will serve as a member of the Company’s Board of Directors for as long as he serves as the Company’s Chief Executive Officer, subject to any required approval of the Company’s shareholders.

The agreement is terminable by the Company for cause or upon thirty days prior written notice without cause and by Mr. Bender upon thirty days prior written notice for “good reason” (as defined in the agreement) or upon ninety days prior written notice without good reason. If the Company terminates Mr. Bender without cause or Mr. Bender terminates his employment for good reason, then the Company will pay Mr. Bender, in addition to any accrued, but unpaid compensation prior to the termination, an amount equal to six months of his base salary. If the Company terminates Mr. Bender without cause or Mr. Bender terminates his employment with good reason within six months after a “change of control” (as defined in the agreement), then the Company will pay Mr. Bender, in addition to any accrued, but unpaid compensation prior to the termination, an amount equal to twelve months of his base salary, and all unvested stock options will automatically vest.

The agreement also includes non-compete and non-solicitation provisions for a period of six months following the termination of Mr. Bender’s employment with the Company.

On April 25, 2012, the Company executed an amendment, effective as of March 31, 2012, to the Employment Agreement dated as of November 12, 2008 by and between the Company and Kenneth S. Kornman, its President and Chief Scientific Officer to extend the term through November 30, 2012.

Operating Lease

The Company leases its office and laboratory space under a non-cancelable operating lease expiring on March 31, 2014. In May 2010, the Company completed a sublease of approximately 6,000 square feet of underutilized office and laboratory space which successfully reduced our total space operating costs. The sublease expires on March 31, 2013 and has a one year renewal option. Rent expense, net of the benefit of the sublease, was $167,000 and $161,000 for the six months ended June 30, 2012 and 2011, respectively.

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6

Convertible Debt
6 Months Ended

Jun. 30, 2012

Convertible Debt

Note 6—Convertible Debt

On August 17, 2006, our existing credit facility with Pyxis was amended to provide the Company with access to approximately $14.3 million of additional working capital borrowings at any time prior to August 17, 2008. Any amounts borrowed thereunder bear interest at the prime rate and require quarterly interest payments. This credit facility has been extended several times. Most recently, on June 29, 2012, the date was extended to November 30, 2012.

On April 13, 2012, the Company borrowed the remaining $1,316,255 of available credit, leaving the full amount of $14,316,255 due on November 30, 2012. The fair value of convertible debt is estimated to be approximately $3.1 million at June 30, 2012. The principal amount of borrowings under this credit facility is convertible at Pyxis’ election into 2,521,222 shares of common stock, reflecting a conversion price of $5.6783 per share.

X

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6

Intangible Assets
6 Months Ended

Jun. 30, 2012

Intangible Assets

Note 7—Intangible Assets

Intangible assets at June 30, 2012 and December 31, 2011 consisted of the following:

June 30, 2012 December 31, 2011

Patent costs $ 1,154,523 $ 1,154,523

Less — Accumulated amortization (697,666 ) (639,939 )

Total $ 456,857 $ 514,584

Patent amortization was $57,726 for the six months ended June 30, 2012 and 2011, respectively.

Patent costs, which are amortized on a straight-line basis over a 10-year life, are scheduled to amortize as follows:

Year ended December 31,

2012 (remaining six months) 57,725

2013. 109,266

2014. 94,100

2015. 77,656

Thereafter. 118,110

$ 456,857

X

- Definition

The entire disclosure for all or part of the information related to intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 44, 45, 46

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16373-109275

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16265-109275

+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6

Capital Stock
6 Months Ended

Jun. 30, 2012

Capital Stock

Note 9—Capital Stock

Authorized Preferred and Common Stock

At June 30, 2012, the Company had authorized 6,000,000 shares of $0.001 par value preferred stock, of which 5,000,000 shares, designated as Series A-1 Convertible Preferred Stock, were issued and outstanding and 500,000 shares, designated as Series B Convertible Preferred Stock, were issued and outstanding (collectively, the “Preferred Stock”). At June 30, 2012, the Company had authorized 100,000,000 shares of $0.001 par value common stock of which 85,317,885 shares were outstanding or reserved for issuance. Of those, 36,761,864 shares were outstanding; 39,089,161 shares were reserved for the conversion of the outstanding Preferred Stock to common stock; 2,521,222 shares were reserved for the conversion of the $14,316,255 of debt outstanding under the credit facility with Pyxis; 4,358,480 shares were reserved for the potential exercise of authorized and outstanding stock options; 400,000 shares were reserved for the exercise of outstanding warrants to purchase common stock at an exercise price of $2.50 per share which are exercisable currently until the expiration date of August 9, 2012; 1,750,000 shares were reserved for the exercise of outstanding warrants to purchase common stock at an exercise price of $1.30 per share which are exercisable currently until the expiration date of March 5, 2015; and 437,158 shares were reserved for the exercise of outstanding warrants to purchase common stock at an exercise price of $0.2745 per share which are exercisable currently until the expiration date of June 29, 2017.

On August 7, 2012, at the Company’s 2012 annual meeting, the Company’s shareholders approved an amendment to the Company’s Charter affecting an increase in authorized shares of common stock from 100,000,000 to 150,000,000 shares. The Company believes that the availability of additional shares for issuance from time to time in the Board of Directors’ discretion in connection with future financings, investment opportunities, stock splits or dividends, possible acquisitions or for other corporate purposes is desirable in order to avoid repeated separate amendments to the Company’s Charter and the delay and expense incurred in holding special meetings of the stockholders to approve such amendments. The Company currently has no specific understandings, arrangements, or agreements with respect to any financings, investment opportunities, stock splits or dividends, or acquisitions or for any other corporate purposes that would require the Company to issue a material amount of new shares of common stock.

Preferred Stock

On June 29, 2012, the Company entered into an agreement with Pyxis to exchange the 5,000,000 shares of Series A Convertible Preferred Stock held for 5,000,000 shares of Series A-1 Convertible Preferred Stock and filed a new Certficate of Designation, Preferences and Rights of Preferred Stock with the State of Delaware for the Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock. Concurrently therewith, the Company completed a financing with Delta Dental pursuant to which Delta Dental purchased 500,000 shares of Series B Convertible Preferred Stock for gross proceeds of $3,000,000. Each share of Series B Preferred Stock is convertible into approximately 21.86 shares of common stock reflecting a conversion price of $0.2745 per share. Net proceeds to the Company after fees and expenses were approximately $2.75 million. In addition, fully vested warrants to purchase 437,158 shares of common stock at an exercise price of $0.2745 per share were issued to the placement agent in the transaction. These warrants expire in five years. For purposes of determining the fair value of the warrants issued in the Preferred Stock transaction, the Black-Scholes pricing model was used with the following assumptions:

Risk-free interest rate 1 %

Expected life 5 years

Expected volatility 142.36 %

Dividend yield 0 %

Using these assumptions, the fair value of the warrants reflected in the June 30, 2012 Statement of Stockholders’ Deficit is $104,907.

The Preferred Stock accrues dividends at the rate of 8% of the original purchase price per year, payable only when, as and if declared by the Board of Directors and are non-cumulative. To date, no dividends have been declared on these shares. If the Company declares a distribution, with certain exceptions, payable in securities of other persons, evidences of indebtedness issued by the Company or other persons, assets (excluding cash dividends) or options or rights to purchase any such securities or evidences of indebtedness, then, in each such case the holders of the Preferred Stock shall be entitled to a proportionate share of any such distribution as though the holders of the Preferred Stock were the holders of the number of shares of common stock into which their respective shares of Preferred Stock are convertible as of the record date fixed for the determination of the holders of common stock entitled to receive such distribution.

In the event of any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, the holders of the Preferred Stock shall be entitled to receive on a pari passu basis, prior and in preference to any distribution of any of the Company’s assets or surplus funds to the holders of its common stock by reason of their ownership thereof, the amount of two times the then-effective purchase price per share, as adjusted for any stock dividends, combinations or splits with respect to such shares, plus all declared but unpaid dividends on such shares for each share of Preferred Stock then held by them. The liquidation preference at June 30, 2012 was $24,000,000, reflecting a liquidation preference of $18,000,000 for the Series A-1 Convertible Preferred Stock and $6,000,000 for the Series B Convertible Preferred Stock. After receiving this amount, the holders of the Preferred Stock are entitled to participate on an as-converted basis with the holders of common stock in any of the remaining assets.

Each share of Series A-1 Preferred Stock is convertible at any time at the option of the holder into a number of shares of the Company’s common stock determined by dividing the then-effective purchase price ($1.80, and subject to further adjustment) by the conversion price in effect on the date the certificate is surrendered for conversion. As of June 30, 2012, the Series A-1 Preferred Stock was convertible into 28,160,200 shares of common stock reflecting a current conversion price of $0.3196 per share. Each share of Series B Preferred Stock is convertible at any time at the option of the holder into a number of shares of the Company’s common stock determined by dividing the then-effective purchase price ($6.00, and subject to further adjustment) by the conversion price in effect on the date the certificate is surrendered for conversion. As of June 30, 2012, the Series B Preferred Stock was convertible into 10,928,961 shares of common stock reflecting a current conversion price of $0.2745 per share.

Each holder of Preferred Stock is entitled to vote its shares of Preferred Stock on an as-converted basis with the holders of common stock as a single class on all matters submitted to a vote of the stockholders, except as otherwise required by applicable law. This means that each share of Preferred Stock will be entitled to a number of votes equal to the number of shares of common stock into which it is convertible on the applicable record date.

X

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section B

-Paragraph 7, 11A

-Chapter 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R34.htm IDEA: XBRL DOCUMENT v2.4.0.6

Capital Stock - Additional Information (Detail) (USD $)
6 Months Ended 6 Months Ended 1 Months Ended 6 Months Ended

Jun. 30, 2012

Jun. 29, 2012

Dec. 31, 2011

Jun. 30, 2012

Warrant 1

Jun. 30, 2012

Warrant 2

Jun. 30, 2012

Warrant 3

Aug. 07, 2012

Subsequent Event

Jun. 30, 2012

Pyxis Innovations Inc

Jun. 30, 2012

Series A-1 Preferred Stock

Jun. 29, 2012

Series A-1 Preferred Stock

Jun. 29, 2012

Series B Preferred Stock

Jun. 30, 2012

Series B Preferred Stock

Stockholders Equity [Line Items]

Convertible preferred stock, par value $ 0.001 $ 0.001

Convertible preferred stock, shares authorized 6,000,000 6,000,000

Convertible preferred stock, shares issued 5,500,000 5,000,000 5,000,000 5,000,000 500,000 500,000

Convertible preferred stock, shares outstanding 5,500,000 5,000,000 5,000,000 5,000,000 500,000

Common stock, shares authorized 100,000,000 100,000,000 150,000,000

Common stock, par value $ 0.001 $ 0.001

Common stock, outstanding or reserved for issuance 85,317,885

Common stock, shares outstanding 36,761,864 36,709,706

Shares reserved for conversion of Preferred to common stock 39,089,161 28,160,200 10,928,961

Shares reserved for conversion of debt 2,521,222

Debt outstanding $ 14,316,255

Shares reserved for potential exercise 4,358,480

Shares reserved for exercise of outstanding warrants 437,158 400,000 1,750,000 437,158

Warrants exercise price per share $ 0.2745 $ 2.50 $ 1.30 $ 0.2745

Expiration date of warrants Aug. 09, 2012 Mar. 05, 2015 Jun. 29, 2017

Proceeds from private placement of preferred stock 3,000,000 3,000,000

Conversion of Series B convertible preferred Stock to Common Stock 21.86

Convertible preferred stock current conversion price $ 0.3196 $ 0.2745 $ 0.2745

Net Proceeds from issuance of Series B Convertible preferred Stock 2,750,000

Warrant expiration period 5 years

Warrants issued in connection with private placement of preferred stock 104,907

Accrued dividend rate 8.00%

Convertible preferred stock, liquidation preference $ 24,000,000 $ 18,000,000 $ 6,000,000

Convertible preferred stock, effective purchase price $ 1.80 $ 6.00

X

- Definition

Average Purchase Price Per Share of Issued Shares

+ References

No definition available.

+ Details

Name: iliu_AveragePurchasePricePerShareOfIssuedShares

Namespace Prefix: iliu_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Class of Warrant or Right, Expiration Period

+ References

No definition available.

+ Details

Name: iliu_ClassOfWarrantOrRightExpirationPeriod

Namespace Prefix: iliu_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition

Common Shares Issuable upon Conversion of Convertible Debt

+ References

No definition available.

+ Details

Name: iliu_CommonSharesIssuableUponConversionOfConvertibleDebt

Namespace Prefix: iliu_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Common Shares Issuable upon Conversion of Convertible Stock

+ References

No definition available.

+ Details

Name: iliu_CommonSharesIssuableUponConversionOfConvertibleStock

Namespace Prefix: iliu_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Common Stock Issuable upon Exercise of Warrants

+ References

No definition available.

+ Details

Name: iliu_CommonStockIssuableUponExerciseOfWarrants

Namespace Prefix: iliu_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Common Stock Shares Outstanding Or Reserved For Issuance

+ References

No definition available.

+ Details

Name: iliu_CommonStockSharesOutstandingOrReservedForIssuance

Namespace Prefix: iliu_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Conversion Of Preferred Stock To Common Stock Shares

+ References

No definition available.

+ Details

Name: iliu_ConversionOfPreferredStockToCommonStockShares

Namespace Prefix: iliu_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Exercise Price Of Warrants

+ References

No definition available.

+ Details

Name: iliu_ExercisePriceOfWarrants

Namespace Prefix: iliu_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Share Based Compensation Arrangement by Share Based Payment Award, Number of Shares to be Issued Upon Exercise of Outstanding Awards

+ References

No definition available.

+ Details

Name: iliu_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesToBeIssuedUponExerciseOfOutstandingAwards

Namespace Prefix: iliu_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Stock Conversion, price per share

+ References

No definition available.

+ Details

Name: iliu_StockConversionPricePerShare

Namespace Prefix: iliu_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: iliu_StockholdersEquityLineItems

Namespace Prefix: iliu_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrant, Expiration Date

+ References

No definition available.

+ Details

Name: iliu_WarrantExpirationDate

Namespace Prefix: iliu_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: instant

X

- Definition

Increase in additional paid in capital due to warrants issued during the period. Includes also the proceeds of debt securities issued with detachable stock purchase warrants that are allocable to the warrants. These warrants qualify for equity classification and provide the holder with a right to purchase stock from the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Warrant

-URI http://asc.fasb.org/extlink&oid=6528364

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 14

-Paragraph 16

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 25

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7656322&loc=d3e4724-112606

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount borrowed under the credit facility as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 22

-Article 5

+ Details

Name: us-gaap_LineOfCreditFacilityAmountOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The percentage rate used to calculate dividend payments on preferred stock.

+ References

No definition available.

+ Details

Name: us-gaap_PreferredStockDividendRatePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of the difference between preference in liquidation and the par or stated values of the preferred shares.

+ References

No definition available.

+ Details

Name: us-gaap_PreferredStockLiquidationPreferenceValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 47 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6

Intangible Assets (Tables)
6 Months Ended

Jun. 30, 2012

Summary of Intangible Assets

Intangible assets at June 30, 2012 and December 31, 2011 consisted of the following:

June 30, 2012 December 31, 2011

Patent costs $ 1,154,523 $ 1,154,523

Less — Accumulated amortization (697,666 ) (639,939 )

Total $ 456,857 $ 514,584

Patent Costs Amortized on a Straight-Line Basis

Patent costs, which are amortized on a straight-line basis over a 10-year life, are scheduled to amortize as follows:

Year ended December 31,

2012 (remaining six months) 57,725

2013. 109,266

2014. 94,100

2015. 77,656

Thereafter. 118,110

$ 456,857

X

- Definition

Tabular disclosure of the estimated aggregate amortization expense for intangible assets subject to amortization for each of the five succeeding fiscal years.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

+ Details

Name: us-gaap_ScheduleOfExpectedAmortizationExpenseTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16265-109275

+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6

Inventory (Detail) (USD $)

Jun. 30, 2012

Dec. 31, 2011

Inventory Disclosure [Line Items]

Raw materials $ 83,895 $ 100,433

Finished goods 4,473 7,325

Total inventory $ 88,368 $ 107,758

X

- Details

Name: iliu_InventoryDisclosureLineItems

Namespace Prefix: iliu_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount before last-in first-out (LIFO) and valuation reserves of merchandise or goods held by the entity that are readily available for sale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryFinishedGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Gross amount of unprocessed items to be consumed in the manufacturing or production process. Also includes purchased parts that will be used as components of a finished product.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 49 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT (USD $)

Total

Convertible Preferred Stock

Common Stock

Additional Paid-in Capital

Accumulated Deficit

Beginning Balance at Dec. 31, 2010 $ (6,658,096) $ 5,000 $ 36,594 $ 90,851,709 $ (97,551,399)

Beginning Balance (in shares) at Dec. 31, 2010 5,000,000 36,594,799

Net loss (2,467,978) (2,467,978)

Common stock issued:

Employee stock purchase plan (in shares) 64,134 64,134

Employee stock purchase plan 16,965 65 16,900

Stock-based compensation expense 130,966 130,966

Ending Balance at Jun. 30, 2011 (8,978,143) 5,000 36,659 90,999,575 (100,019,377)

Ending Balance (in shares) at Jun. 30, 2011 5,000,000 36,658,933

Beginning Balance at Dec. 31, 2011 (11,423,231) 5,000 36,710 91,111,640 (102,576,581)

Beginning Balance (in shares) at Dec. 31, 2011 5,000,000 36,709,706

Net loss (2,644,540) (2,644,540)

Private placement of preferred stock, net of offering costs of $354,907 (in shares) 500,000

Private placement of preferred stock, net of offering costs of $354,907 2,645,093 500 2,644,593

Warrants issued in connection with private placement of preferred stock 104,907 104,907

Common stock issued:

Employee stock purchase plan (in shares) 52,158 52,158

Employee stock purchase plan 8,810 52 8,758

Stock-based compensation expense 96,131 96,131

Ending Balance at Jun. 30, 2012 $ (11,212,830) $ 5,500 $ 36,762 $ 93,966,029 $ (105,221,121)

Ending Balance (in shares) at Jun. 30, 2012 5,500,000 36,761,864

X

- Details

Name: iliu_CommonStockTransactionsAbstract

Namespace Prefix: iliu_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11178-113907

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415241&loc=d3e4534-113899

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A91

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11149-113907

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 39

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Increase in additional paid in capital due to warrants issued during the period. Includes also the proceeds of debt securities issued with detachable stock purchase warrants that are allocable to the warrants. These warrants qualify for equity classification and provide the holder with a right to purchase stock from the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Warrant

-URI http://asc.fasb.org/extlink&oid=6528364

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 14

-Paragraph 16

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 25

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7656322&loc=d3e4724-112606

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares issued and outstanding as of the balance sheet date.

+ References

No definition available.

+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of shares issued during the period as a result of an employee stock purchase plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 50 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6

Discontinued Operations
6 Months Ended

Jun. 30, 2012

Discontinued Operations

Note 3—Discontinued Operations

In August 2006, the Company acquired the assets and business of the Alan James Group, LLC (the Alan James Group). The Alan James Group was a provider of products and services in the consumer healthcare marketplace and the acquired business primarily developed, marketed and sold nutritional products and engaged in related activities. Prior to the opening of business on July 1, 2009, the Company and its wholly-owned subsidiary, AJG Brands, Inc. entered into an asset purchase agreement with Nutraceutical Corporation and Pep Products, Inc., a wholly-owned subsidiary of Nutraceutical Corporation, pursuant to which substantially all of the Alan James Group business and assets of AJG Brands, Inc. were sold to Pep Products, Inc.

Prior to June 30, 2011, we reserved for estimated sales returns, discontinued items and trade promotions applicable to the non-acquired accounts resulting from our sale of substantially all of the assets of the Alan James Group business. The Company completed an analysis of all return activity since the time of sale and determined that the remaining reserve was no longer required. The adjustment is reflected in income from discontinued operations in the June 30, 2011 statement of operations.

X

- Definition

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 43-48

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

+ Details

Name: us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6

Potential Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share (Detail)
6 Months Ended

Jun. 30, 2012

Jun. 30, 2011

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Potential common stock equivalents excluded from the calculation of diluted net loss per share 46,297,808 34,464,667

Stock option grants beginning of period

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Potential common stock equivalents excluded from the calculation of diluted net loss per share 2,100,267 2,217,267

Warrant

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Potential common stock equivalents excluded from the calculation of diluted net loss per share 2,587,158 2,150,000

Convertible Preferred Stock

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Potential common stock equivalents excluded from the calculation of diluted net loss per share 39,089,161 28,160,200

Convertible Debt

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Potential common stock equivalents excluded from the calculation of diluted net loss per share 2,521,222 1,937,200

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 78 195 1 false 27 0 false 5 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.ilgenetics.com/taxonomy/role/DocumentDocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - CONDENSED BALANCE SHEETS Sheet http://www.ilgenetics.com/taxonomy/role/StatementOfFinancialPositionClassified CONDENSED BALANCE SHEETS false false R3.htm 104 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) Sheet http://www.ilgenetics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical CONDENSED BALANCE SHEETS (Parenthetical) false false R4.htm 105 - Statement - CONDENSED STATEMENTS OF OPERATIONS Sheet http://www.ilgenetics.com/taxonomy/role/StatementOfIncome CONDENSED STATEMENTS OF OPERATIONS false false R5.htm 106 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT Sheet http://www.ilgenetics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT false false R6.htm 107 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical) Sheet http://www.ilgenetics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical) false false R7.htm 108 - Statement - CONDENSED STATEMENTS OF CASH FLOWS Sheet http://www.ilgenetics.com/taxonomy/role/StatementOfCashFlowsIndirect CONDENSED STATEMENTS OF CASH FLOWS false false R8.htm 109 - Disclosure - Basis of Presentation Sheet http://www.ilgenetics.com/taxonomy/role/NotesToFinancialStatementsBasisOfAccounting Basis of Presentation false false R9.htm 110 - Disclosure - Operating Matters and Liquidity Sheet http://www.ilgenetics.com/taxonomy/role/NotesToFinancialStatementsGoingConcernDisclosureTextBlock Operating Matters and Liquidity false false R10.htm 111 - Disclosure - Discontinued Operations Sheet http://www.ilgenetics.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock Discontinued Operations false false R11.htm 112 - Disclosure - Significant Accounting Policies Sheet http://www.ilgenetics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Significant Accounting Policies false false R12.htm 113 - Disclosure - Strategic Alliance with Alticor Inc. Sheet http://www.ilgenetics.com/taxonomy/role/NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock Strategic Alliance with Alticor Inc. false false R13.htm 114 - Disclosure - Convertible Debt Sheet http://www.ilgenetics.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock Convertible Debt false false R14.htm 115 - Disclosure - Intangible Assets Sheet http://www.ilgenetics.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock Intangible Assets false false R15.htm 116 - Disclosure - Commitments and Contingencies Sheet http://www.ilgenetics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies false false R16.htm 117 - Disclosure - Capital Stock Sheet http://www.ilgenetics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Capital Stock false false R17.htm 118 - Disclosure - Stock-Based Compensation Arrangements Sheet http://www.ilgenetics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-Based Compensation Arrangements false false R18.htm 119 - Disclosure - Industry Risk and Concentration Sheet http://www.ilgenetics.com/taxonomy/role/NotesToFinancialStatementsConcentrationRiskDisclosureTextBlock Industry Risk and Concentration false false R19.htm 120 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.ilgenetics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies Significant Accounting Policies (Policies) false false R20.htm 121 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.ilgenetics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables Significant Accounting Policies (Tables) false false R21.htm 122 - Disclosure - Intangible Assets (Tables) Sheet http://www.ilgenetics.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables Intangible Assets (Tables) false false R22.htm 123 - Disclosure - Capital Stock (Tables) Sheet http://www.ilgenetics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables Capital Stock (Tables) false false R23.htm 124 - Disclosure - Stock-Based Compensation Arrangements (Tables) Sheet http://www.ilgenetics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock-Based Compensation Arrangements (Tables) false false R24.htm 125 - Disclosure - Operating Matters and Liquidity - Additional Information (Detail) Sheet http://www.ilgenetics.com/taxonomy/role/DisclosureOperatingMattersAndLiquidityAdditionalInformation Operating Matters and Liquidity - Additional Information (Detail) false false R25.htm 126 - Disclosure - Significant Accounting Policies - Additional Information (Detail) Sheet http://www.ilgenetics.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation Significant Accounting Policies - Additional Information (Detail) false false R26.htm 127 - Disclosure - Inventory (Detail) Sheet http://www.ilgenetics.com/taxonomy/role/DisclosureInventory Inventory (Detail) false false R27.htm 128 - Disclosure - Potential Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share (Detail) Sheet http://www.ilgenetics.com/taxonomy/role/DisclosurePotentialCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShare Potential Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share (Detail) false false R28.htm 129 - Disclosure - Strategic Alliance with Alticor Inc - Additional Information (Detail) Sheet http://www.ilgenetics.com/taxonomy/role/DisclosureStrategicAllianceWithAlticorIncAdditionalInformation Strategic Alliance with Alticor Inc - Additional Information (Detail) false false R29.htm 130 - Disclosure - Convertible Debt - Additional Information (Detail) Sheet http://www.ilgenetics.com/taxonomy/role/DisclosureConvertibleDebtAdditionalInformation Convertible Debt - Additional Information (Detail) false false R30.htm 131 - Disclosure - Intangible Assets (Detail) Sheet http://www.ilgenetics.com/taxonomy/role/DisclosureIntangibleAssets Intangible Assets (Detail) false false R31.htm 132 - Disclosure - Intangible Assets - Additional Information (Detail) Sheet http://www.ilgenetics.com/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation Intangible Assets - Additional Information (Detail) false false R32.htm 133 - Disclosure - Patent Costs Amortized on Straight-Line Basis (Detail) Sheet http://www.ilgenetics.com/taxonomy/role/DisclosurePatentCostsAmortizedOnStraightLineBasis Patent Costs Amortized on Straight-Line Basis (Detail) false false R33.htm 134 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.ilgenetics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) false false R34.htm 135 - Disclosure - Capital Stock - Additional Information (Detail) Sheet http://www.ilgenetics.com/taxonomy/role/DisclosureCapitalStockAdditionalInformation Capital Stock - Additional Information (Detail) false false R35.htm 136 - Disclosure - Black-Scholes Pricing Model Assumptions to Determine Fair Value of Warrants (Detail) Sheet http://www.ilgenetics.com/taxonomy/role/DisclosureBlackScholesPricingModelAssumptionsToDetermineFairValueOfWarrants Black-Scholes Pricing Model Assumptions to Determine Fair Value of Warrants (Detail) false false R36.htm 137 - Disclosure - Total Compensation Cost Recorded for Stock-Based Compensation (Detail) Sheet http://www.ilgenetics.com/taxonomy/role/DisclosureTotalCompensationCostRecordedForStockBasedCompensation Total Compensation Cost Recorded for Stock-Based Compensation (Detail) false false R37.htm 138 - Disclosure - Stock Option and Restricted Stock Activity (Detail) Sheet http://www.ilgenetics.com/taxonomy/role/DisclosureStockOptionAndRestrictedStockActivity Stock Option and Restricted Stock Activity (Detail) false false R38.htm 139 - Disclosure - Stock-Based Compensation Arrangements - Additional Information (Detail) Sheet http://www.ilgenetics.com/taxonomy/role/DisclosureStockBasedCompensationArrangementsAdditionalInformation Stock-Based Compensation Arrangements - Additional Information (Detail) false false R39.htm 140 - Disclosure - Industry Risk and Concentration - Additional Information (Detail) Sheet http://www.ilgenetics.com/taxonomy/role/DisclosureIndustryRiskAndConcentrationAdditionalInformation Industry Risk and Concentration - Additional Information (Detail) false false All Reports Book All Reports Element iliu_ExercisePriceOfWarrants had a mix of decimals attribute values: 2 4. 'Monetary' elements on report '130 - Disclosure - Convertible Debt - Additional Information (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 103 - Statement - CONDENSED BALANCE SHEETS Process Flow-Through: Removing column 'Jun. 30, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 104 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) Process Flow-Through: Removing column 'Jun. 29, 2012' Process Flow-Through: 105 - Statement - CONDENSED STATEMENTS OF OPERATIONS Process Flow-Through: 107 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical) Process Flow-Through: 108 - Statement - CONDENSED STATEMENTS OF CASH FLOWS iliu-20120630.xml iliu-20120630.xsd iliu-20120630_cal.xml iliu-20120630_def.xml iliu-20120630_lab.xml iliu-20120630_pre.xml true true XML 53 R38.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stock-Based Compensation Arrangements - Additional Information (Detail) (USD $)
3 Months Ended 6 Months Ended 6 Months Ended

Jun. 30, 2012

Jun. 30, 2012

Jun. 30, 2011

Aug. 07, 2012

Subsequent Event

Jun. 30, 2012

2004 Employee, Director and Consultant Stock Plan

Jun. 30, 2012

Restricted Stock

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares of common stock available for grant 2,258,213

Stock purchase price 85.00%

Employee stock purchase plan, shares authorized 500,000 500,000 750,000

Shares reserved for issuance 5,631 5,631

Number of shares purchased by employees 5,628 52,158 64,134

Weighted-average purchase price $ 0.17 $ 0.26

Weighted-average fair value $ 0.20 $ 0.31

Compensation expense $ 1,332 $ 2,855

Unrecognized compensation cost $ 217,000

X

- Definition

Employee Service Share Based Compensation Unrecognized Compensation Costs On Nonvested Stock

+ References

No definition available.

+ Details

Name: iliu_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsOnNonvestedStock

Namespace Prefix: iliu_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Share Based Compensation Arrangement by Employee Stock Purchase Plan, Number of Shares Authorized

+ References

No definition available.

+ Details

Name: iliu_ShareBasedCompensationArrangementByEmployeeStockPurchasePlanNumberOfSharesAuthorized

Namespace Prefix: iliu_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Share Based Compensation Arrangement By Share Based Payment Shares Reserved For Future Issuance

+ References

No definition available.

+ Details

Name: iliu_ShareBasedCompensationArrangementByShareBasedPaymentSharesReservedForFutureIssuance

Namespace Prefix: iliu_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The amount of plan compensation cost recognized during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 93-6

-Paragraph 53

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Weighted average purchase price of capital shares purchased through an employee stock ownership plan.

+ References

No definition available.

+ Details

Name: us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph c(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Purchase price of common stock expressed as a percentage of its fair market value.

+ References

No definition available.

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares issued during the period as a result of an employee stock purchase plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 54 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6

Significant Accounting Policies (Tables)
6 Months Ended

Jun. 30, 2012

Inventory

Inventory consisted of the following at June 30, 2012 and December 31, 2011:

June 30, 2012 December 31, 2011

Raw materials $ 83,895 $ 100,433

Finished goods 4,473 7,325

Total inventory $ 88,368 $ 107,758

Potential Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share

Potential common stock equivalents excluded from the calculation of diluted net loss per share consists of stock options, warrants, convertible preferred stock and convertible debt as set forth in the table below:

As of June 30,

2012 2011

Options outstanding 2,100,267 2,217,267

Warrants outstanding 2,587,158 2,150,000

Convertible preferred stock 39,089,161 28,160,200

Convertible debt 2,521,222 1,937,200

Total 46,297,808 34,464,667

X

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Capital Stock - Additional Information (Detail) (USD $)	6 Months Ended								6 Months Ended		1 Months Ended	6 Months Ended
Capital Stock - Additional Information (Detail) (USD $)	Jun. 30, 2012	Jun. 29, 2012	Dec. 31, 2011	Jun. 30, 2012 Warrant 1	Jun. 30, 2012 Warrant 2	Jun. 30, 2012 Warrant 3	Aug. 07, 2012 Subsequent Event	Jun. 30, 2012 Pyxis Innovations Inc	Jun. 30, 2012 Series A-1 Preferred Stock	Jun. 29, 2012 Series A-1 Preferred Stock	Jun. 29, 2012 Series B Preferred Stock	Jun. 30, 2012 Series B Preferred Stock
Stockholders Equity [Line Items]
Convertible preferred stock, par value	$ 0.001		$ 0.001
Convertible preferred stock, shares authorized	6,000,000		6,000,000
Convertible preferred stock, shares issued	5,500,000		5,000,000						5,000,000	5,000,000	500,000	500,000
Convertible preferred stock, shares outstanding	5,500,000	5,000,000	5,000,000						5,000,000			500,000
Common stock, shares authorized	100,000,000		100,000,000				150,000,000
Common stock, par value	$ 0.001		$ 0.001
Common stock, outstanding or reserved for issuance	85,317,885
Common stock, shares outstanding	36,761,864		36,709,706
Shares reserved for conversion of Preferred to common stock	39,089,161								28,160,200			10,928,961
Shares reserved for conversion of debt								2,521,222
Debt outstanding								$ 14,316,255
Shares reserved for potential exercise	4,358,480
Shares reserved for exercise of outstanding warrants		437,158		400,000	1,750,000	437,158
Warrants exercise price per share		$ 0.2745		$ 2.50	$ 1.30	$ 0.2745
Expiration date of warrants				Aug. 09, 2012	Mar. 05, 2015	Jun. 29, 2017
Proceeds from private placement of preferred stock	3,000,000										3,000,000
Conversion of Series B convertible preferred Stock to Common Stock											21.86
Convertible preferred stock current conversion price									$ 0.3196		$ 0.2745	$ 0.2745
Net Proceeds from issuance of Series B Convertible preferred Stock											2,750,000
Warrant expiration period		5 years
Warrants issued in connection with private placement of preferred stock	104,907
Accrued dividend rate	8.00%
Convertible preferred stock, liquidation preference	$ 24,000,000								$ 18,000,000			$ 6,000,000
Convertible preferred stock, effective purchase price									$ 1.80			$ 6.00

Inventory (Detail) (USD $)	Jun. 30, 2012	Dec. 31, 2011
Inventory Disclosure [Line Items]
Raw materials	$ 83,895	$ 100,433
Finished goods	4,473	7,325
Total inventory	$ 88,368	$ 107,758

CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT (USD $)	Total	Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning Balance at Dec. 31, 2010	$ (6,658,096)	$ 5,000	$ 36,594	$ 90,851,709	$ (97,551,399)
Beginning Balance (in shares) at Dec. 31, 2010		5,000,000	36,594,799
Net loss	(2,467,978)				(2,467,978)
Common stock issued:
Employee stock purchase plan (in shares)	64,134		64,134
Employee stock purchase plan	16,965		65	16,900
Stock-based compensation expense	130,966			130,966
Ending Balance at Jun. 30, 2011	(8,978,143)	5,000	36,659	90,999,575	(100,019,377)
Ending Balance (in shares) at Jun. 30, 2011		5,000,000	36,658,933
Beginning Balance at Dec. 31, 2011	(11,423,231)	5,000	36,710	91,111,640	(102,576,581)
Beginning Balance (in shares) at Dec. 31, 2011		5,000,000	36,709,706
Net loss	(2,644,540)				(2,644,540)
Private placement of preferred stock, net of offering costs of $354,907 (in shares)		500,000
Private placement of preferred stock, net of offering costs of $354,907	2,645,093	500		2,644,593
Warrants issued in connection with private placement of preferred stock	104,907			104,907
Common stock issued:
Employee stock purchase plan (in shares)	52,158		52,158
Employee stock purchase plan	8,810		52	8,758
Stock-based compensation expense	96,131			96,131
Ending Balance at Jun. 30, 2012	$ (11,212,830)	$ 5,500	$ 36,762	$ 93,966,029	$ (105,221,121)
Ending Balance (in shares) at Jun. 30, 2012		5,500,000	36,761,864

Potential Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share (Detail)	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from the calculation of diluted net loss per share	46,297,808	34,464,667
Stock option grants beginning of period
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from the calculation of diluted net loss per share	2,100,267	2,217,267
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from the calculation of diluted net loss per share	2,587,158	2,150,000
Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from the calculation of diluted net loss per share	39,089,161	28,160,200
Convertible Debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from the calculation of diluted net loss per share	2,521,222	1,937,200